**CUMULATIVE SUPPLEMENT 3**
**MARCH 2013**



# APPROVED DRUG PRODUCTS

## WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

## 33rd EDITION

**Department of Health and Human Services**
**Food and Drug Administration**
**Center for Drug Evaluation and Research**
**Office of Generic Drugs**

**2013**

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

# APPROVED DRUG PRODUCTS
# with
# THERAPEUTIC EQUIVALENCE EVALUATIONS

## 33rd EDITION

## Cumulative Supplement 3

## March 2013

## CONTENTS

*PAGE*

# APPROVED DRUG PRODUCTS
# with
# THERAPEUTIC EQUIVALENCE EVALUATIONS

## 33rd EDITION

## CUMULATIVE SUPPLEMENT 3
## March 2013

## 1.0 INTRODUCTION

### 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

## 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

| FORMER APPLICANT NAME (FORMER ABBREVIATED NAME) | NEW APPLICANT NAME (NEW ABBREVIATED NAME) |
|---|---|
| BIONICHE PHARMA USA LLC (BIONICHE PHARMA USA) | MYLAN INSTITUTIONAL LLC (MYLAN LLC) |

## 1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck

KGAA ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

| Trade Name | Applicant | Potency | TE Code | Appl No | Product No |
|---|---|---|---|---|---|
| UNITHROID | STEVENS J | 0.025MG | AB1 | 21210 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB1 | 76187 | 001 |
| LEVOXYL | KING PHARMS | 0.025MG | AB1 | 21301 | 001 |
| SYNTHROID | ABBOTT | 0.025MG | AB1 | 21402 | 001 |
| LEVO-T | ALARA PHARM | 0.025MG | AB1 | 21342 | 001 |
| | | | | | |
| SYNTHROID | ABBOTT | 0.025MG | AB2 | 21402 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB2 | 76187 | 001 |
| LEVO-T | ALARA PHARM | 0.025MG | AB2 | 21342 | 001 |
| UNITHROID | STEVENS J | 0.025MG | AB2 | 21210 | 001 |
| LEVOTHYROXINE SODIUM | MERCK KGAA | 0.025MG | AB2 | 76752 | 001 |
| | | | | | |
| LEVOXYL | KUNG PHARMS | 0.025MG | AB3 | 21301 | 001 |
| LEVO-T | ALARA PHARM | 0.025MG | AB3 | 21342 | 001 |
| UNITHROID | STEVENS J | 0.025MG | AB3 | 21210 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB3 | 76187 | 001 |
| LEVOTHYROXINE SODIUM | MERCK KGAA | 0.025MG | AB3 | 76752 | 001 |
| | | | | | |
| LEVOTHROID | LLOYD | 0.025MG | AB4 | 21116 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB4 | 76187 | 001 |
| | | | | | |

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper

versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

| CATEGORIES COUNTED | DEC 2012 | MAR 2013 | JUN 2013 | SEPT 2013 | DEC 2013 |
|---|---|---|---|---|---|
| DRUG PRODUCTS LISTED | 15343 | 15445 | | | |
| SINGLE SOURCE | 2400 (15.9%) | 2467 (16.0%) | | | |
| MULTISOURCE | 12825 (83.6%) | 12900 (83.5) | | | |
| THERAPEUTICALLY EQUIVALENT | 12683 (82.7%) | 12758 (82.6%) | | | |
| NOT THERAPEUTICALLY EQUIVALENT | 142 (0.9%) | 142 (0.9%) | | | |
| EXCEPTIONS[1] | 78 (0.5%) | 78 (0.5%) | | | |
| NEW MOLECULAR ENTITIES APPROVED | 17 | 9 | | | |
| NUMBER OF APPLICANTS | 835 | 844 | | | |

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

| | |
|---|---|
| NEWA | New drug product approval usually in the supplement month. |
| CAHN | Applicant holder firm name has changed. |
| CAIN | Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name. |
| CDFR | Change. Dosage Form; Route of Administration. |
| CFTG | Change. A first time generic for the innovator product. A TE Code is added. |

| | |
|---|---|
| CMFD | Change. The product is moved from the Discontinued Section due to a change in marketing status. |
| CMS1 | Change. Miscellaneous addition to list. |
| CMS2 | Change. Miscellaneous deletion from list. |
| CPOT | Change. Potency amount/unit. |
| CRLD | Change. Reference Listed Drug. |
| CTEC | Change. Therapeutic Equivalence Code. |
| CTNA | Change. Trade Name. |
| DISC | Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition. |

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ MIRROR PHARMS LLC | 500MG;50MG;40MG | A040883 | 001 | Dec 23, 2008 | Feb | | DISC |

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ MIKART | 356.4MG;30MG;16MG | A040109 | 001 | Aug 26, 1997 | Feb | | DISC |

TABLET; ORAL
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ MIKART | 712.8MG;60MG;32MG | A040316 | 001 | Apr 28, 1999 | Feb | | DISC |

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ MIKART | 650MG;30MG | A089231 | 001 | Mar 03, 1986 | Feb | | DISC |
| | | @ | 650MG;60MG | A089363 | 001 | Sep 09, 1991 | Feb | | DISC |

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ MIKART | 500MG;5MG | A081067 | 001 | Nov 30, 1989 | Feb | | DISC |

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ MIKART | 500MG;2.5MG | A089698 | 001 | Aug 25, 1989 | Feb | | DISC |
| | | @ | 650MG;5MG | A040849 | 001 | Jun 09, 2010 | Feb | | DISC |
| >A> | AA | TRIS PHARMA INC | 325MG;5MG | A202214 | 001 | Mar 27, 2013 | Mar | | NEWA |
| >A> | AA | | 325MG;7.5MG | A202214 | 002 | Mar 27, 2013 | Mar | | NEWA |
| >A> | AA | | 325MG;10MG | A202214 | 003 | Mar 27, 2013 | Mar | | NEWA |

ACETAZOLAMIDE

TABLET; ORAL
ACETAZOLAMIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ WATSON LABS | 250MG | A088882 | 001 | Oct 22, 1985 | Jan | | DISC |

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AP | SAGENT AGILA | EQ 500MG BASE/VIAL | A200880 | 001 | May 09, 2012 | Jan | | CAHN |

ACITRETIN

CAPSULE; ORAL
>A> ACITRETIN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | BARR LABS INC | 10MG | A091455 | 001 | Apr 04, 2013 | Mar | | NEWA |
| >A> | AB | | 17.5MG | A202897 | 001 | Apr 04, 2013 | Mar | | NEWA |
| >A> | AB | | 22.5MG | A202897 | 002 | Apr 04, 2013 | Mar | | NEWA |
| >A> | AB | | 25MG | A091455 | 002 | Apr 04, 2013 | Mar | | NEWA |

SORIATANE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | STIEFEL LABS INC | 10MG | N019821 | 001 | Oct 28, 1996 | Mar | | CFTG |
| >A> | AB | | 10MG | N019821 | 001 | Oct 28, 1996 | Mar | | CFTG |
| >D> | | | 17.5MG | N019821 | 003 | Aug 06, 2009 | Mar | | CFTG |
| >A> | AB | | 17.5MG | N019821 | 003 | Aug 06, 2009 | Mar | | CFTG |

CAPSULE; ORAL
SORIATANE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | | STIEFEL LABS INC | 22.5MG | N019821 | 004 | Aug 06, 2009 | Mar | CFTG |
| >A> | AB | | | 22.5MG | N019821 | 004 | Aug 06, 2009 | Mar | CFTG |
| >D> | | + | | 25MG | N019821 | 002 | Oct 28, 1996 | Mar | CFTG |
| >A> | AB | + | | 25MG | N019821 | 002 | Oct 28, 1996 | Mar | CFTG |

ACYCLOVIR

OINTMENT; TOPICAL
>A> ACYCLOVIR

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | | MYLAN PHARMS INC | 5% | A202459 | 001 | Apr 03, 2013 | Mar | NEWA |

ZOVIRAX

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | + | VALEANT INTL | 5% | N018604 | 001 | Mar 29, 1982 | Mar | CFTG |
| >A> | AB | + | | 5% | N018604 | 001 | Mar 29, 1982 | Mar | CFTG |

ALBENDAZOLE

TABLET; ORAL
ALBENZA

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | + | AMEDRA PHARMS | 200MG | N020666 | 001 | Jun 11, 1996 | Feb | CAHN |

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AN | + | MYLAN SPECLT | EQ 0.083% BASE | A072652 | 001 | Feb 21, 1992 | Jan | CAHN |
| >D> | AN | | WOCKHARDT | EQ 0.083% BASE | A075394 | 001 | Nov 22, 1999 | Mar | DISC |
| >A> | | | @ WOCKHARDT EU OPERATN | EQ 0.083% BASE | A075394 | 001 | Nov 22, 1999 | Mar | DISC |

ALENDRONATE SODIUM

SOLUTION; ORAL
ALENDRONATE SODIUM

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AA | | ROXANE | EQ 70MG BASE/75ML | A090520 | 001 | Feb 25, 2013 | Feb | NEWA |

FOSAMAX

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AA | + | MERCK | EQ 70MG BASE/75ML | N021575 | 001 | Sep 17, 2003 | Feb | CFTG |

ALOGLIPTIN BENZOATE

TABLET; ORAL
NESINA

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | TAKEDA PHARMS USA | EQ 6.25MG BASE | N022271 | 001 | Jan 25, 2013 | Jan | NEWA |
| | | | | EQ 12.5MG BASE | N022271 | 002 | Jan 25, 2013 | Jan | NEWA |
| | | + | | EQ 25MG BASE | N022271 | 003 | Jan 25, 2013 | Jan | NEWA |

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
KAZANO

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | TAKEDA PHARMS USA | EQ 12.5MG BASE;500MG | N203414 | 001 | Jan 25, 2013 | Jan | NEWA |
| | | + | | EQ 12.5MG BASE;1GM | N203414 | 002 | Jan 25, 2013 | Jan | NEWA |

ALOGLIPTIN BENZOATE; PIOGLITAZONE

TABLET; ORAL
OSENI

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | TAKEDA PHARMS USA | EQ 12.5MG BASE;EQ 15MG BASE | N022426 | 004 | Jan 25, 2013 | Jan | NEWA |
| | | | | EQ 12.5MG BASE;EQ 30MG BASE | N022426 | 005 | Jan 25, 2013 | Jan | NEWA |
| | | | | EQ 12.5MG BASE;EQ 45MG BASE | N022426 | 006 | Jan 25, 2013 | Jan | NEWA |
| | | | | EQ 25MG BASE;EQ 15MG BASE | N022426 | 001 | Jan 25, 2013 | Jan | NEWA |
| | | | | EQ 25MG BASE;EQ 30MG BASE | N022426 | 002 | Jan 25, 2013 | Jan | NEWA |
| | | + | | EQ 25MG BASE;EQ 45MG BASE | N022426 | 003 | Jan 25, 2013 | Jan | NEWA |

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSENI

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | TAKEDA PHARMS USA | EQ 12.5MG BASE;EQ 15MG BASE | N022426 | 004 | Jan 25, 2013 | Feb | CAIN |
| | | | EQ 12.5MG BASE;EQ 30MG BASE | N022426 | 005 | Jan 25, 2013 | Feb | CAIN |
| | | | EQ 12.5MG BASE;EQ 45MG BASE | N022426 | 006 | Jan 25, 2013 | Feb | CAIN |
| | | | EQ 25MG BASE;EQ 15MG BASE | N022426 | 001 | Jan 25, 2013 | Feb | CAIN |
| | | | EQ 25MG BASE;EQ 30MG BASE | N022426 | 002 | Jan 25, 2013 | Feb | CAIN |
| | + | | EQ 25MG BASE;EQ 45MG BASE | N022426 | 003 | Jan 25, 2013 | Feb | CAIN |

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AP | | HOSPIRA | EQ 250MG BASE/ML | A063264 | 001 | Nov 30, 1994 | Mar | DISC |
| >A> | | | @ | EQ 250MG BASE/ML | A063264 | 001 | Nov 30, 1994 | Mar | DISC |

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

>A> AMLODIPINE BESYLATE AND VALSARTAN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | | PAR PHARM INC | EQ 5MG BASE;160MG | A090011 | 001 | Mar 28, 2013 | Mar | NEWA |
| >A> | AB | | | EQ 5MG BASE;320MG | A090144 | 001 | Mar 28, 2013 | Mar | NEWA |
| >A> | AB | | | EQ 10MG BASE;160MG | A090011 | 002 | Mar 28, 2013 | Mar | NEWA |
| >A> | AB | | | EQ 10MG BASE;320MG | A090011 | 004 | Mar 28, 2013 | Mar | NEWA |

EXFORGE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | | NOVARTIS | EQ 5MG BASE;160MG | N021990 | 002 | Jun 20, 2007 | Mar | CFTG |
| >A> | AB | | | EQ 5MG BASE;160MG | N021990 | 002 | Jun 20, 2007 | Mar | CFTG |
| >D> | | | | EQ 5MG BASE;320MG | N021990 | 004 | Jun 20, 2007 | Mar | CFTG |
| >A> | AB | | | EQ 5MG BASE;320MG | N021990 | 004 | Jun 20, 2007 | Mar | CFTG |
| >D> | | + | | EQ 10MG BASE;160MG | N021990 | 003 | Jun 20, 2007 | Mar | CFTG |
| >A> | AB | + | | EQ 10MG BASE;160MG | N021990 | 003 | Jun 20, 2007 | Mar | CFTG |
| >D> | | + | | EQ 10MG BASE;320MG | N021990 | 005 | Jun 20, 2007 | Mar | CFTG |
| >A> | AB | + | | EQ 10MG BASE;320MG | N021990 | 005 | Jun 20, 2007 | Mar | CFTG |

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AP | | CARDINAL HEALTH 414 | 30MCI-300MCI/8ML (3.75-37.5MCI/ML) | A203700 | 001 | Feb 25, 2013 | Feb | NEWA |
| | AP | + | FEINSTEIN | 30MCI-300MCI/8ML (3.75-37.5MCI/ML) | N022119 | 001 | Aug 23, 2007 | Feb | CFTG |
| | AP | | MCPRF | 30MCI-300MCI/8ML (3.75-37.5MCI/ML) | A203321 | 001 | Feb 25, 2013 | Feb | NEWA |

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | @ RANBAXY | 200MG/5ML | A065113 | 001 | Nov 29, 2002 | Feb | DISC |
| | | | @ | 400MG/5ML | A065113 | 002 | Nov 29, 2002 | Feb | DISC |

TABLET, CHEWABLE; ORAL

AMOXICILLIN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | | DAVA PHARMS INC | 125MG | A064139 | 001 | Jan 29, 1996 | Mar | DISC |
| >A> | | | @ | 125MG | A064139 | 001 | Jan 29, 1996 | Mar | DISC |
| >D> | AB | | | 250MG | A064139 | 002 | Jan 29, 1996 | Mar | DISC |
| >A> | | | @ | 250MG | A064139 | 002 | Jan 29, 1996 | Mar | DISC |
| | | | @ RANBAXY | 200MG | A065060 | 001 | Nov 29, 2000 | Feb | DISC |
| | | | @ | 400MG | A065060 | 002 | Nov 29, 2000 | Feb | DISC |

TABLET, CHEWABLE; ORAL
AMOXIL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ DR REDDYS LABS INC | 200MG | N050761 | 001 | Apr 15, 1999 | Feb | DISC |
| | @ | 400MG | N050761 | 002 | Apr 15, 1999 | Feb | DISC |

TABLET, FOR SUSPENSION; ORAL
AMOXICILLIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ AUROBINDO PHARMA LTD | 200MG | A065324 | 001 | Jan 17, 2007 | Jan | DISC |
| | @ | 400MG | A065324 | 002 | Jan 17, 2007 | Jan | DISC |

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | BARR LABS INC | 1.25MG;1.25MG;1.25MG;1.25MG | A076536 | 001 | Feb 12, 2013 | Jan | NEWA |
| AB | | 2.5MG;2.5MG;2.5MG;2.5MG | A076536 | 002 | Feb 12, 2013 | Jan | NEWA |
| AB | | 3.75MG;3.75MG;3.75MG;3.75MG | A076536 | 003 | Feb 12, 2013 | Jan | NEWA |
| AB | | 5MG;5MG;5MG;5MG | A076536 | 004 | Feb 12, 2013 | Jan | NEWA |
| AB | | 6.25MG;6.25MG;6.25MG;6.25MG | A076536 | 005 | Feb 12, 2013 | Jan | NEWA |
| AB | | 7.5MG;7.5MG;7.5MG;7.5MG | A076536 | 006 | Feb 12, 2013 | Jan | NEWA |

TABLET; ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| @ TEVA PHARMS | 1.25MG;1.25MG;1.25MG;1.25MG | A040472 | 001 | Sep 30, 2003 | Jan | DISC |
| @ | 2.5MG;2.5MG;2.5MG;2.5MG | A040472 | 002 | Sep 30, 2003 | Jan | DISC |
| @ | 5MG;5MG;5MG;5MG | A040472 | 003 | Sep 30, 2003 | Jan | DISC |
| @ | 7.5MG;7.5MG;7.5MG;7.5MG | A040472 | 004 | Sep 30, 2003 | Jan | DISC |

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AP | ACS DOBFAR SPA | EQ 500MG BASE/VIAL | A090884 | 001 | Apr 03, 2013 | Mar | NEWA |
| >A> | AP | | EQ 1GM BASE/VIAL | A090884 | 002 | Apr 03, 2013 | Mar | NEWA |
| >A> | AP | | EQ 2GM BASE/VIAL | A090884 | 003 | Apr 03, 2013 | Mar | NEWA |
| >A> | AP | | EQ 10GM BASE/VIAL | A090889 | 001 | Apr 03, 2013 | Mar | NEWA |

ANASTROZOLE

TABLET; ORAL
ANASTROZOLE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ KUDCO IRELAND | 1MG | A091331 | 001 | Jan 05, 2011 | Feb | DISC |

ARIPIPRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
ABILIFY MAINTENA KIT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | OTSUKA PHARM CO LTD | 300MG/VIAL | N202971 | 001 | Feb 28, 2013 | Feb | NEWA |
| + | | 400MG/VIAL | N202971 | 002 | Feb 28, 2013 | Feb | NEWA |

ATENOLOL

TABLET; ORAL
ATENOLOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | WATSON LABS | 50MG | A073352 | 001 | Dec 27, 1991 | Mar | DISC |
| >A> | | @ | 50MG | A073352 | 001 | Dec 27, 1991 | Mar | DISC |
| >D> | AB | | 100MG | A073353 | 001 | Dec 27, 1991 | Mar | DISC |
| >A> | | @ | 100MG | A073353 | 001 | Dec 27, 1991 | Mar | DISC |

ATORVASTATIN CALCIUM

TABLET; ORAL
ATORVASTATIN CALCIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | KUDCO IRELAND | EQ 10MG BASE | A091624 | 001 | Apr 05, 2013 | Mar | NEWA |
| >A> | AB | | EQ 20MG BASE | A091624 | 002 | Apr 05, 2013 | Mar | NEWA |
| >A> | AB | | EQ 40MG BASE | A091624 | 003 | Apr 05, 2013 | Mar | NEWA |
| >A> | AB | | EQ 80MG BASE | A091624 | 004 | Apr 05, 2013 | Mar | NEWA |

AZITHROMYCIN

INJECTABLE; INJECTION
AZITHROMYCIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AP | SUN PHARM INDS LTD | EQ 500MG BASE/VIAL | A090923 | 001 | Apr 02, 2013 | Mar | NEWA |

BACITRACIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | POWDER; FOR RX COMPOUNDING | | | | | | |
| >D> | | BACI-RX | | | | | | |
| >D> | | X GEN PHARMS | 5,000,000 UNITS/BOT | A061580 | 001 | | Mar | DISC |
| >A> | | @ | 5,000,000 UNITS/BOT | A061580 | 001 | | Mar | DISC |

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL
BENZPHETAMINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ COREPHARMA | 50MG | A040714 | 001 | Oct 29, 2007 | Feb | DISC |

BENZTROPINE MESYLATE

INJECTABLE; INJECTION
BENZTROPINE MESYLATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | NAVINTA LLC | 1MG/ML | A091525 | 001 | Feb 05, 2013 | Jan | NEWA |

TABLET; ORAL
BENZTROPINE MESYLATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AA | PROSAM LABS | 0.5MG | A040699 | 001 | Feb 14, 2008 | Mar | DISC |
| >A> | | @ | 0.5MG | A040699 | 001 | Feb 14, 2008 | Mar | DISC |
| >D> | AA | | 1MG | A040705 | 001 | Feb 14, 2008 | Mar | DISC |
| >A> | | @ | 1MG | A040705 | 001 | Feb 14, 2008 | Mar | DISC |
| >D> | AA | | 2MG | A040706 | 001 | Feb 14, 2008 | Mar | DISC |
| >A> | | @ | 2MG | A040706 | 001 | Feb 14, 2008 | Mar | DISC |

BEXAROTENE

GEL; TOPICAL
TARGRETIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | + | VALEANT PHARMS INC | 1% | N021056 | 001 | Jun 28, 2000 | Feb | CAHN |

BLEOMYCIN SULFATE

INJECTABLE; INJECTION
BLEOMYCIN SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ PHARMACHEMIE BV | EQ 15 UNITS BASE/VIAL | A065201 | 001 | Dec 13, 2007 | Feb | DISC |

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
BROMFENAC SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AT | LUITPOLD | 0.09% | A202030 | 001 | Jan 09, 2013 | Feb | CAHN |

BUDESONIDE

TABLET, EXTENDED RELEASE; ORAL

UCERIS

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| + | | SANTARUS | 9MG | N203634 | 001 | Jan 14, 2013 | Jan | NEWA |

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | ACTAVIS ELIZABETH | EQ 2MG BASE;EQ 0.5MG BASE | A091422 | 001 | Feb 22, 2013 | Feb | NEWA |
| | AB | | | EQ 8MG BASE;EQ 2MG BASE | A091422 | 002 | Feb 22, 2013 | Feb | NEWA |
| | AB | | AMNEAL PHARMS | EQ 2MG BASE;EQ 0.5MG BASE | A203136 | 001 | Feb 22, 2013 | Feb | NEWA |
| | AB | | | EQ 8MG BASE;EQ 2MG BASE | A203136 | 002 | Feb 22, 2013 | Feb | NEWA |
| >D> | | | SUBOXONE | | | | | | |
| >D> | AB | | RECKITT BENCKISER | EQ 2MG BASE;EQ 0.5MG BASE | N020733 | 001 | Oct 08, 2002 | Mar | DISC |
| >A> | | | @ | EQ 2MG BASE;EQ 0.5MG BASE | N020733 | 001 | Oct 08, 2002 | Mar | DISC |
| | AB | | | EQ 2MG BASE;EQ 0.5MG BASE | N020733 | 001 | Oct 08, 2002 | Feb | CFTG |
| >D> | AB | + | | EQ 8MG BASE;EQ 2MG BASE | N020733 | 002 | Oct 08, 2002 | Mar | DISC |
| >A> | | | @ | EQ 8MG BASE;EQ 2MG BASE | N020733 | 002 | Oct 08, 2002 | Mar | DISC |
| | AB | + | | EQ 8MG BASE;EQ 2MG BASE | N020733 | 002 | Oct 08, 2002 | Feb | CFTG |

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | @ TEVA | 75MG | A075310 | 001 | Nov 29, 1999 | Feb | CDFR |
| | | | @ | 100MG | A075310 | 002 | Nov 29, 1999 | Feb | DISC |

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | | PERRIGO ISRAEL | 2% | A200923 | 001 | May 18, 2012 | Mar | CRLD |
| >A> | | + | | 2% | A200923 | 001 | May 18, 2012 | Mar | CRLD |
| >D> | | | GYNAZOLE-1 | | | | | | |
| >D> | AB | + | KV PHARM | 2% | N019881 | 001 | Feb 07, 1997 | Mar | DISC |
| >A> | | | @ | 2% | N019881 | 001 | Feb 07, 1997 | Mar | DISC |

CABERGOLINE

TABLET; ORAL

CABERGOLINE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | APOTEX CORP | 0.5MG | A201503 | 001 | Mar 08, 2013 | Feb | NEWA |

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | | @ MIKART | 100MG;1MG | A040590 | 001 | Sep 16, 2005 | Mar | CMFD |
| >A> | AA | | | 100MG;1MG | A040590 | 001 | Sep 16, 2005 | Mar | CMFD |
| | | | @ | 100MG;1MG | A040590 | 001 | Sep 16, 2005 | Jan | DISC |

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | INVAGEN PHARMS | EQ 169MG CALCIUM | A203135 | 001 | Feb 07, 2013 | Jan | NEWA |

TABLET; ORAL

CALCIUM ACETATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | INVAGEN PHARMS | EQ 169MG CALCIUM | A202420 | 001 | Feb 05, 2013 | Jan | NEWA |

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | + | B BRAUN | 35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML | N019867 | 001 | Dec 20, 1993 | Mar | DISC |
| >A> | @ | | 35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML | N019867 | 001 | Dec 20, 1993 | Mar | DISC |

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | FRESENIUS | 18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N020374 | 001 | Jun 13, 1994 | Feb | DISC |

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | FRESENIUS | 18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N020374 | 002 | Jun 13, 1994 | Feb | DISC |

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | FRESENIUS | 18.4MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N020374 | 003 | Jun 13, 1994 | Feb | DISC |

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | FRESENIUS | 18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N020374 | 004 | Jun 13, 1994 | Feb | DISC |

>A> CANAGLIFLOZIN

>A> TABLET; ORAL

>A> INVOKANA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | JANSSEN RES AND DEV | 100MG | N204042 | 001 | Mar 29, 2013 | Mar | NEWA |
| >A> | + | | 300MG | N204042 | 002 | Mar 29, 2013 | Mar | NEWA |

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ACCORD HLTHCARE | 25MG;100MG | A202323 | 001 | Feb 08, 2013 | Jan | NEWA |
| AB | | | 50MG;200MG | A202323 | 002 | Feb 08, 2013 | Jan | NEWA |

CARBINOXAMINE MALEATE

>A> SUSPENSION, EXTENDED RELEASE; ORAL

>A> KARBINAL ER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | + | TRIS PHARMA INC | 4MG/5ML | N022556 | 001 | Mar 28, 2013 | Mar | NEWA |

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | PLIVA | 50MG/VIAL | A076602 | 001 | Nov 16, 2004 | Feb | DISC |
| @ | | 150MG/VIAL | A076602 | 002 | Nov 16, 2004 | Feb | DISC |
| @ | | 450MG/VIAL | A076602 | 003 | Nov 16, 2004 | Feb | DISC |

INJECTABLE; IV (INFUSION)

CARBOPLATIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AP | FRESENIUS KABI USA | 50MG/5ML (10MG/ML) | A077266 | 001 | Feb 15, 2006 | Mar | DISC |
| >A> | @ | | 50MG/5ML (10MG/ML) | A077266 | 001 | Feb 15, 2006 | Mar | DISC |
| >D> | AP | | 150MG/15ML (10MG/ML) | A077266 | 002 | Feb 15, 2006 | Mar | DISC |
| >A> | @ | | 150MG/15ML (10MG/ML) | A077266 | 002 | Feb 15, 2006 | Mar | DISC |

PARAPLATIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | @ | BRISTOL MYERS SQUIBB | 50MG/5ML (10MG/ML) | N020452 | 001 | Jul 14, 2003 | Mar | CAHN |
| >D> | @ | | 150MG/15ML (10MG/ML) | N020452 | 002 | Jul 14, 2003 | Mar | CAHN |

INJECTABLE; IV (INFUSION)
PARAPLATIN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | @ BRISTOL MYERS SQUIBB | 450MG/45ML (10MG/ML) | N020452 | 003 | Jul 14, 2003 | Mar | CAHN |
| >D> | | @ | 600MG/60ML (10MG/ML) | N020452 | 004 | Jan 15, 2004 | Mar | CAHN |
| >A> | | @ CORDENPHARMA | 50MG/5ML (10MG/ML) | N020452 | 001 | Jul 14, 2003 | Mar | CAHN |
| >A> | | @ | 150MG/15ML (10MG/ML) | N020452 | 002 | Jul 14, 2003 | Mar | CAHN |
| >A> | | @ | 450MG/45ML (10MG/ML) | N020452 | 003 | Jul 14, 2003 | Mar | CAHN |
| >A> | | @ | 600MG/60ML (10MG/ML) | N020452 | 004 | Jan 15, 2004 | Mar | CAHN |

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ COREPHARMA | 350MG | A040397 | 001 | Sep 21, 2000 | Feb | DISC |

CARMUSTINE

IMPLANT; INTRACRANIAL
GLIADEL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | + ARBOR PHARMS INC | 7.7MG | N020637 | 001 | Sep 23, 1996 | Mar | CAHN |
| >A> | | + ARBOR PHARMS LLC | 7.7MG | N020637 | 001 | Sep 23, 1996 | Mar | CAHN |

INJECTABLE; INJECTION
BICNU

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | + EMCURE PHARMS LTD | 100MG/VIAL | N017422 | 001 | | Jan | CAHN |

CARVEDILOL

TABLET; ORAL
CARVEDILOL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ WOCKHARDT LTD | 3.125MG | A078786 | 001 | Dec 22, 2009 | Feb | DISC |
| | | @ | 6.25MG | A078786 | 002 | Dec 22, 2009 | Feb | DISC |
| | | @ | 12.5MG | A078786 | 003 | Dec 22, 2009 | Feb | DISC |
| | | @ | 25MG | A078786 | 004 | Dec 22, 2009 | Feb | DISC |

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL
CEFADROXIL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | TEVA PHARMS | EQ 250MG BASE/5ML | A065278 | 001 | Jan 20, 2006 | Mar | DISC |
| >D> | AB | | EQ 500MG BASE/5ML | A065278 | 002 | Jan 20, 2006 | Mar | DISC |
| >A> | | @ TEVA PHARMS USA | EQ 250MG BASE/5ML | A065278 | 001 | Jan 20, 2006 | Mar | DISC |
| >A> | | @ | EQ 500MG BASE/5ML | A065278 | 002 | Jan 20, 2006 | Mar | DISC |

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AP | + HOSPIRA INC | EQ 500MG BASE/VIAL | A065226 | 001 | Apr 21, 2005 | Feb | CRLD |
| | AP | + | EQ 1GM BASE/VIAL | A065226 | 002 | Apr 21, 2005 | Feb | CRLD |
| | AP | + | EQ 1GM BASE/VIAL | A065244 | 001 | Aug 12, 2005 | Feb | CRLD |
| | AP | + | EQ 10GM BASE/VIAL | A065247 | 001 | Aug 12, 2005 | Feb | CRLD |

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AP | SANDOZ | EQ 500MG BASE/VIAL | A090291 | 001 | Dec 21, 2010 | Mar | DISC |
| >A> | | @ | EQ 500MG BASE/VIAL | A090291 | 001 | Dec 21, 2010 | Mar | DISC |
| >D> | AP | | EQ 1GM BASE/VIAL | A090291 | 002 | Dec 21, 2010 | Mar | DISC |
| >A> | | @ | EQ 1GM BASE/VIAL | A090291 | 002 | Dec 21, 2010 | Mar | DISC |
| >D> | AP | | EQ 2GM BASE/VIAL | A090291 | 003 | Dec 21, 2010 | Mar | DISC |
| >A> | | @ | EQ 2GM BASE/VIAL | A090291 | 003 | Dec 21, 2010 | Mar | DISC |

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | + | LUPIN LTD | 500MG/5ML | N202091 | 001 | Feb 20, 2013 | Feb | CDFR |
| | | | LUPIN PHARMS | 100MG/5ML | A065129 | 001 | Feb 23, 2004 | Feb | CDFR |
| | | | | 200MG/5ML | A065355 | 001 | Apr 10, 2007 | Feb | CDFR |

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | | ALKEM LABS LTD | EQ 333MG BASE | A090836 | 003 | Mar 29, 2013 | Mar | NEWA |
| >A> | AB | | | EQ 750MG BASE | A090836 | 004 | Mar 29, 2013 | Mar | NEWA |

KEFLEX

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | + | SHIONOGI INC | EQ 750MG BASE | N050405 | 005 | May 12, 2006 | Mar | CTEC |
| >A> | AB | + | | EQ 750MG BASE | N050405 | 005 | May 12, 2006 | Mar | CTEC |

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | AUROBINDO PHARMA LTD | 5MG/5ML | A090751 | 001 | Dec 16, 2009 | Feb | DISC |

CHLOROTHIAZIDE

TABLET; ORAL

DIURIL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | OAK PHARMS AKORN | 250MG | N011145 | 004 | | Jan | CAHN |
| | | @ | | 500MG | N011145 | 002 | | Jan | CAHN |

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

DIURIL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AP | + | OAK PHARMS AKORN | EQ 500MG BASE/VIAL | N011145 | 005 | | Jan | CAHN |

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

VITUZ

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | + | CYPRESS PHARM | 4MG/5ML;5MG/5ML | N204307 | 001 | Feb 20, 2013 | Feb | NEWA |

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | WATSON LABS INC | 100MG | A088852 | 001 | Sep 26, 1984 | Jan | DISC |
| | | @ | | 250MG | A088826 | 001 | Sep 26, 1984 | Jan | DISC |

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | | MYLAN PHARMS INC | EQ 45MG FENOFIBRIC ACID | A200913 | 001 | Mar 25, 2013 | Mar | NEWA |
| >A> | AB | | | EQ 135MG FENOFIBRIC ACID | A200913 | 002 | Mar 25, 2013 | Mar | NEWA |

TRILIPIX

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | | ABBVIE | EQ 45MG FENOFIBRIC ACID | N022224 | 001 | Dec 15, 2008 | Mar | CFTG |
| >A> | AB | | | EQ 45MG FENOFIBRIC ACID | N022224 | 001 | Dec 15, 2008 | Mar | CFTG |
| >D> | | + | | EQ 135MG FENOFIBRIC ACID | N022224 | 002 | Dec 15, 2008 | Mar | CFTG |
| >A> | AB | + | | EQ 135MG FENOFIBRIC ACID | N022224 | 002 | Dec 15, 2008 | Mar | CFTG |

CICLOPIROX

SOLUTION; TOPICAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | CICLOPIROX | | | | | | | |
| | | @ TEVA PHARMS | 8% | A078079 | 001 | Sep 18, 2007 | Jan | DISC | |
| | | PENLAC | | | | | | | |
| | AT | + VALEANT INTL | 8% | N021022 | 001 | Dec 17, 1999 | Feb | CAHN | |

CISPLATIN

INJECTABLE; INJECTION

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | PLATINOL | | | | | | | |
| | | @ HQ SPCLT PHARMA | 10MG/VIAL | N018057 | 001 | | Jan | CAHN | |
| | | @ | 50MG/VIAL | N018057 | 002 | | Jan | CAHN | |
| | | PLATINOL-AQ | | | | | | | |
| | | @ HQ SPCLT PHARMA | 0.5MG/ML | N018057 | 003 | Jul 18, 1984 | Jan | CAHN | |
| | | @ | 1MG/ML | N018057 | 004 | Nov 08, 1988 | Jan | CAHN | |

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | CITALOPRAM HYDROBROMIDE | | | | | | | |
| | | @ COREPHARMA | EQ 10MG BASE | A077036 | 001 | Oct 28, 2004 | Feb | DISC | |
| | | @ | EQ 20MG BASE | A077036 | 002 | Oct 28, 2004 | Feb | DISC | |
| | | @ | EQ 40MG BASE | A077036 | 003 | Oct 28, 2004 | Feb | DISC | |

CLEMASTINE FUMARATE

SYRUP; ORAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | CLEMASTINE FUMARATE | | | | | | | |
| >D> | AA | SILARX | EQ 0.5MG BASE/5ML | A074884 | 001 | Dec 17, 1997 | Mar | DISC | |
| >A> | | @ | EQ 0.5MG BASE/5ML | A074884 | 001 | Dec 17, 1997 | Mar | DISC | |

CLEVIDIPINE

EMULSION; INTRAVENOUS

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | CLEVIPREX | | | | | | | |
| | | + MEDICINES CO | 25MG/50ML (0.5MG/ML) | N022156 | 001 | Aug 01, 2008 | Feb | CAIN | |
| | | + | 50MG/100ML (0.5MG/ML) | N022156 | 002 | Aug 01, 2008 | Feb | CAIN | |

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER | | | | | | | |
| >A> | AP | AKORN INC | EQ 6MG BASE/ML | A203048 | 001 | Apr 04, 2013 | Mar | NEWA | |
| >A> | AP | | EQ 12MG BASE/ML | A203048 | 002 | Apr 04, 2013 | Mar | NEWA | |
| >A> | AP | | EQ 18MG BASE/ML | A203048 | 003 | Apr 04, 2013 | Mar | NEWA | |

SOLUTION; TOPICAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | CLINDAMYCIN PHOSPHATE | | | | | | | |
| | | @ PERRIGO NEW YORK | EQ 1% BASE | A064050 | 001 | Nov 30, 1995 | Feb | DISC | |

CLONAZEPAM

TABLET; ORAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | CLONAZEPAM | | | | | | | |
| | | @ APOTEX INC | 0.5MG | A075468 | 001 | Oct 06, 2000 | Feb | DISC | |
| | | @ | 1MG | A075468 | 002 | Oct 06, 2000 | Feb | DISC | |
| | | @ | 2MG | A075468 | 003 | Oct 06, 2000 | Feb | DISC | |

CLOPIDOGREL BISULFATE

TABLET; ORAL
CLOPIDOGREL BISULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | ACCORD HLTHCARE | EQ 75MG BASE | A202925 | 001 | Mar 27, 2013 | Mar | NEWA |
| >A> | AB | | EQ 300MG BASE | A202925 | 002 | Mar 27, 2013 | Mar | NEWA |

CLOZAPINE

SUSPENSION; ORAL
VERSACLOZ

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | + DOUGLAS PHARMS | 50MG/ML | N203479 | 001 | Feb 06, 2013 | Mar | CAHN |
| | | + | 50MG/ML | N203479 | 001 | Feb 06, 2013 | Feb | NEWA |
| >A> | | + JAZZ PHARMS III | 50MG/ML | N203479 | 001 | Feb 06, 2013 | Mar | CAHN |

COSYNTROPIN

INJECTABLE; INJECTION
COSYNTROPIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | MYLAN LLC | 0.25MG/VIAL | A090574 | 001 | Dec 17, 2009 | Feb | CAHN |

CROMOLYN SODIUM

CONCENTRATE; ORAL
CROMOLYN SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AA | MICRO LABS LTD INDIA | 100MG/5ML | A202745 | 001 | Apr 04, 2013 | Mar | NEWA |

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
AMRIX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | IVAX INTL | 15MG | N021777 | 001 | Feb 01, 2007 | Jan | CAHN |
| | AB | + | 30MG | N021777 | 002 | Feb 01, 2007 | Jan | CAHN |

CYCLOBENZAPRINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | TWI PHARMS INC | 15MG | A091281 | 001 | Jan 31, 2013 | Jan | NEWA |
| | AB | | 30MG | A091281 | 002 | Jan 31, 2013 | Jan | NEWA |

TABLET; ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | MYLAN PHARMS INC | 7.5MG | A073144 | 003 | Mar 25, 2013 | Mar | NEWA |
| >D> | AB | PROSAM LABS | 5MG | A077291 | 001 | Feb 03, 2006 | Mar | DISC |
| >A> | | @ | 5MG | A077291 | 001 | Feb 03, 2006 | Mar | DISC |

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
AKPENTOLATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AT | AKORN | 2% | A040165 | 001 | Jan 13, 1997 | Mar | DISC |
| >A> | | @ | 2% | A040165 | 001 | Jan 13, 1997 | Mar | DISC |

CYCLOGYL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AT | + ALCON | 2% | A084108 | 001 | | Mar | CTEC |
| >A> | | + ALCON LABS INC | 2% | A084108 | 001 | | Mar | CTEC |

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
CYTOXAN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | | | | | | | |
| >D> | AP | + BAXTER HLTHCARE | 500MG/VIAL | N012142 | 003 | | Mar | CTNA |
| >D> | AP | + | 1GM/VIAL | N012142 | 004 | Aug 30, 1982 | Mar | CTNA |
| >D> | AP | + | 2GM/VIAL | N012142 | 005 | Aug 30, 1982 | Mar | CTNA |
| >A> | | CYTOXAN (LYOPHILIZED) | | | | | | |
| >A> | AP | + BAXTER HLTHCARE | 500MG/VIAL | N012142 | 003 | | Mar | CTNA |
| | | @ | 500MG/VIAL | N012142 | 008 | Jan 04, 1984 | Jan | CTNA |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | INJECTABLE; INJECTION | | | | | | |
| >A> | | | CYTOXAN (LYOPHILIZED) | | | | | | |
| >A> | AP | + | BAXTER HLTHCARE | 1GM/VIAL | N012142 | 004 | Aug 30, 1982 | Mar | CTNA |
| | | @ | | 1GM/VIAL | N012142 | 010 | Sep 24, 1985 | Jan | CTNA |
| >A> | AP | + | | 2GM/VIAL | N012142 | 005 | Aug 30, 1982 | Mar | CTNA |
| | | @ | | 2GM/VIAL | N012142 | 009 | Dec 10, 1985 | Jan | CTNA |
| | | | CYPROHEPTADINE HYDROCHLORIDE | | | | | | |
| | | | SYRUP; ORAL | | | | | | |
| | | | CYPROHEPTADINE HYDROCHLORIDE | | | | | | |
| >A> | AA | | PHARM ASSOC | 2MG/5ML | A091295 | 001 | Mar 28, 2013 | Mar | NEWA |
| | | | DESMOPRESSIN ACETATE | | | | | | |
| | | | INJECTABLE; INJECTION | | | | | | |
| | | | DESMOPRESSIN ACETATE | | | | | | |
| | AP | | SUN PHARM INDS LTD | 0.004MG/ML | A091280 | 001 | Jan 25, 2013 | Jan | NEWA |
| | | | DESOGESTREL; ETHINYL ESTRADIOL | | | | | | |
| | | | TABLET; ORAL-28 | | | | | | |
| | | | ENSKYCE | | | | | | |
| | AB | | LUPIN LTD | 0.15MG;0.03MG | A201887 | 001 | Mar 07, 2013 | Feb | NEWA |
| | | | DESVENLAFAXINE | | | | | | |
| >A> | | | TABLET, EXTENDED RELEASE; ORAL | | | | | | |
| >A> | | | DESVENLAFAXINE | | | | | | |
| >A> | | | ALEMBIC PHARMS LTD | 50MG | N204150 | 001 | Mar 04, 2013 | Mar | NEWA |
| >A> | | + | | 100MG | N204150 | 002 | Mar 04, 2013 | Mar | NEWA |
| | | | DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE | | | | | | |
| | | | SUSPENSION/DROPS; OPHTHALMIC | | | | | | |
| | | | NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE | | | | | | |
| | | @ | ALCON PHARMS LTD | 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A062721 | 001 | Nov 17, 1986 | Jan | DISC |
| | | | DEXMEDETOMIDINE HYDROCHLORIDE | | | | | | |
| | | | INJECTABLE; INJECTION | | | | | | |
| | | | PRECEDEX | | | | | | |
| >A> | | + | HOSPIRA | EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) | N021038 | 002 | Mar 13, 2013 | Mar | NEWA |
| >A> | | + | | EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) | N021038 | 003 | Mar 13, 2013 | Mar | NEWA |
| | | | DEXTROSE; POTASSIUM CHLORIDE | | | | | | |
| | | | INJECTABLE; INJECTION | | | | | | |
| | | | POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | | | |
| | | @ | B BRAUN | 5GM/100ML;220MG/100ML | N018744 | 003 | Nov 09, 1982 | Jan | DISC |
| | | | DILTIAZEM HYDROCHLORIDE | | | | | | |
| | | | CAPSULE, EXTENDED RELEASE; ORAL | | | | | | |
| | | | DILTIAZEM HYDROCHLORIDE | | | | | | |
| | AB3 | | PAR PHARM | 120MG | A074984 | 001 | Dec 20, 1999 | Jan | CAHN |
| | AB3 | | | 180MG | A074984 | 002 | Dec 20, 1999 | Jan | CAHN |
| | AB3 | | | 240MG | A074984 | 003 | Dec 20, 1999 | Jan | CAHN |
| | AB3 | | | 300MG | A074984 | 004 | Dec 20, 1999 | Jan | CAHN |
| | AB4 | | SANDOZ | 120MG | A091022 | 001 | Sep 28, 2012 | Feb | CAHN |
| | AB4 | | | 180MG | A091022 | 002 | Sep 28, 2012 | Feb | CAHN |
| | AB4 | | | 240MG | A091022 | 003 | Sep 28, 2012 | Feb | CAHN |

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB4 | SANDOZ | 300MG | A091022 | 004 | Sep 28, 2012 | Feb | CAHN |
| AB4 | | 360MG | A091022 | 005 | Sep 28, 2012 | Feb | CAHN |
| AB4 | | 420MG | A091022 | 006 | Sep 28, 2012 | Feb | CAHN |

TABLET; ORAL
DILTIAZEM HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ DAVA PHARMS INC | 30MG | A074093 | 001 | Nov 05, 1992 | Jan | DISC |
| | @ | 60MG | A074093 | 002 | Nov 05, 1992 | Jan | DISC |
| | @ | 90MG | A074093 | 003 | Nov 05, 1992 | Jan | DISC |
| | @ | 120MG | A074093 | 004 | Nov 05, 1992 | Jan | DISC |

>A> DIMETHYL FUMARATE

>A> CAPSULE, DELAYED RELEASE; ORAL
>A> TECFIDERA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | BIOGEN IDEC INC | 120MG | N204063 | 001 | Mar 27, 2013 | Mar | NEWA |
| >A> | + | 240MG | N204063 | 002 | Mar 27, 2013 | Mar | NEWA |

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | + WATSON LABS | 10MG/ML | A080873 | 001 | | Mar | DISC |
| >D> | AP | 50MG/ML | A080873 | 002 | | Mar | DISC |
| >A> | @ WATSON LABS INC | 10MG/ML | A080873 | 001 | | Mar | DISC |
| >A> | @ | 50MG/ML | A080873 | 002 | | Mar | DISC |

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AP BD RX | 50MG/ML | A091526 | 001 | Mar 26, 2013 | Mar | NEWA |
| >D> | AP WATSON LABS | 50MG/ML | A080873 | 003 | | Mar | DISC |
| >A> | @ WATSON LABS INC | 50MG/ML | A080873 | 003 | | Mar | DISC |

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL
DIVALPROEX SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB TEVA PHARMS | EQ 500MG VALPROIC ACID | A078700 | 001 | Aug 03, 2009 | Mar | DISC |
| >A> | @ TEVA PHARMS USA | EQ 500MG VALPROIC ACID | A078700 | 001 | Aug 03, 2009 | Mar | DISC |

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL
DONEPEZIL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ ACCORD HLTHCARE | 5MG | A201335 | 001 | Aug 29, 2011 | Jan | DISC |
| | @ | 10MG | A201335 | 002 | Aug 29, 2011 | Jan | DISC |
| AB | ALEMBIC PHARMS LTD | 5MG | A201724 | 001 | Feb 25, 2013 | Feb | NEWA |
| AB | | 10MG | A201724 | 002 | Feb 25, 2013 | Feb | NEWA |

DOXAZOSIN MESYLATE

TABLET; ORAL
DOXAZOSIN MESYLATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ WATSON LABS INC | EQ 1MG BASE | A075426 | 001 | Oct 18, 2000 | Jan | DISC |
| | @ | EQ 2MG BASE | A075426 | 002 | Oct 18, 2000 | Jan | DISC |
| | @ | EQ 4MG BASE | A075426 | 003 | Oct 18, 2000 | Jan | DISC |
| | @ | EQ 8MG BASE | A075426 | 004 | Oct 18, 2000 | Jan | DISC |

DOXEPIN HYDROCHLORIDE

CONCENTRATE; ORAL
DOXEPIN HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AA PHARM ASSOC | EQ 10MG BASE/ML | A075924 | 001 | Jan 15, 2004 | Mar | DISC |

CONCENTRATE; ORAL
DOXEPIN HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | | @ PHARM ASSOC | EQ 10MG BASE/ML | A075924 | 001 | Jan 15, 2004 | Mar | DISC |

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AP | | SAGENT PHARMS | 2MG/ML | A091495 | 001 | Mar 18, 2013 | Mar | NEWA |

INJECTABLE, LIPOSOMAL; INJECTION
DOXIL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | + | JANSSEN RES AND DEV | 20MG/10ML (2MG/ML) | N050718 | 001 | Nov 17, 1995 | Jan | CFTG |
| | AB | + | | 50MG/25ML (2MG/ML) | N050718 | 002 | Jun 13, 2000 | Jan | CFTG |

DOXORUBICIN HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | SUN PHARMA GLOBAL | 20MG/10ML (2MG/ML) | A203263 | 001 | Feb 04, 2013 | Jan | NEWA |
| | AB | | | 50MG/25ML (2MG/ML) | A203263 | 002 | Feb 04, 2013 | Jan | NEWA |

DOXYCYCLINE

FOR SUSPENSION; ORAL
DOXYCYCLINE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | | LUPIN LTD | EQ 25MG BASE/5ML | A201678 | 001 | Mar 18, 2013 | Mar | NEWA |

DOXYCYCLINE HYCLATE

TABLET; ORAL
DOXYCYCLINE HYCLATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | | @ BLU CARIBE INC | EQ 50MG BASE | A062269 | 003 | | Mar | CAHN |
| >A> | | | @ | EQ 100MG BASE | A062269 | 002 | Nov 08, 1982 | Mar | CAHN |
| >D> | | | @ TRUXTON INC | EQ 50MG BASE | A062269 | 003 | | Mar | CAHN |
| >D> | | | @ | EQ 100MG BASE | A062269 | 002 | Nov 08, 1982 | Mar | CAHN |

ECONAZOLE NITRATE

CREAM; TOPICAL
ECONAZOLE NITRATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | | IGI LABS INC | 1% | A076574 | 001 | Dec 17, 2004 | Mar | CAHN |
| >D> | AB | | PRASCO | 1% | A076574 | 001 | Dec 17, 2004 | Mar | CAHN |

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | @ MYLAN LLC | 50MG/25ML (2MG/ML) | A065371 | 001 | Nov 28, 2007 | Feb | DISC |
| | | | @ | 200MG/100ML (2MG/ML) | A065371 | 002 | Nov 28, 2007 | Feb | DISC |

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
ERYC

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | + | HOSPIRA | 250MG | N050536 | 001 | | Mar | CAHN |
| >A> | AB | + | MAYNE PHARMA | 250MG | N050536 | 001 | | Mar | CAHN |

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS
>A> ESOMEPRAZOLE SODIUM

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AP | | SUN PHARMA GLOBAL | EQ 20MG BASE/VIAL | A200882 | 001 | Mar 18, 2013 | Mar | NEWA |
| >A> | AP | | | EQ 40MG BASE/VIAL | A200882 | 002 | Mar 18, 2013 | Mar | NEWA |

NEXIUM IV

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | + | ASTRAZENECA | EQ 20MG BASE/VIAL | N021689 | 001 | Mar 31, 2005 | Mar | CFTG |
| >A> | AP | + | | EQ 20MG BASE/VIAL | N021689 | 001 | Mar 31, 2005 | Mar | CFTG |
| >D> | | + | | EQ 40MG BASE/VIAL | N021689 | 002 | Mar 31, 2005 | Mar | CFTG |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | INJECTABLE; INTRAVENOUS | | | | | | |
| | | | NEXIUM IV | | | | | | |
| >A> | AP | + | ASTRAZENECA | EQ 40MG BASE/VIAL | N021689 | 002 | Mar 31, 2005 | Mar | CFTG |
| | | | ESZOPICLONE | | | | | | |
| | | | TABLET; ORAL | | | | | | |
| >A> | | | ESZOPICLONE | | | | | | |
| >A> | AB | | MYLAN PHARMS INC | 1MG | A091151 | 001 | Mar 26, 2013 | Mar | NEWA |
| >A> | AB | | | 2MG | A091151 | 002 | Mar 26, 2013 | Mar | NEWA |
| >A> | AB | | | 3MG | A091151 | 003 | Mar 26, 2013 | Mar | NEWA |
| >A> | AB | | SUN PHARMA GLOBAL | 1MG | A091103 | 001 | Apr 03, 2013 | Mar | NEWA |
| >A> | AB | | | 2MG | A091103 | 002 | Apr 03, 2013 | Mar | NEWA |
| >A> | AB | | | 3MG | A091103 | 003 | Apr 03, 2013 | Mar | NEWA |
| | | | LUNESTA | | | | | | |
| >D> | | | SUNOVION PHARMS INC | 1MG | N021476 | 001 | Dec 15, 2004 | Mar | CTEC |
| >A> | AB | | | 1MG | N021476 | 001 | Dec 15, 2004 | Mar | CTEC |
| >D> | | | | 2MG | N021476 | 002 | Dec 15, 2004 | Mar | CTEC |
| >A> | AB | | | 2MG | N021476 | 002 | Dec 15, 2004 | Mar | CTEC |
| >D> | | + | | 3MG | N021476 | 003 | Dec 15, 2004 | Mar | CTEC |
| >A> | AB | + | | 3MG | N021476 | 003 | Dec 15, 2004 | Mar | CTEC |
| | | | ETHINYL ESTRADIOL; LEVONORGESTREL | | | | | | |
| | | | TABLET; ORAL | | | | | | |
| >A> | | | DAYSEE | | | | | | |
| >A> | AB | | LUPIN LTD | 0.03MG,0.01MG;0.15MG,N/A | A091467 | 001 | Apr 10, 2013 | Mar | NEWA |
| >A> | | | QUARTETTE | | | | | | |
| >A> | | + | TEVA BRANDED PHARM | 0.02MG,0.15MG;0.025MG,0.15MG;0.03 MG,0.15MG;0.01MG,N/A | N204061 | 001 | Mar 28, 2013 | Mar | NEWA |
| | | | TABLET; ORAL-28 | | | | | | |
| | | | LEVONORGESTREL AND ETHINYL ESTRADIOL | | | | | | |
| | AB1 | | LUPIN LTD | 0.02MG;0.1MG | A091425 | 001 | Jan 18, 2013 | Jan | NEWA |
| | | | ETHINYL ESTRADIOL; NORETHINDRONE ACETATE | | | | | | |
| | | | TABLET; ORAL | | | | | | |
| | | | FEMHRT | | | | | | |
| | | | @ WARNER CHILCOTT LLC | 0.005MG;1MG | N021065 | 002 | Oct 15, 1999 | Jan | DISC |
| | | | NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL | | | | | | |
| | | + | BARR LABS INC | 0.005MG;1MG | A076221 | 001 | Nov 06, 2009 | Jan | CRLD |
| | | | ETHINYL ESTRADIOL; NORGESTIMATE | | | | | | |
| | | | TABLET; ORAL-28 | | | | | | |
| | | | ESTARYLLA | | | | | | |
| | AB | | SANDOZ | 0.035MG;0.25MG | A090794 | 001 | Jan 30, 2013 | Jan | NEWA |
| | | | TRI-ESTARYLLA | | | | | | |
| | AB | | SANDOZ | 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG | A090793 | 001 | Jan 30, 2013 | Jan | NEWA |
| | | | ETODOLAC | | | | | | |
| | | | TABLET; ORAL | | | | | | |
| | | | ETODOLAC | | | | | | |
| >D> | AB | | PROSAM LABS | 400MG | A074819 | 001 | Feb 28, 1997 | Mar | DISC |
| >A> | | | @ | 400MG | A074819 | 001 | Feb 28, 1997 | Mar | DISC |
| >D> | AB | | | 500MG | A074819 | 002 | Apr 28, 1998 | Mar | DISC |
| >A> | | | @ | 500MG | A074819 | 002 | Apr 28, 1998 | Mar | DISC |

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE PRESERVATIVE FREE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AP | | AKORN INC | 10MG/ML | A076324 | 001 | Nov 27, 2002 | Mar | CAHN |
| >D> | AP | | CLARIS LIFESCIENCES | 10MG/ML | A076324 | 001 | Nov 27, 2002 | Mar | CAHN |

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AP | | AKORN INC | 10MG/ML | A076322 | 001 | Nov 27, 2002 | Mar | CAHN |
| >D> | AP | | CLARIS LIFESCIENCES | 10MG/ML | A076322 | 001 | Nov 27, 2002 | Mar | CAHN |

FENOFIBRIC ACID

TABLET; ORAL

FIBRICOR

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | MUTUAL PHARM CO INC | 35MG | N022418 | 001 | Aug 14, 2009 | Feb | CAHN |
| | | + | | 105MG | N022418 | 002 | Aug 14, 2009 | Feb | CAHN |

FENOPROFEN CALCIUM

TABLET; ORAL

FENOPROFEN CALCIUM

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | | IVAX SUB TEVA PHARMS | EQ 600MG BASE | A072557 | 001 | Aug 29, 1988 | Mar | DISC |
| >A> | | @ | | EQ 600MG BASE | A072557 | 001 | Aug 29, 1988 | Mar | DISC |
| >D> | AB | + | MYLAN | EQ 600MG BASE | A072267 | 001 | Aug 17, 1988 | Mar | CTEC |
| >A> | | + | MYLAN PHARMS INC | EQ 600MG BASE | A072267 | 001 | Aug 17, 1988 | Mar | CTEC |

FENTANYL CITRATE

TABLET; BUCCAL, SUBLINGUAL

FENTORA

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | CEPHALON | EQ 0.1MG BASE | N021947 | 001 | Sep 25, 2006 | Feb | CDFR |
| | AB | | | EQ 0.2MG BASE | N021947 | 002 | Sep 25, 2006 | Feb | CDFR |
| | | @ | | EQ 0.3MG BASE | N021947 | 006 | Mar 02, 2007 | Feb | CDFR |
| | AB | + | | EQ 0.4MG BASE | N021947 | 003 | Sep 25, 2006 | Feb | CDFR |
| | AB | | | EQ 0.6MG BASE | N021947 | 004 | Sep 25, 2006 | Feb | CDFR |
| | AB | | | EQ 0.8MG BASE | N021947 | 005 | Sep 25, 2006 | Feb | CDFR |

FERUMOXSIL

SUSPENSION; ORAL

GASTROMARK

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | AMAG PHARMS INC | EQ 0.175MG IRON/ML | N020410 | 001 | Dec 06, 1996 | Feb | DISC |

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | | TARO PHARM INDS | 50MG/5ML | A076918 | 001 | Dec 18, 2006 | Mar | DISC |
| >A> | | @ | | 50MG/5ML | A076918 | 001 | Dec 18, 2006 | Mar | DISC |
| >D> | AB | | | 200MG/5ML | A076918 | 002 | Dec 18, 2006 | Mar | DISC |
| >A> | | @ | | 200MG/5ML | A076918 | 002 | Dec 18, 2006 | Mar | DISC |

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AP | + | FRESENIUS KABI USA | 50MG/2ML (25MG/ML) | A078393 | 001 | Oct 15, 2007 | Jan | CRLD |
| | AP | | TEVA PARENTERAL | 50MG/2ML (25MG/ML) | A076661 | 001 | Apr 28, 2004 | Jan | CRLD |

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | + | FEINSTEIN | 20-300mCi/ML | N021870 | 002 | Nov 21, 2008 | Jan | CFTG |
| | | HOUSTON CYCLOTRON | 20-500mCi/ML | A203665 | 001 | Feb 14, 2013 | Jan | NEWA |

FLUOCINONIDE

CREAM; TOPICAL
LIDEX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ CNTY LINE PHARMS | 0.05% | N016908 | 002 | | Jan | CAHN |

LIDEX-E

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ CNTY LINE PHARMS | 0.05% | N016908 | 003 | | Jan | CAHN |

GEL; TOPICAL
FLUOCINONIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | TARO | 0.05% | A074935 | 001 | Jul 29, 1997 | Jan | CRLD |

LIDEX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ CNTY LINE PHARMS | 0.05% | N017373 | 001 | | Jan | CAHN |

OINTMENT; TOPICAL
FLUOCINONIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | + | TARO | 0.05% | A075008 | 001 | Jun 30, 1999 | Jan | CRLD |

LIDEX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ CNTY LINE PHARMS | 0.05% | N016909 | 002 | | Jan | CAHN |

SOLUTION; TOPICAL
FLUOCINONIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AT | + | TARO | 0.05% | A074799 | 001 | Dec 31, 1996 | Jan | CRLD |

LIDEX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ MEDICIS | 0.05% | N018849 | 001 | Apr 06, 1984 | Jan | DISC |

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | + | MYLAN LLC | 500MG/10ML (50MG/ML) | A040743 | 002 | Apr 26, 2007 | Feb | CAHN |
| AP | + | | 1GM/20ML (50MG/ML) | A040743 | 001 | Apr 26, 2007 | Feb | CAHN |

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
FLUOXETINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB1 | BEIJING DOUBLE CRANE | EQ 10MG BASE | A076165 | 001 | Feb 01, 2002 | Mar | CAHN |
| >D> | AB1 | | EQ 20MG BASE | A076165 | 002 | Feb 01, 2002 | Mar | CAHN |
| >D> | AB1 | CARLSBAD | EQ 10MG BASE | A076022 | 001 | Jan 30, 2002 | Mar | DISC |
| >A> | | @ | EQ 10MG BASE | A076022 | 001 | Jan 30, 2002 | Mar | DISC |
| >D> | AB1 | | EQ 20MG BASE | A076022 | 002 | Jan 30, 2002 | Mar | DISC |
| >A> | | @ | EQ 20MG BASE | A076022 | 002 | Jan 30, 2002 | Mar | DISC |
| >A> | AB1 | CR DOUBLE CRANE | EQ 10MG BASE | A076165 | 001 | Feb 01, 2002 | Mar | CAHN |
| >A> | AB1 | | EQ 20MG BASE | A076165 | 002 | Feb 01, 2002 | Mar | CAHN |
| | | @ WOCKHARDT LTD | EQ 10MG BASE | A078143 | 001 | Jan 16, 2008 | Feb | DISC |
| | | @ | EQ 20MG BASE | A078143 | 002 | Jan 16, 2008 | Feb | DISC |
| | | @ | EQ 40MG BASE | A078143 | 003 | Jan 16, 2008 | Feb | DISC |

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | TEVA PHARMS | EQ 25MG BASE;EQ 3MG BASE | A202074 | 001 | Mar 25, 2013 | Mar | NEWA |

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | FLUVOXAMINE MALEATE | | | | | | | |
| >A> | AB | ANCHEN PHARMS | 100MG | A091476 | 001 | Mar 13, 2013 | Mar | NEWA | |
| >A> | AB | | 150MG | A091476 | 002 | Mar 13, 2013 | Mar | NEWA | |
| | | LUVOX CR | | | | | | | |
| >D> | | JAZZ PHARMS | 100MG | N022033 | 001 | Feb 28, 2008 | Mar | CFTG | |
| >A> | AB | | 100MG | N022033 | 001 | Feb 28, 2008 | Mar | CFTG | |
| >D> | + | | 150MG | N022033 | 002 | Feb 28, 2008 | Mar | CFTG | |
| >A> | AB + | | 150MG | N022033 | 002 | Feb 28, 2008 | Mar | CFTG | |

FOSINOPRIL SODIUM

TABLET; ORAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | FOSINOPRIL SODIUM | | | | | | | |
| >D> | AB | WATSON LABS | 10MG | A076987 | 001 | Dec 23, 2004 | Mar | DISC | |
| >A> | | @ | 10MG | A076987 | 001 | Dec 23, 2004 | Mar | DISC | |
| >D> | AB | | 20MG | A076987 | 002 | Dec 23, 2004 | Mar | DISC | |
| >A> | | @ | 20MG | A076987 | 002 | Dec 23, 2004 | Mar | DISC | |
| >D> | AB | | 40MG | A076987 | 003 | Dec 23, 2004 | Mar | DISC | |
| >A> | | @ | 40MG | A076987 | 003 | Dec 23, 2004 | Mar | DISC | |

FUROSEMIDE

INJECTABLE; INJECTION

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | FUROSEMIDE | | | | | | | |
| | | @ INTL MEDICATION | 10MG/ML | N018025 | 001 | | Jan | DISC | |

TABLET; ORAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | FUROSEMIDE | | | | | | | |
| | | @ DAVA PHARMS INC | 20MG | N018415 | 001 | Jul 27, 1982 | Feb | DISC | |
| | | @ | 40MG | N018415 | 002 | Jul 27, 1982 | Feb | DISC | |
| | | @ | 80MG | N018415 | 003 | Nov 26, 1984 | Feb | DISC | |

>A> GADOTERATE MEGLUMINE

>A> SOLUTION; INTRAVENOUS

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | DOTAREM | | | | | | | |
| >A> | + | GUERBET | 37.69GM/100ML (376.9MG/ML) | N204781 | 001 | Mar 20, 2013 | Mar | NEWA | |
| >A> | + | | 3.769GM/10ML (376.9MG/ML) | N204781 | 002 | Mar 20, 2013 | Mar | NEWA | |
| >A> | + | | 5.6535GM/15ML (376.9MG/ML) | N204781 | 003 | Mar 20, 2013 | Mar | NEWA | |
| >A> | + | | 7.538GM/20ML (376.9MG/ML) | N204781 | 004 | Mar 20, 2013 | Mar | NEWA | |

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | EOVIST | | | | | | | |
| | | BAYER HLTHCARE | 2.72145GM/15ML (181.43MG/ML) | N022090 | 002 | Feb 04, 2013 | Feb | NEWA | |

GLIMEPIRIDE

TABLET; ORAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | GLIMEPIRIDE | | | | | | | |
| | | @ COREPHARMA | 1MG | A077274 | 001 | Oct 06, 2005 | Feb | DISC | |
| | | @ | 2MG | A077274 | 002 | Oct 06, 2005 | Feb | DISC | |
| | | @ | 4MG | A077274 | 003 | Oct 06, 2005 | Feb | DISC | |

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | RAVICTI | | | | | | | |
| | + | HYPERION THERAP INC | 1.1GM/ML | N203284 | 001 | Feb 01, 2013 | Feb | NEWA | |

GLYCOPYRROLATE

TABLET; ORAL
GLYCOPYRROLATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AA | COREPHARMA | 1MG | A040568 | 001 | Dec 22, 2004 | Mar | DISC |
| >A> | | @ | 1MG | A040568 | 001 | Dec 22, 2004 | Mar | DISC |
| >D> | AA | | 2MG | A040568 | 002 | Dec 22, 2004 | Mar | DISC |
| >A> | | @ | 2MG | A040568 | 002 | Dec 22, 2004 | Mar | DISC |

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION
GRANISETRON HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ EBEWE PHARMA | EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) | A078808 | 001 | Apr 29, 2008 | Feb | DISC |

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL
HALOBETASOL PROPIONATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | TARO | 0.05% | A076994 | 001 | Dec 16, 2004 | Mar | DISC |
| >A> | | @ | 0.05% | A076994 | 001 | Dec 16, 2004 | Mar | DISC |

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AP | NAVINTA LLC | 20MG/ML | A202938 | 001 | Mar 28, 2013 | Mar | NEWA |

TABLET; ORAL
HYDRALAZINE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AA | ACTAVIS PHARMA | 10MG | A091679 | 001 | Mar 04, 2013 | Feb | NEWA |
| | AA | | 25MG | A091679 | 002 | Mar 04, 2013 | Feb | NEWA |
| | AA | | 50MG | A091679 | 003 | Mar 04, 2013 | Feb | NEWA |
| | AA | | 100MG | A091679 | 004 | Mar 04, 2013 | Feb | NEWA |

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | WATSON LABS | 25MG | A081189 | 001 | Jan 24, 1992 | Mar | DISC |
| >A> | | @ | 25MG | A081189 | 001 | Jan 24, 1992 | Mar | DISC |

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
IRBESARTAN AND HYDROCHLOROTHIAZIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | AUROBINDO PHARMA LTD | 12.5MG;150MG | A203630 | 001 | Feb 22, 2013 | Feb | NEWA |
| | AB | | 12.5MG;300MG | A203630 | 002 | Feb 22, 2013 | Feb | NEWA |
| | AB | LUPIN LTD | 12.5MG;150MG | A201524 | 001 | Feb 27, 2013 | Feb | NEWA |
| | AB | | 12.5MG;300MG | A201524 | 002 | Feb 27, 2013 | Feb | NEWA |

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | IPCA LABS LTD | 12.5MG;50MG | A201682 | 001 | Mar 01, 2013 | Feb | NEWA |
| | AB | | 12.5MG;100MG | A201682 | 002 | Mar 01, 2013 | Feb | NEWA |
| | AB | | 25MG;100MG | A201682 | 003 | Mar 01, 2013 | Feb | NEWA |

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | APOTEX CORP | 12.5MG;EQ 10MG BASE | A091524 | 001 | Mar 12, 2013 | Mar | NEWA |
| >A> | AB | | 12.5MG;EQ 20MG BASE | A091524 | 002 | Mar 12, 2013 | Mar | NEWA |
| >A> | AB | | 25MG;EQ 20MG BASE | A091524 | 003 | Mar 12, 2013 | Mar | NEWA |

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ WATSON LABS | 50MG;75MG | A071969 | 001 | Apr 17, 1988 | Jan | DISC |

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL
VALSARTAN AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | ALEMBIC LTD | 12.5MG;80MG | A201662 | 001 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 12.5MG;160MG | A201662 | 002 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 12.5MG;320MG | A201662 | 003 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 25MG;160MG | A201662 | 004 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 25MG;320MG | A201662 | 005 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | APOTEX INC | 12.5MG;80MG | A203026 | 001 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 12.5MG;160MG | A203026 | 002 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 12.5MG;320MG | A203026 | 003 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 25MG;160MG | A203026 | 004 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 25MG;320MG | A203026 | 005 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | AUROBINDO PHARMA LTD | 12.5MG;80MG | A202519 | 001 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 12.5MG;160MG | A202519 | 002 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 12.5MG;320MG | A202519 | 003 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 25MG;160MG | A202519 | 004 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 25MG;320MG | A202519 | 005 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | LUPIN LTD | 12.5MG;80MG | A078946 | 003 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 12.5MG;160MG | A078946 | 004 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 12.5MG;320MG | A078946 | 001 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 25MG;160MG | A078946 | 005 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 25MG;320MG | A078946 | 002 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | WATSON LABS INC | 12.5MG;80MG | A091519 | 001 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 12.5MG;160MG | A091519 | 002 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 12.5MG;320MG | A091519 | 003 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 25MG;160MG | A091519 | 004 | Mar 21, 2013 | Mar | NEWA |
| >A> | AB | | 25MG;320MG | A091519 | 005 | Mar 21, 2013 | Mar | NEWA |

HYDROCORTISONE

LOTION; TOPICAL
STIE-CORT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ PERRIGO CO | 1% | A089066 | 001 | Nov 25, 1985 | Feb | DISC |

OINTMENT; TOPICAL
HYDROCORTISONE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AT | TARO | 2.5% | A040310 | 001 | Dec 29, 2000 | Mar | DISC |
| >A> | | @ | 2.5% | A040310 | 001 | Dec 29, 2000 | Mar | DISC |

HYDROCORTISONE ACETATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | PASTE; TOPICAL | | | | | | |
| >D> | | ORABASE HCA | | | | | | |
| >D> | | COLGATE | 0.5% | A083205 | 001 | | Mar | DISC |
| >A> | | @ | 0.5% | A083205 | 001 | | Mar | DISC |

HYDROCORTISONE VALERATE

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | FOUGERA PHARMS | 0.2% | A075085 | 001 | Jul 31, 2001 | Feb | DISC |
| | | + | TARO | 0.2% | A075043 | 001 | Aug 25, 1998 | Feb | CRLD |

WESTCORT

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | RANBAXY | 0.2% | N018726 | 001 | Aug 08, 1983 | Feb | DISC |

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EXALGO

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | MALLINCKRODT INC | 16MG | N021217 | 003 | Mar 01, 2010 | Jan | CRLD |
| | | + | | 32MG | N021217 | 004 | Aug 24, 2012 | Jan | CRLD |

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | | PROSAM LABS | 10MG | A040753 | 001 | Feb 28, 2008 | Mar | DISC |
| >A> | | @ | | 10MG | A040753 | 001 | Feb 28, 2008 | Mar | DISC |
| >D> | AB | | | 25MG | A040752 | 001 | Feb 28, 2008 | Mar | DISC |
| >A> | | @ | | 25MG | A040752 | 001 | Feb 28, 2008 | Mar | DISC |
| >D> | AB | | | 50MG | A040751 | 001 | Feb 28, 2008 | Mar | DISC |
| >A> | | @ | | 50MG | A040751 | 001 | Feb 28, 2008 | Mar | DISC |

INDOMETHACIN

CAPSULE; ORAL

INDOCIN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | @ | ICEUTICA OPERATIONS | 25MG | N016059 | 001 | | Mar | CAHN |
| >A> | | @ | | 50MG | N016059 | 002 | | Mar | CAHN |
| >D> | | @ | IROKO PHARMS | 25MG | N016059 | 001 | | Mar | CAHN |
| >D> | | @ | | 50MG | N016059 | 002 | | Mar | CAHN |

INDOMETHACIN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | | SUN PHARM INDS INC | 25MG | A091401 | 001 | Mar 28, 2013 | Mar | NEWA |
| >A> | AB | | | 50MG | A091401 | 002 | Mar 28, 2013 | Mar | NEWA |

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AN | | TEVA PHARMS | 0.02% | A075313 | 001 | Feb 07, 2000 | Mar | DISC |
| >A> | | @ | TEVA PHARMS USA | 0.02% | A075313 | 001 | Feb 07, 2000 | Mar | DISC |

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | | LUITPOLD | EQ 65MG BASE/3.25ML (EQ 20MG/ML) | N021135 | 005 | Mar 29, 2013 | Mar | NEWA |

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AP | | INTL MEDICATION | 0.2MG/ML | A083724 | 001 | | Mar | DISC |
| >A> | | @ | | 0.2MG/ML | A083724 | 001 | | Mar | DISC |

ISUPREL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AP | + | HOSPIRA | 0.2MG/ML | N010515 | 001 | | Mar | CTEC |
| >A> | | + | | 0.2MG/ML | N010515 | 001 | | Mar | CTEC |

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | | VALEANT INTL | 5MG | N012093 | 007 | Jul 29, 1988 | Mar | CAHN |
| >D> | AB | | | 10MG | N012093 | 002 | Jul 29, 1988 | Mar | CAHN |
| >D> | AB | | | 20MG | N012093 | 006 | Jul 29, 1988 | Mar | CAHN |
| >D> | AB | + | | 30MG | N012093 | 005 | Jul 29, 1988 | Mar | CAHN |
| >D> | | + | | 40MG | N012093 | 001 | Jul 29, 1988 | Mar | CAHN |
| >A> | AB | | VALEANT PHARM NORTH | 5MG | N012093 | 007 | Jul 29, 1988 | Mar | CAHN |
| >A> | AB | | | 10MG | N012093 | 002 | Jul 29, 1988 | Mar | CAHN |
| >A> | AB | | | 20MG | N012093 | 006 | Jul 29, 1988 | Mar | CAHN |
| >A> | AB | + | | 30MG | N012093 | 005 | Jul 29, 1988 | Mar | CAHN |
| >A> | | + | | 40MG | N012093 | 001 | Jul 29, 1988 | Mar | CAHN |

ISOSORBIDE DINITRATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | @ PAR PHARM | 5MG | A086923 | 001 | Mar 12, 1987 | Feb | DISC |

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | BX | | RANBAXY | 10MG | N021951 | 001 | May 25, 2012 | Feb | CAHN |
| | BX | | | 20MG | N021951 | 002 | May 25, 2012 | Feb | CAHN |
| | BX | | | 30MG | N021951 | 003 | May 25, 2012 | Feb | CAHN |
| | BX | | | 40MG | N021951 | 004 | May 25, 2012 | Feb | CAHN |

ZENATANE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | | ZENATANE | | | | | | |
| >A> | AB | | DR REDDYS LABS LTD | 10MG | A202099 | 001 | Mar 25, 2013 | Mar | NEWA |
| >A> | AB | | | 20MG | A202099 | 002 | Mar 25, 2013 | Mar | NEWA |
| >A> | AB | | | 40MG | A202099 | 003 | Mar 25, 2013 | Mar | NEWA |

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | + | SANDOZ | 200MG | A075113 | 002 | Aug 04, 1998 | Jan | CRLD |

TRANDATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | @ PROMETHEUS LABS | 100MG | N018716 | 001 | May 24, 1985 | Jan | DISC |
| | | | @ | 200MG | N018716 | 002 | Aug 01, 1984 | Jan | DISC |

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | + | GLAXOSMITHKLINE | 25MG | N020241 | 005 | Dec 27, 1994 | Mar | CAHN |
| >D> | | | @ | 50MG | N020241 | 006 | Dec 27, 1994 | Mar | CAHN |
| >D> | AB | | | 100MG | N020241 | 001 | Dec 27, 1994 | Mar | CAHN |
| >D> | AB | | | 150MG | N020241 | 002 | Dec 27, 1994 | Mar | CAHN |
| >D> | AB | | | 200MG | N020241 | 003 | Dec 27, 1994 | Mar | CAHN |
| >D> | | | @ | 250MG | N020241 | 004 | Dec 27, 1994 | Mar | CAHN |
| >A> | AB | + | GLAXOSMITHKLINE LLC | 25MG | N020241 | 005 | Dec 27, 1994 | Mar | CAHN |
| >A> | | | @ | 50MG | N020241 | 006 | Dec 27, 1994 | Mar | CAHN |
| >A> | AB | | | 100MG | N020241 | 001 | Dec 27, 1994 | Mar | CAHN |
| >A> | AB | | | 150MG | N020241 | 002 | Dec 27, 1994 | Mar | CAHN |
| >A> | AB | | | 200MG | N020241 | 003 | Dec 27, 1994 | Mar | CAHN |
| >A> | | | @ | 250MG | N020241 | 004 | Dec 27, 1994 | Mar | CAHN |

TABLET, CHEWABLE; ORAL

LAMICTAL CD

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | | GLAXOSMITHKLINE | 2MG | N020764 | 004 | Sep 08, 2000 | Mar | CAHN |
| >D> | AB | | | 5MG | N020764 | 001 | Aug 24, 1998 | Mar | CAHN |

TABLET, CHEWABLE; ORAL
LAMICTAL CD

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | + | GLAXOSMITHKLINE | 25MG | N020764 | 002 | Aug 24, 1998 | Mar | CAHN |
| >D> | | @ | | 100MG | N020764 | 003 | Aug 24, 1998 | Mar | CAHN |
| >A> | AB | | GLAXOSMITHKLINE LLC | 2MG | N020764 | 004 | Sep 08, 2000 | Mar | CAHN |
| >A> | AB | | | 5MG | N020764 | 001 | Aug 24, 1998 | Mar | CAHN |
| >A> | AB | + | | 25MG | N020764 | 002 | Aug 24, 1998 | Mar | CAHN |
| >A> | | @ | | 100MG | N020764 | 003 | Aug 24, 1998 | Mar | CAHN |

TABLET, EXTENDED RELEASE; ORAL
LAMICTAL XR

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | | GLAXOSMITHKLINE LLC | 25MG | N022115 | 001 | May 29, 2009 | Mar | CAHN |
| >A> | AB | + | | 50MG | N022115 | 002 | May 29, 2009 | Mar | CAHN |
| >A> | AB | | | 100MG | N022115 | 003 | May 29, 2009 | Mar | CAHN |
| >A> | AB | | | 200MG | N022115 | 004 | May 29, 2009 | Mar | CAHN |
| >A> | AB | | | 250MG | N022115 | 006 | Jun 21, 2011 | Mar | CAHN |
| >A> | AB | | | 300MG | N022115 | 005 | Apr 14, 2010 | Mar | CAHN |
| >D> | AB | | SMITHKLINE BEECHAM | 25MG | N022115 | 001 | May 29, 2009 | Mar | CAHN |
| >D> | AB | + | | 50MG | N022115 | 002 | May 29, 2009 | Mar | CAHN |
| >D> | AB | | | 100MG | N022115 | 003 | May 29, 2009 | Mar | CAHN |
| >D> | AB | | | 200MG | N022115 | 004 | May 29, 2009 | Mar | CAHN |
| >D> | AB | | | 250MG | N022115 | 006 | Jun 21, 2011 | Mar | CAHN |
| >D> | AB | | | 300MG | N022115 | 005 | Apr 14, 2010 | Mar | CAHN |

LAMOTRIGINE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | PAR PHARM | 25MG | A201791 | 001 | Jan 18, 2013 | Jan | NEWA |
| | AB | | | 50MG | A201791 | 002 | Jan 18, 2013 | Jan | NEWA |
| | AB | | | 100MG | A201791 | 003 | Jan 18, 2013 | Jan | NEWA |
| | AB | | | 200MG | A201791 | 004 | Jan 18, 2013 | Jan | NEWA |
| | AB | | | 250MG | A201791 | 005 | Jan 18, 2013 | Jan | NEWA |
| | AB | | | 300MG | A201791 | 006 | Jan 18, 2013 | Jan | NEWA |

TABLET, ORALLY DISINTEGRATING; ORAL
LAMICTAL ODT

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | | GLAXOSMITHKLINE LLC | 25MG | N022251 | 001 | May 08, 2009 | Mar | CAHN |
| >A> | | + | | 50MG | N022251 | 002 | May 08, 2009 | Mar | CAHN |
| >A> | | | | 100MG | N022251 | 003 | May 08, 2009 | Mar | CAHN |
| >A> | | | | 200MG | N022251 | 004 | May 08, 2009 | Mar | CAHN |
| >D> | | | SMITHKLINE BEECHAM | 25MG | N022251 | 001 | May 08, 2009 | Mar | CAHN |
| >D> | | + | | 50MG | N022251 | 002 | May 08, 2009 | Mar | CAHN |
| >D> | | | | 100MG | N022251 | 003 | May 08, 2009 | Mar | CAHN |
| >D> | | | | 200MG | N022251 | 004 | May 08, 2009 | Mar | CAHN |

## LATANOPROST

SOLUTION/DROPS; OPHTHALMIC
LATANOPROST

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AT | | DR REDDYS LABS LTD | 0.005% | A202077 | 001 | Feb 11, 2013 | Jan | NEWA |

## LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AP | | TEVA PARENTERAL | EQ 100MG BASE/VIAL | A081277 | 001 | Sep 28, 1993 | Mar | CAHN |
| >D> | AP | | | EQ 350MG BASE/VIAL | A040174 | 001 | Jun 12, 1997 | Mar | CAHN |
| >A> | AP | | TEVA PHARMS USA | EQ 100MG BASE/VIAL | A081277 | 001 | Sep 28, 1993 | Mar | CAHN |
| >A> | AP | | | EQ 350MG BASE/VIAL | A040174 | 001 | Jun 12, 1997 | Mar | CAHN |

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LEUPROLIDE ACETATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AP | TEVA PARENTERAL | 1MG/0.2ML | A075471 | 001 | Oct 25, 2000 | Mar | CAHN |
| >A> | AP | TEVA PHARMS USA | 1MG/0.2ML | A075471 | 001 | Oct 25, 2000 | Mar | CAHN |

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION
LEVALBUTEROL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AN | DEY | EQ 0.0103% BASE | A077800 | 001 | Mar 15, 2013 | Mar | NEWA |
| >A> | AN | | EQ 0.021% BASE | A077800 | 002 | Mar 15, 2013 | Mar | NEWA |
| >A> | AN | | EQ 0.042% BASE | A077800 | 003 | Mar 15, 2013 | Mar | NEWA |

LEVETIRACETAM

SOLUTION; ORAL
LEVETIRACETAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AA | HETERO DRUGS LTD | 100MG/ML | A203052 | 001 | Feb 28, 2013 | Feb | NEWA |

TABLET, EXTENDED RELEASE; ORAL
LEVETIRACETAM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | SANDOZ | 500MG | A091668 | 001 | Nov 01, 2012 | Mar | DISC |
| >A> | | @ | 500MG | A091668 | 001 | Nov 01, 2012 | Mar | DISC |
| >D> | AB | | 750MG | A091668 | 002 | Nov 01, 2012 | Mar | DISC |
| >A> | | @ | 750MG | A091668 | 002 | Nov 01, 2012 | Mar | DISC |
| | AB | VINTAGE PHARMS LLC | 500MG | A202533 | 001 | Jul 20, 2012 | Jan | NEWA |
| | AB | | 750MG | A202533 | 002 | Jul 20, 2012 | Jan | NEWA |

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | SANDOZ | 5MG | A090486 | 001 | Mar 26, 2013 | Mar | NEWA |
| | AB | SUN PHARMA GLOBAL | 5MG | A090362 | 001 | Jan 31, 2013 | Jan | NEWA |

LEVOFLOXACIN

INJECTABLE; INJECTION
LEVOFLOXACIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | AUROBINDO PHARMA LTD | EQ 500MG/20ML (EQ 25MG/ML) | A202328 | 001 | Jan 24, 2013 | Jan | NEWA |
| | AP | | EQ 750MG/30ML (EQ 25MG/ML) | A202328 | 002 | Jan 24, 2013 | Jan | NEWA |
| | AP | EMCURE PHARMS LTD | EQ 500MG/20ML (EQ 25MG/ML) | A202590 | 001 | Jan 24, 2013 | Jan | NEWA |
| | AP | | EQ 750MG/30ML (EQ 25MG/ML) | A202590 | 002 | Jan 24, 2013 | Jan | NEWA |

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE
SKYLA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| + | | BAYER HLTHCARE | 13.5MG | N203159 | 001 | Jan 09, 2013 | Jan | NEWA |

TABLET; ORAL
LEVONORGESTREL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | LUPIN LTD | 0.75MG | A091328 | 001 | Jan 23, 2013 | Jan | NEWA |
| | AB | NOVEL LABS INC | 1.5MG | A202508 | 001 | Feb 22, 2013 | Feb | NEWA |

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL
LEVOXYL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB1, AB3 | KING PHARMS | 0.05MG | N021301 | 002 | May 25, 2001 | Mar | CAHN |

TABLET; ORAL

LEVOXYL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB1, AB3 | | KING PHARMS | 0.075MG | N021301 | 003 | May 25, 2001 | Mar | CAHN |
| >D> | AB1, AB3 | | | 0.088MG | N021301 | 004 | May 25, 2001 | Mar | CAHN |
| >D> | AB1, AB3 | | | 0.1MG | N021301 | 005 | May 25, 2001 | Mar | CAHN |
| >D> | AB1, AB3 | | | 0.112MG | N021301 | 006 | May 25, 2001 | Mar | CAHN |
| >D> | AB1, AB3 | | | 0.125MG | N021301 | 007 | May 25, 2001 | Mar | CAHN |
| >D> | AB1, AB3 | | | 0.137MG | N021301 | 008 | May 25, 2001 | Mar | CAHN |
| >D> | AB1, AB3 | | | 0.15MG | N021301 | 009 | May 25, 2001 | Mar | CAHN |
| >D> | AB1, AB3 | | | 0.175MG | N021301 | 010 | May 25, 2001 | Mar | CAHN |
| >D> | AB1, AB3 | + | | 0.2MG | N021301 | 011 | May 25, 2001 | Mar | CAHN |
| >D> | | @ | | 0.3MG | N021301 | 012 | May 25, 2001 | Mar | CAHN |
| >D> | AB1, AB3 | | KING PHARMS R AND D | 0.025MG | N021301 | 001 | May 25, 2001 | Mar | CAHN |
| >A> | AB1, AB3 | | | 0.025MG | N021301 | 001 | May 25, 2001 | Mar | CAHN |
| >A> | AB1, AB3 | | | 0.05MG | N021301 | 002 | May 25, 2001 | Mar | CAHN |
| >A> | AB1, AB3 | | | 0.075MG | N021301 | 003 | May 25, 2001 | Mar | CAHN |
| >A> | AB1, AB3 | | | 0.088MG | N021301 | 004 | May 25, 2001 | Mar | CAHN |
| >A> | AB1, AB3 | | | 0.1MG | N021301 | 005 | May 25, 2001 | Mar | CAHN |
| >A> | AB1, AB3 | | | 0.112MG | N021301 | 006 | May 25, 2001 | Mar | CAHN |
| >A> | AB1, AB3 | | | 0.125MG | N021301 | 007 | May 25, 2001 | Mar | CAHN |
| >A> | AB1, AB3 | | | 0.137MG | N021301 | 008 | May 25, 2001 | Mar | CAHN |
| >A> | AB1, AB3 | | | 0.15MG | N021301 | 009 | May 25, 2001 | Mar | CAHN |
| >A> | AB1, AB3 | | | 0.175MG | N021301 | 010 | May 25, 2001 | Mar | CAHN |
| >A> | AB1, AB3 | + | | 0.2MG | N021301 | 011 | May 25, 2001 | Mar | CAHN |
| >A> | | @ | | 0.3MG | N021301 | 012 | May 25, 2001 | Mar | CAHN |

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AP | | LUITPOLD | 2% | A083198 | 001 | | Mar | DISC |
| >A> | | @ | | 2% | A083198 | 001 | | Mar | DISC |

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AP | | AUROBINDO PHARMA LTD | 1% | A203082 | 001 | Mar 14, 2013 | Mar | NEWA |
| >A> | AP | | | 1% | A203040 | 001 | Mar 14, 2013 | Mar | NEWA |
| >A> | AP | | | 2% | A203082 | 002 | Mar 14, 2013 | Mar | NEWA |
| >A> | AP | | | 2% | A203040 | 002 | Mar 14, 2013 | Mar | NEWA |

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | | KING PHARMS | EQ 0.005MG BASE | N010379 | 001 | | Mar | CAHN |
| >D> | AB | | | EQ 0.025MG BASE | N010379 | 002 | | Mar | CAHN |
| >D> | AB | + | | EQ 0.05MG BASE | N010379 | 003 | | Mar | CAHN |
| >A> | AB | | KING PHARMS R AND D | EQ 0.005MG BASE | N010379 | 001 | | Mar | CAHN |

TABLET; ORAL
CYTOMEL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | | KING PHARMS R AND D | EQ 0.025MG BASE | N010379 | 002 | | Mar | CAHN |
| >A> | AB | + | | EQ 0.05MG BASE | N010379 | 003 | | Mar | CAHN |

LISINOPRIL

TABLET; ORAL
LISINOPRIL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | SANDOZ | 2.5MG | A075999 | 001 | Jul 01, 2002 | Jan | CAHN |
| | | @ | | 5MG | A075999 | 002 | Jul 01, 2002 | Jan | CAHN |
| | | @ | | 10MG | A075999 | 003 | Jul 01, 2002 | Jan | CAHN |
| | | @ | | 20MG | A075999 | 004 | Jul 01, 2002 | Jan | CAHN |
| | | @ | | 30MG | A075999 | 005 | Jul 01, 2002 | Jan | CAHN |
| | | @ | | 40MG | A075999 | 006 | Jul 01, 2002 | Jan | CAHN |

LITHIUM CARBONATE

CAPSULE; ORAL
LITHIUM CARBONATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | APOTEX INC | 300MG | A076795 | 001 | Nov 22, 2004 | Feb | DISC |

LORAZEPAM

CONCENTRATE; ORAL
LORAZEPAM

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AA | | LUPIN LTD | 2MG/ML | A091407 | 001 | Feb 19, 2013 | Feb | NEWA |

LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | | ACTAVIS GRP PTC | 25MG | A090382 | 001 | Oct 06, 2010 | Mar | CAHN |
| >A> | AB | | | 50MG | A090382 | 002 | Oct 06, 2010 | Mar | CAHN |
| >A> | AB | | | 100MG | A090382 | 003 | Oct 06, 2010 | Mar | CAHN |
| >D> | AB | | ACTAVIS INC | 25MG | A090382 | 001 | Oct 06, 2010 | Mar | CAHN |
| >D> | AB | | | 50MG | A090382 | 002 | Oct 06, 2010 | Mar | CAHN |
| >D> | AB | | | 100MG | A090382 | 003 | Oct 06, 2010 | Mar | CAHN |

LOVASTATIN

TABLET; ORAL
LOVASTATIN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | + | CARLSBAD | 40MG | A075991 | 003 | Jun 05, 2002 | Feb | CRLD |

MEVACOR

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | MERCK | 20MG | N019643 | 003 | Aug 31, 1987 | Feb | DISC |
| | | @ | | 40MG | N019643 | 004 | Dec 14, 1988 | Feb | DISC |

MAFENIDE ACETATE

FOR SOLUTION; TOPICAL
MAFENIDE ACETATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | PAR FORM | 5% | A201511 | 001 | Feb 12, 2013 | Jan | NEWA |

SULFAMYLON

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | + | MYLAN LLC | 5% | N019832 | 003 | Jun 05, 1998 | Jan | CFTG |

MAGNESIUM SULFATE, POTASSIUM SULFATE, SODIUM SULFATE; POLYETHYLENE GLYCOL 3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

SOLUTION, FOR SOLUTION;ORAL, ORAL
SUCLEAR

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | + | BRAINTREE LABS | 1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A,N/A,N/A;N/A,N/A,N/A,210GM, 0.74GM,2.86GM,5.6GM | N203595 | 001 | Jan 18, 2013 | Jan | NEWA |

MANNITOL

INJECTABLE; INJECTION
MANNITOL 20%

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ B BRAUN | 20GM/100ML | N014738 | 001 | | Jan | DISC |

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | MECAMYLAMINE HYDROCHLORIDE | | | | | | | |
| >A> | | NEXGEN PHARMA | 2.5MG | A204054 | 001 | Mar 19, 2013 | Mar | NEWA |

MEFENAMIC ACID

CAPSULE; ORAL
MEFENAMIC ACID

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | CYPRESS PHARM | 250MG | A090359 | 001 | Feb 05, 2013 | Jan | NEWA |

MELOXICAM

TABLET; ORAL
MELOXICAM

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | BEIJING DOUBLE CRANE | 7.5MG | A078039 | 001 | Dec 14, 2006 | Mar | CAHN |
| >D> | AB | | 15MG | A078039 | 002 | Dec 14, 2006 | Mar | CAHN |
| | | @ COREPHARMA | 7.5MG | A077930 | 001 | Jul 19, 2006 | Feb | DISC |
| | | @ | 15MG | A077930 | 002 | Jul 19, 2006 | Feb | DISC |
| >A> | AB | CR DOUBLE CRANE | 7.5MG | A078039 | 001 | Dec 14, 2006 | Mar | CAHN |
| >A> | AB | | 15MG | A078039 | 002 | Dec 14, 2006 | Mar | CAHN |

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ TARO | 200MG | A200998 | 001 | May 23, 2011 | Jan | DISC |
| | | @ | 400MG | A200998 | 002 | May 23, 2011 | Jan | DISC |

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL
DELZICOL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | + | WARNER CHILCOTT LLC | 400MG | N204412 | 001 | Feb 01, 2013 | Feb | NEWA |

SUPPOSITORY; RECTAL
CANASA

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | + | APTALIS PHARMA US | 1GM | N021252 | 002 | Nov 05, 2004 | Feb | CRLD |

METAPROTERENOL SULFATE

SYRUP; ORAL
METAPROTERENOL SULFATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ NOVEX | 10MG/5ML | A075235 | 001 | Jan 27, 2000 | Feb | DISC |
| | + | SILARX | 10MG/5ML | A073632 | 001 | Jul 22, 1992 | Feb | CTEC |

TABLET; ORAL
METAPROTERENOL SULFATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | PAR PHARM | 10MG | A072024 | 001 | Jun 28, 1988 | Mar | CTEC |
| >A> | | | 10MG | A072024 | 001 | Jun 28, 1988 | Mar | CTEC |
| >D> | AB | + | 20MG | A072025 | 001 | Jun 28, 1988 | Mar | CTEC |
| >A> | | + | 20MG | A072025 | 001 | Jun 28, 1988 | Mar | CTEC |
| >D> | AB | WATSON LABS | 10MG | A073013 | 001 | Jan 31, 1991 | Mar | DISC |
| >A> | | @ | 10MG | A073013 | 001 | Jan 31, 1991 | Mar | DISC |
| >D> | AB | | 20MG | A072795 | 001 | Jan 31, 1991 | Mar | DISC |
| >A> | | @ | 20MG | A072795 | 001 | Jan 31, 1991 | Mar | DISC |

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | | SANDOZ | 500MG | A075965 | 001 | Jan 25, 2002 | Mar | DISC |
| >A> | | @ | | 500MG | A075965 | 001 | Jan 25, 2002 | Mar | DISC |
| >D> | AB | | | 850MG | A075965 | 002 | Jan 25, 2002 | Mar | DISC |
| >A> | | @ | | 850MG | A075965 | 002 | Jan 25, 2002 | Mar | DISC |
| >D> | AB | | | 1GM | A075965 | 003 | Jan 25, 2002 | Mar | DISC |
| >A> | | @ | | 1GM | A075965 | 003 | Jan 25, 2002 | Mar | DISC |

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB1 | | WATSON LABS INC | 500MG | A076818 | 001 | Dec 14, 2004 | Mar | DISC |
| >A> | | @ | | 500MG | A076818 | 001 | Dec 14, 2004 | Mar | DISC |

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | AUROBINDO PHARMA LTD | 500MG;EQ 15MG BASE | A200823 | 001 | Feb 13, 2013 | Jan | NEWA |
| | AB | | | 850MG;EQ 15MG BASE | A200823 | 002 | Feb 13, 2013 | Jan | NEWA |
| | AB | | TORRENT PHARMS LTD | 500MG;EQ 15MG BASE | A202001 | 001 | Feb 13, 2013 | Jan | NEWA |
| | AB | | | 850MG;EQ 15MG BASE | A202001 | 002 | Feb 13, 2013 | Jan | NEWA |

METHADONE HYDROCHLORIDE

>D> TABLET; ORAL
>D> METHADONE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AA | | MALLINCKRODT | 40MG | A077142 | 001 | Jul 12, 2005 | Mar | CDFR |
| >D> | AA | + | ROXANE | 40MG | N017058 | 001 | | Mar | CDFR |
| >D> | AA | | SANDOZ | 40MG | A075082 | 001 | Mar 25, 1998 | Mar | CDFR |

>D> METHADOSE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AA | | MALLINCKRODT | 40MG | A074184 | 001 | Apr 29, 1993 | Mar | CDFR |

>A> TABLET, FOR SUSPENSION; ORAL
>A> METHADONE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AA | | MALLINCKRODT INC | 40MG | A077142 | 001 | Jul 12, 2005 | Mar | CDFR |
| >A> | AA | + | ROXANE | 40MG | N017058 | 001 | | Mar | CDFR |
| >A> | AA | | SANDOZ | 40MG | A075082 | 001 | Mar 25, 1998 | Mar | CDFR |

>A> METHADOSE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AA | | MALLINCKRODT | 40MG | A074184 | 001 | Apr 29, 1993 | Mar | CDFR |

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | AUSTARPHARMA LLC | 500MG | A200958 | 001 | Oct 21, 2011 | Jan | DISC |
| | | @ | | 750MG | A200958 | 002 | Oct 21, 2011 | Jan | DISC |
| | AA | | PRINSTON INC | 500MG | A086989 | 001 | | Feb | CMFD |
| | AA | | | 750MG | A086988 | 001 | | Feb | CAHN |
| | | @ | SOLCO HLTHCARE | 500MG | A086989 | 001 | | Jan | DISC |

METHYCLOTHIAZIDE

TABLET; ORAL
METHYCLOTHIAZIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | + | MYLAN PHARMS INC | 5MG | A087672 | 001 | Aug 17, 1982 | Jan | CTEC |
| | | @ | WATSON LABS | 5MG | A088724 | 001 | Sep 06, 1984 | Jan | DISC |

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
METHYLIN ER

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | MALLINCKRODT INC | 10MG | A075629 | 001 | May 09, 2000 | Feb | CTEC |

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ TEVA PARENTERAL | EQ 5MG BASE/ML | A073135 | 001 | Nov 27, 1991 | Feb | DISC |

METOLAZONE

TABLET; ORAL
METOLAZONE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | TEVA | 2.5MG | A076600 | 001 | Jan 06, 2004 | Mar | DISC |
| >A> | | @ | 2.5MG | A076600 | 001 | Jan 06, 2004 | Mar | DISC |

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
METOPROLOL SUCCINATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ NESHER PHARMS | EQ 25MG TARTRATE | A077779 | 001 | Mar 20, 2008 | Feb | DISC |

METOPROLOL TARTRATE

INJECTABLE; INJECTION
METOPROLOL TARTRATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AP | WATSON LABS | 1MG/ML | A074032 | 001 | Dec 21, 1993 | Mar | DISC |
| >A> | | @ | 1MG/ML | A074032 | 001 | Dec 21, 1993 | Mar | DISC |

TABLET; ORAL
METOPROLOL TARTRATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | @ PRINSTON INC | 50MG | A074453 | 001 | Apr 27, 1995 | Mar | CAHN |
| >A> | | @ | 100MG | A074453 | 002 | Apr 27, 1995 | Mar | CAHN |
| >D> | | @ SOLCO HLTHCARE | 50MG | A074453 | 001 | Apr 27, 1995 | Mar | CAHN |
| >D> | | @ | 100MG | A074453 | 002 | Apr 27, 1995 | Mar | CAHN |

METRONIDAZOLE

TABLET; ORAL
METRONIDAZOLE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | PLIVA | 250MG | A070027 | 001 | Nov 06, 1984 | Mar | CAHN |
| >A> | AB | TEVA PHARMS USA | 250MG | A070027 | 001 | Nov 06, 1984 | Mar | CAHN |

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ CLARIS LIFESCIENCES | EQ 1MG BASE/ML | A075637 | 001 | Oct 31, 2000 | Jan | DISC |
| | | @ | EQ 5MG BASE/ML | A075637 | 002 | Oct 31, 2000 | Jan | DISC |

MIPOMERSEN SODIUM

SOLUTION; SUBCUTANEOUS
KYNAMRO

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | + | GENZYME CORP | 200MG/ML (200MG/ML) | N203568 | 001 | Jan 29, 2013 | Jan | NEWA |

>D> MITOXANTRONE

>D> INJECTABLE; INJECTION
>D> MITOXANTRONE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AP | ONCO THERAPIES LTD | EQ 20MG BASE/10ML (EQ 2MG BASE/ML) | A201014 | 001 | Dec 11, 2012 | Mar | CAIN |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| >A> | | MITOXANTRONE HYDROCHLORIDE | | | | | | | | |
| >A> | | INJECTABLE; INJECTION | | | | | | | | |
| >A> | | MITOXANTRONE HYDROCHLORIDE | | | | | | | | |
| >A> | AP | ONCO THERAPIES LTD | EQ 20MG BASE/10ML (EQ 2MG BASE/ML) | | A201014 | 001 | Dec 11, 2012 | Mar | CAIN | |
| | | MUPIROCIN CALCIUM | | | | | | | | |
| | | CREAM; TOPICAL | | | | | | | | |
| | | BACTROBAN | | | | | | | | |
| | AB | + GLAXOSMITHKLINE | EQ 2% BASE | | N050746 | 001 | Dec 11, 1997 | Jan | CFTG | |
| | | MUPIROCIN | | | | | | | | |
| | AB | GLENMARK GENERICS | EQ 2% BASE | | A201587 | 001 | Jan 24, 2013 | Jan | NEWA | |
| | | NABUMETONE | | | | | | | | |
| | | TABLET; ORAL | | | | | | | | |
| | | NABUMETONE | | | | | | | | |
| >D> | AB | PROSAM LABS | 500MG | | A079093 | 001 | Feb 27, 2009 | Mar | DISC | |
| >A> | | @ | 500MG | | A079093 | 001 | Feb 27, 2009 | Mar | DISC | |
| >D> | AB | | 750MG | | A079093 | 002 | Feb 27, 2009 | Mar | DISC | |
| >A> | | @ | 750MG | | A079093 | 002 | Feb 27, 2009 | Mar | DISC | |
| | | NARATRIPTAN HYDROCHLORIDE | | | | | | | | |
| | | TABLET; ORAL | | | | | | | | |
| | | AMERGE | | | | | | | | |
| >D> | AB | GLAXOSMITHKLINE | EQ 1MG BASE | | N020763 | 002 | Feb 10, 1998 | Mar | CAHN | |
| >D> | AB | + | EQ 2.5MG BASE | | N020763 | 001 | Feb 10, 1998 | Mar | CAHN | |
| >A> | AB | GLAXOSMITHKLINE LLC | EQ 1MG BASE | | N020763 | 002 | Feb 10, 1998 | Mar | CAHN | |
| >A> | AB | + | EQ 2.5MG BASE | | N020763 | 001 | Feb 10, 1998 | Mar | CAHN | |
| | | NEOMYCIN SULFATE | | | | | | | | |
| >D> | | POWDER; FOR RX COMPOUNDING | | | | | | | | |
| >D> | | NEO-RX | | | | | | | | |
| >D> | | X GEN PHARMS | 100% | | A061579 | 001 | | Mar | DISC | |
| >A> | | @ | 100% | | A061579 | 001 | | Mar | DISC | |
| | | NITROFURANTOIN, MACROCRYSTALLINE | | | | | | | | |
| | | CAPSULE; ORAL | | | | | | | | |
| | | MACRODANTIN | | | | | | | | |
| >D> | AB | ALVOGEN INC | 25MG | | N016620 | 003 | | Mar | CTEC | |
| >A> | | | 25MG | | N016620 | 003 | | Mar | CTEC | |
| | AB | | 25MG | | N016620 | 003 | | Feb | CAHN | |
| | AB | | 50MG | | N016620 | 001 | | Feb | CAHN | |
| | AB | + | 100MG | | N016620 | 002 | | Feb | CAHN | |
| | | NITROFURANTOIN | | | | | | | | |
| >D> | AB | WATSON LABS | 25MG | | A073696 | 001 | Dec 31, 1992 | Mar | DISC | |
| >A> | | @ | 25MG | | A073696 | 001 | Dec 31, 1992 | Mar | DISC | |
| >D> | AB | | 50MG | | A073696 | 002 | Dec 31, 1992 | Mar | DISC | |
| >A> | | @ | 50MG | | A073696 | 002 | Dec 31, 1992 | Mar | DISC | |
| >D> | AB | | 100MG | | A073696 | 003 | Dec 31, 1992 | Mar | DISC | |
| >A> | | @ | 100MG | | A073696 | 003 | Dec 31, 1992 | Mar | DISC | |
| | | NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE | | | | | | | | |
| | | CAPSULE; ORAL | | | | | | | | |
| | | MACROBID | | | | | | | | |
| >D> | AB | + ALMATICA | 75MG;25MG | | N020064 | 001 | Dec 24, 1991 | Mar | CAHN | |

CAPSULE; ORAL
MACROBID

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | + | ALVOGEN INC | 75MG;25MG | N020064 | 001 | Dec 24, 1991 | Mar | CAHN |

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
NITRO-DUR

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| >D> | AB1 | + | KEY PHARMS | 0.1MG/HR | N020145 | 001 | Apr 04, 1995 | Mar | CAHN |
| >D> | AB1 | + | | 0.2MG/HR | N020145 | 002 | Apr 04, 1995 | Mar | CAHN |
| >D> | | + | | 0.3MG/HR | N020145 | 003 | Apr 04, 1995 | Mar | CAHN |
| >D> | AB1 | + | | 0.4MG/HR | N020145 | 004 | Apr 04, 1995 | Mar | CAHN |
| >D> | AB1 | + | | 0.6MG/HR | N020145 | 005 | Apr 04, 1995 | Mar | CAHN |
| >D> | | + | | 0.8MG/HR | N020145 | 006 | Apr 04, 1995 | Mar | CAHN |
| >A> | AB1 | + | MERCK SHARP DOHME | 0.1MG/HR | N020145 | 001 | Apr 04, 1995 | Mar | CAHN |
| >A> | AB1 | + | | 0.2MG/HR | N020145 | 002 | Apr 04, 1995 | Mar | CAHN |
| >A> | | + | | 0.3MG/HR | N020145 | 003 | Apr 04, 1995 | Mar | CAHN |
| >A> | AB1 | + | | 0.4MG/HR | N020145 | 004 | Apr 04, 1995 | Mar | CAHN |
| >A> | AB1 | + | | 0.6MG/HR | N020145 | 005 | Apr 04, 1995 | Mar | CAHN |
| >A> | | + | | 0.8MG/HR | N020145 | 006 | Apr 04, 1995 | Mar | CAHN |

NIZATIDINE

CAPSULE; ORAL
NIZATIDINE

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | @ | APOTEX INC | 150MG | A076383 | 001 | Jan 23, 2003 | Feb | DISC |
| | | @ | | 300MG | A076383 | 002 | Jan 23, 2003 | Feb | DISC |

NORETHINDRONE

TABLET; ORAL-28
JENCYCLA

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | | LUPIN LTD | 0.35MG | A091323 | 001 | Mar 28, 2013 | Mar | NEWA |

NYSTATIN

SUSPENSION; ORAL
NILSTAT

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | @ | GLENMARK GENERICS | 100,000 UNITS/ML | N050299 | 001 | | Feb | DISC |

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | AP | | CLARIS LIFESCIENCES | 2MG/ML | A078288 | 001 | Feb 22, 2013 | Feb | NEWA |
| >D> | AP | | LUITPOLD | EQ 2MG BASE/ML | A077582 | 001 | Dec 26, 2006 | Mar | DISC |
| >A> | | @ | | EQ 2MG BASE/ML | A077582 | 001 | Dec 26, 2006 | Mar | DISC |
| | | @ | PLIVA HRVATSKA DOO | EQ 2MG BASE/ML | A077544 | 001 | Dec 26, 2006 | Feb | DISC |

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | @ | CLARIS LIFESCIENCES | EQ 0.64MG BASE/ML | A078308 | 001 | Mar 17, 2008 | Jan | DISC |
| | | @ | HOSPIRA | EQ 0.64MG BASE/ML | A077348 | 001 | Feb 01, 2007 | Jan | DISC |

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | AP | | CLARIS LIFESCIENCES | 2MG/ML | A078287 | 001 | Feb 22, 2013 | Feb | NEWA |
| >D> | AP | | LUITPOLD | EQ 2MG BASE/ML | A077387 | 001 | Dec 26, 2006 | Mar | DISC |
| >A> | | @ | | EQ 2MG BASE/ML | A077387 | 001 | Dec 26, 2006 | Mar | DISC |

OSPEMIFENE

TABLET; ORAL
OSPHENA

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | + | SHIONOGI INC | 60MG | N203505 | 001 | Feb 26, 2013 | Feb | NEWA |

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | AUROBINDO PHARMA LTD | EQ 1GM BASE/VIAL | A201539 | 001 | Jan 18, 2013 | Jan | NEWA |
| AP | | EQ 2GM BASE/VIAL | A201539 | 002 | Jan 18, 2013 | Jan | NEWA |
| AP | | EQ 10GM BASE/VIAL | A201538 | 001 | Jan 18, 2013 | Jan | NEWA |

OXAPROZIN

TABLET; ORAL
OXAPROZIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | CARACO | 600MG | A075844 | 001 | Jan 03, 2002 | Jan | DISC |

OXCARBAZEPINE

TABLET; ORAL
OXCARBAZEPINE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | TEVA PHARMS | 150MG | A078005 | 001 | Dec 11, 2007 | Mar | DISC |
| >D> | AB | | 300MG | A078005 | 002 | Dec 11, 2007 | Mar | DISC |
| >D> | AB | | 600MG | A078005 | 003 | Dec 11, 2007 | Mar | DISC |
| >A> | @ | TEVA PHARMS USA | 150MG | A078005 | 001 | Dec 11, 2007 | Mar | DISC |
| >A> | @ | | 300MG | A078005 | 002 | Dec 11, 2007 | Mar | DISC |
| >A> | @ | | 600MG | A078005 | 003 | Dec 11, 2007 | Mar | DISC |

OXYBUTYNIN CHLORIDE

TABLET; ORAL
OXYBUTYNIN CHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | PLIVA | 5MG | A071655 | 001 | Nov 14, 1988 | Mar | CAHN |
| >A> | AB | TEVA PHARMS USA | 5MG | A071655 | 001 | Nov 14, 1988 | Mar | CAHN |

OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | NESHER PHARMS | 5MG | A077290 | 001 | Dec 08, 2005 | Mar | DISC |
| >A> | @ | | 5MG | A077290 | 001 | Dec 08, 2005 | Mar | DISC |
| >D> | AB | | 10MG | A077290 | 002 | Dec 08, 2005 | Mar | DISC |
| >A> | @ | | 10MG | A077290 | 002 | Dec 08, 2005 | Mar | DISC |
| >D> | AB | | 15MG | A077290 | 003 | Dec 08, 2005 | Mar | DISC |
| >A> | @ | | 15MG | A077290 | 003 | Dec 08, 2005 | Mar | DISC |
| >D> | AB | | 20MG | A077290 | 004 | Dec 08, 2005 | Mar | DISC |
| >A> | @ | | 20MG | A077290 | 004 | Dec 08, 2005 | Mar | DISC |
| >D> | AB | | 30MG | A077290 | 005 | Dec 08, 2005 | Mar | DISC |
| >A> | @ | | 30MG | A077290 | 005 | Dec 08, 2005 | Mar | DISC |

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL
OXYMORPHONE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | AVANTHI INC | 5MG | A203601 | 001 | Jan 30, 2013 | Jan | NEWA |
| AB | | 10MG | A203601 | 002 | Jan 30, 2013 | Jan | NEWA |

OXYTOCIN

INJECTABLE; INJECTION
OXYTOCIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AP | HIKMA FARMACEUTICA | 10USP UNITS/ML (10USP UNITS/ML) | A200219 | 001 | Feb 13, 2013 | Jan | NEWA |

PACLITAXEL

INJECTABLE; INJECTION
TAXOL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | HQ SPCLT PHARMA | 6MG/ML | N020262 | 001 | Dec 29, 1992 | Jan | CAHN |

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
PAMIDRONATE DISODIUM

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AP | | TEVA PARENTERAL | 30MG/10ML (3MG/ML) | A076153 | 001 | Mar 27, 2002 | Mar | CAHN |
| >D> | AP | | | 90MG/10ML (9MG/ML) | A076153 | 002 | Mar 27, 2002 | Mar | CAHN |
| >A> | AP | | TEVA PHARMS USA | 30MG/10ML (3MG/ML) | A076153 | 001 | Mar 27, 2002 | Mar | CAHN |
| >A> | AP | | | 90MG/10ML (9MG/ML) | A076153 | 002 | Mar 27, 2002 | Mar | CAHN |

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL
CREON

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | | ABBVIE | 180,000USP UNITS;36,000USP UNITS;114,000USP UNITS | N020725 | 005 | Mar 14, 2013 | Mar | NEWA |

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AP | + | TEVA PARENTERAL | 2MG/ML | A072760 | 001 | Jul 31, 1990 | Mar | CAHN |
| >A> | AP | + | TEVA PHARMS USA | 2MG/ML | A072760 | 001 | Jul 31, 1990 | Mar | CAHN |

PHENYLEPHRINE HYDROCHLORIDE

>A> SOLUTION/DROPS; OPHTHALMIC
>A> PHENYLEPHRINE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | | PARAGON BIOTECK | 2.5% | N203510 | 001 | Mar 21, 2013 | Mar | NEWA |
| >A> | | + | | 10% | N203510 | 002 | Mar 21, 2013 | Mar | NEWA |

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AP | | HOSPIRA | 50MG/ML | A089744 | 001 | Dec 18, 1987 | Mar | DISC |
| >A> | | @ | | 50MG/ML | A089744 | 001 | Dec 18, 1987 | Mar | DISC |

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
PIOGLITAZONE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | ACCORD HLTHCARE | EQ 15MG BASE | A200044 | 001 | Feb 13, 2013 | Jan | NEWA |
| | AB | | | EQ 30MG BASE | A200044 | 002 | Feb 13, 2013 | Jan | NEWA |
| | AB | | | EQ 45MG BASE | A200044 | 003 | Feb 13, 2013 | Jan | NEWA |
| | AB | | AUROBINDO PHARMA LTD | EQ 15MG BASE | A200268 | 001 | Feb 13, 2013 | Jan | NEWA |
| | AB | | | EQ 30MG BASE | A200268 | 002 | Feb 13, 2013 | Jan | NEWA |
| | AB | | | EQ 45MG BASE | A200268 | 003 | Feb 13, 2013 | Jan | NEWA |
| >A> | AB | | DR REDDYS LABS LTD | EQ 15MG BASE | A078383 | 001 | Mar 12, 2013 | Mar | NEWA |
| >A> | AB | | | EQ 30MG BASE | A078383 | 002 | Mar 12, 2013 | Mar | NEWA |
| >A> | AB | | | EQ 45MG BASE | A078383 | 003 | Mar 12, 2013 | Mar | NEWA |
| | AB | | MACLEODS PHARMS LTD | EQ 15MG BASE | A202467 | 001 | Feb 06, 2013 | Jan | NEWA |
| | AB | | | EQ 30MG BASE | A202467 | 002 | Feb 06, 2013 | Jan | NEWA |
| | AB | | | EQ 45MG BASE | A202467 | 003 | Feb 06, 2013 | Jan | NEWA |
| | AB | | SANDOZ | EQ 15MG BASE | A078670 | 001 | Feb 13, 2013 | Jan | NEWA |
| | AB | | | EQ 30MG BASE | A078670 | 002 | Feb 13, 2013 | Jan | NEWA |
| | AB | | | EQ 45MG BASE | A078670 | 003 | Feb 13, 2013 | Jan | NEWA |

TABLET; ORAL
PIOGLITAZONE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | SYNTHON PHARMS | EQ 15MG BASE | A078472 | 001 | Feb 13, 2013 | Jan | NEWA |
| AB | | EQ 30MG BASE | A078472 | 002 | Feb 13, 2013 | Jan | NEWA |
| AB | | EQ 45MG BASE | A078472 | 003 | Feb 13, 2013 | Jan | NEWA |
| AB | TORRENT PHARMS LTD | EQ 15MG BASE | A091298 | 001 | Feb 13, 2013 | Jan | NEWA |
| AB | | EQ 30MG BASE | A091298 | 002 | Feb 13, 2013 | Jan | NEWA |
| AB | | EQ 45MG BASE | A091298 | 003 | Feb 13, 2013 | Jan | NEWA |
| AB | ZYDUS PHARMS USA INC | EQ 15MG BASE | A202456 | 001 | Feb 13, 2013 | Jan | NEWA |
| AB | | EQ 30MG BASE | A202456 | 002 | Feb 13, 2013 | Jan | NEWA |
| AB | | EQ 45MG BASE | A202456 | 003 | Feb 13, 2013 | Jan | NEWA |

POLYMYXIN B SULFATE

POWDER; FOR RX COMPOUNDING
POLY-RX

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | + X GEN PHARMS | 100,000,000 UNITS/BOT | A061578 | 001 | | Mar | DISC |
| >A> | @ | 100,000,000 UNITS/BOT | A061578 | 001 | | Mar | DISC |

POMALIDOMIDE

CAPSULE; ORAL
POMALYST

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | CELGENE | 1MG | N204026 | 001 | Feb 08, 2013 | Feb | NEWA |
| | | 2MG | N204026 | 002 | Feb 08, 2013 | Feb | NEWA |
| | | 3MG | N204026 | 003 | Feb 08, 2013 | Feb | NEWA |
| | + | 4MG | N204026 | 004 | Feb 08, 2013 | Feb | NEWA |

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | AMNEAL PHARMS | 10MEQ | A202128 | 001 | Feb 22, 2013 | Feb | NEWA |

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | AB | ACTAVIS GRP PTC | 0.125MG | A091254 | 001 | Nov 30, 2010 | Mar | CAHN |
| >A> | AB | | 0.25MG | A091254 | 002 | Nov 30, 2010 | Mar | CAHN |
| >A> | AB | | 0.5MG | A091254 | 003 | Nov 30, 2010 | Mar | CAHN |
| >A> | AB | | 0.75MG | A091254 | 004 | Nov 30, 2010 | Mar | CAHN |
| >A> | AB | | 1MG | A091254 | 005 | Nov 30, 2010 | Mar | CAHN |
| >A> | AB | | 1.5MG | A091254 | 006 | Nov 30, 2010 | Mar | CAHN |
| >D> | AB | ACTAVIS PHARMA | 0.125MG | A091254 | 001 | Nov 30, 2010 | Mar | CAHN |
| >D> | AB | | 0.25MG | A091254 | 002 | Nov 30, 2010 | Mar | CAHN |
| >D> | AB | | 0.5MG | A091254 | 003 | Nov 30, 2010 | Mar | CAHN |
| >D> | AB | | 0.75MG | A091254 | 004 | Nov 30, 2010 | Mar | CAHN |
| >D> | AB | | 1MG | A091254 | 005 | Nov 30, 2010 | Mar | CAHN |
| >D> | AB | | 1.5MG | A091254 | 006 | Nov 30, 2010 | Mar | CAHN |
| >A> | AB | SUN PHARM INDS INC | 0.125MG | A091683 | 001 | Mar 27, 2013 | Mar | NEWA |
| >A> | AB | | 0.25MG | A091683 | 002 | Mar 27, 2013 | Mar | NEWA |
| >A> | AB | | 0.5MG | A091683 | 003 | Mar 27, 2013 | Mar | NEWA |
| >A> | AB | | 0.75MG | A091683 | 004 | Mar 27, 2013 | Mar | NEWA |
| >A> | AB | | 1MG | A091683 | 005 | Mar 27, 2013 | Mar | NEWA |
| >A> | AB | | 1.5MG | A091683 | 006 | Mar 27, 2013 | Mar | NEWA |

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | AMYLIN PHARMS | EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML) | N021332 | 002 | Sep 25, 2007 | Jan | CAHN |
| | | | | EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML) | N021332 | 003 | Sep 25, 2007 | Jan | CAHN |
| | | + | | EQ 3MG BASE/5ML (EQ 600MCG BASE/ML) | N021332 | 001 | Mar 16, 2005 | Jan | CAHN |

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AA | | PHARM ASSOC | EQ 5MG BASE/5ML | A076123 | 001 | Dec 23, 2002 | Mar | DISC |
| >A> | | | @ | EQ 5MG BASE/5ML | A076123 | 001 | Dec 23, 2002 | Mar | DISC |
| >D> | AA | | WE PHARMS | EQ 15MG BASE/5ML | A075250 | 001 | Jul 12, 2002 | Mar | DISC |
| >A> | | | @ | EQ 15MG BASE/5ML | A075250 | 001 | Jul 12, 2002 | Mar | DISC |

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | | SHIONOGI INC | EQ 10MG BASE | N021959 | 001 | Jun 01, 2006 | Mar | CFTG |
| >A> | AB | | | EQ 10MG BASE | N021959 | 001 | Jun 01, 2006 | Mar | CFTG |
| >D> | | | | EQ 15MG BASE | N021959 | 002 | Jun 01, 2006 | Mar | CFTG |
| >A> | AB | | | EQ 15MG BASE | N021959 | 002 | Jun 01, 2006 | Mar | CFTG |
| >D> | | + | | EQ 30MG BASE | N021959 | 003 | Jun 01, 2006 | Mar | CFTG |
| >A> | AB | + | | EQ 30MG BASE | N021959 | 003 | Jun 01, 2006 | Mar | CFTG |

PREDNISOLONE SODIUM PHOSPHATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | | MYLAN PHARMS INC | EQ 10MG BASE | A202179 | 001 | Apr 10, 2013 | Mar | NEWA |
| >A> | AB | | | EQ 15MG BASE | A202179 | 002 | Apr 10, 2013 | Mar | NEWA |
| >A> | AB | | | EQ 30MG BASE | A202179 | 003 | Apr 10, 2013 | Mar | NEWA |

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AP | + | TEVA PARENTERAL | 25MG/ML | A040454 | 001 | Aug 22, 2002 | Mar | CAHN |
| >D> | AP | + | | 50MG/ML | A040454 | 002 | Aug 22, 2002 | Mar | CAHN |
| >A> | AP | + | TEVA PHARMS USA | 25MG/ML | A040454 | 001 | Aug 22, 2002 | Mar | CAHN |
| >A> | AP | + | | 50MG/ML | A040454 | 002 | Aug 22, 2002 | Mar | CAHN |

PROPOFOL

INJECTABLE; INJECTION

PROPOFOL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | | TEVA PARENTERAL | 10MG/ML | A075102 | 001 | Jan 04, 1999 | Mar | CAHN |
| >A> | AB | | TEVA PHARMS USA | 10MG/ML | A075102 | 001 | Jan 04, 1999 | Mar | CAHN |

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | GLATT AIR | 60MG | A078065 | 001 | Jan 26, 2007 | Feb | CAHN |
| | AB | | | 80MG | A078065 | 002 | Jan 26, 2007 | Feb | CAHN |
| | AB | | | 120MG | A078065 | 003 | Jan 26, 2007 | Feb | CAHN |
| | AB | | | 160MG | A078065 | 004 | Jan 26, 2007 | Feb | CAHN |

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | | @ TEVA WOMENS | 5MG | N016012 | 001 | | Mar | CAHN |

TABLET; ORAL
VIVACTIL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | @ TEVA WOMENS | 10MG | N016012 | 002 | | Mar | CAHN |
| >D> | | @ TEVA WOMENS R AND D | 5MG | N016012 | 001 | | Mar | CAHN |
| >D> | | @ | 10MG | N016012 | 002 | | Mar | CAHN |

QUETIAPINE FUMARATE

TABLET; ORAL
QUETIAPINE FUMARATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | ACTAVIS PHARMA | EQ 25MG BASE | A201762 | 001 | Feb 27, 2013 | Feb | NEWA |
| | AB | | EQ 50MG BASE | A201762 | 002 | Feb 27, 2013 | Feb | NEWA |
| | AB | | EQ 100MG BASE | A201762 | 003 | Feb 27, 2013 | Feb | NEWA |
| | AB | | EQ 150MG BASE | A201762 | 004 | Feb 27, 2013 | Feb | NEWA |
| | AB | | EQ 200MG BASE | A201762 | 005 | Feb 27, 2013 | Feb | NEWA |
| | AB | | EQ 300MG BASE | A201762 | 006 | Feb 27, 2013 | Feb | NEWA |
| | AB | | EQ 400MG BASE | A201762 | 007 | Feb 27, 2013 | Feb | NEWA |
| | AB | ALKEM LABS LTD | EQ 25MG BASE | A201504 | 001 | Feb 12, 2013 | Jan | NEWA |
| | AB | | EQ 50MG BASE | A201504 | 002 | Feb 12, 2013 | Jan | NEWA |
| | AB | | EQ 100MG BASE | A201504 | 003 | Feb 12, 2013 | Jan | NEWA |
| | AB | | EQ 150MG BASE | A201504 | 004 | Feb 12, 2013 | Jan | NEWA |
| | AB | | EQ 200MG BASE | A201504 | 005 | Feb 12, 2013 | Jan | NEWA |
| | AB | | EQ 300MG BASE | A201504 | 006 | Feb 12, 2013 | Jan | NEWA |
| | AB | | EQ 400MG BASE | A201504 | 007 | Feb 12, 2013 | Jan | NEWA |

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | APOTEX | EQ 5MG BASE | A076240 | 001 | Jan 26, 2006 | Mar | DISC |
| >D> | AB | | EQ 10MG BASE | A076240 | 002 | Jan 26, 2006 | Mar | DISC |
| >D> | AB | | EQ 20MG BASE | A076240 | 003 | Jan 26, 2006 | Mar | DISC |
| >D> | AB | | EQ 40MG BASE | A076240 | 004 | Jan 26, 2006 | Mar | DISC |
| >A> | | @ APOTEX INC | EQ 5MG BASE | A076240 | 001 | Jan 26, 2006 | Mar | DISC |
| >A> | | @ | EQ 10MG BASE | A076240 | 002 | Jan 26, 2006 | Mar | DISC |
| >A> | | @ | EQ 20MG BASE | A076240 | 003 | Jan 26, 2006 | Mar | DISC |
| >A> | | @ | EQ 40MG BASE | A076240 | 004 | Jan 26, 2006 | Mar | DISC |

RABEPRAZOLE SODIUM

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | CAPSULE, DELAYED RELEASE; ORAL | | | | | | |
| >A> | | ACIPHEX SPRINKLE | | | | | | |
| >A> | | EISAI INC | 5MG | N204736 | 001 | Mar 26, 2013 | Mar | NEWA |
| >A> | | + | 10MG | N204736 | 002 | Mar 26, 2013 | Mar | NEWA |

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
RANITIDINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AP | ZYDUS PHARMS USA INC | 25MG/ML | A091534 | 001 | Feb 22, 2013 | Feb | NEWA |

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | AB | WATSON LABS | EQ 150MG BASE | A077426 | 001 | Dec 19, 2005 | Mar | DISC |
| | | @ | EQ 150MG BASE | A074864 | 001 | Oct 20, 1997 | Jan | DISC |
| >D> | AB | | EQ 300MG BASE | A077426 | 002 | Dec 19, 2005 | Mar | DISC |
| | | @ | EQ 300MG BASE | A074864 | 002 | Oct 20, 1997 | Jan | DISC |
| >A> | | @ WATSON LABS INC | EQ 150MG BASE | A077426 | 001 | Dec 19, 2005 | Mar | DISC |
| >A> | | @ | EQ 300MG BASE | A077426 | 002 | Dec 19, 2005 | Mar | DISC |

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL
RIMANTADINE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | COREPHARMA | 100MG | A075916 | 001 | Nov 02, 2001 | Feb | DISC |

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERIDONE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | MYLAN PHARMS INC | 0.25MG | A091537 | 006 | Feb 12, 2013 | Feb | NEWA |
| | AB | | PAR PHARM | 0.25MG | A077494 | 001 | Apr 30, 2009 | Feb | CTEC |
| >A> | AB | | SUN PHARM INDS LTD | 0.5MG | A078464 | 001 | Apr 08, 2013 | Mar | NEWA |
| >A> | AB | | | 1MG | A078464 | 002 | Apr 08, 2013 | Mar | NEWA |
| >A> | AB | | | 2MG | A078464 | 003 | Apr 08, 2013 | Mar | NEWA |
| >A> | AB | | | 3MG | A078464 | 004 | Apr 08, 2013 | Mar | NEWA |
| >A> | AB | | | 4MG | A078464 | 005 | Apr 08, 2013 | Mar | NEWA |

RIZATRIPTAN BENZOATE

TABLET; ORAL
RIZATRIPTAN BENZOATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | | CIPLA LTD | EQ 5MG BASE | A077526 | 001 | Mar 26, 2013 | Mar | NEWA |
| >A> | AB | | | EQ 10MG BASE | A077526 | 002 | Mar 26, 2013 | Mar | NEWA |

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ZEMURON

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | ORGANON USA INC | 10MG/ML (10MG/ML) | N020214 | 002 | Mar 17, 1994 | Jan | CAHN |
| | AP | + | | 50MG/5ML (10MG/ML) | N020214 | 001 | Mar 17, 1994 | Jan | CAHN |
| | AP | + | | 100MG/10ML (10MG/ML) | N020214 | 003 | Mar 17, 1994 | Jan | CAHN |

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
REQUIP

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | + | GLAXOSMITHKLINE | EQ 0.25MG BASE | N020658 | 001 | Sep 19, 1997 | Mar | CAHN |
| >D> | AB | | | EQ 0.5MG BASE | N020658 | 002 | Sep 19, 1997 | Mar | CAHN |
| >D> | AB | | | EQ 1MG BASE | N020658 | 003 | Sep 19, 1997 | Mar | CAHN |
| >D> | AB | | | EQ 2MG BASE | N020658 | 004 | Sep 19, 1997 | Mar | CAHN |
| >D> | AB | | | EQ 3MG BASE | N020658 | 006 | Jan 27, 1999 | Mar | CAHN |
| >D> | AB | | | EQ 4MG BASE | N020658 | 007 | Jan 27, 1999 | Mar | CAHN |
| >D> | AB | | | EQ 5MG BASE | N020658 | 005 | Sep 19, 1997 | Mar | CAHN |
| >A> | AB | + | GLAXOSMITHKLINE LLC | EQ 0.25MG BASE | N020658 | 001 | Sep 19, 1997 | Mar | CAHN |
| >A> | AB | | | EQ 0.5MG BASE | N020658 | 002 | Sep 19, 1997 | Mar | CAHN |
| >A> | AB | | | EQ 1MG BASE | N020658 | 003 | Sep 19, 1997 | Mar | CAHN |
| >A> | AB | | | EQ 2MG BASE | N020658 | 004 | Sep 19, 1997 | Mar | CAHN |
| >A> | AB | | | EQ 3MG BASE | N020658 | 006 | Jan 27, 1999 | Mar | CAHN |
| >A> | AB | | | EQ 4MG BASE | N020658 | 007 | Jan 27, 1999 | Mar | CAHN |
| >A> | AB | | | EQ 5MG BASE | N020658 | 005 | Sep 19, 1997 | Mar | CAHN |

TABLET, EXTENDED RELEASE; ORAL
REQUIP XL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | + | GLAXOSMITHKLINE LLC | EQ 2MG BASE | N022008 | 001 | Jun 13, 2008 | Mar | CAHN |
| >A> | | @ | | EQ 3MG BASE | N022008 | 002 | Jun 13, 2008 | Mar | CAHN |
| >A> | AB | | | EQ 4MG BASE | N022008 | 003 | Jun 13, 2008 | Mar | CAHN |
| >A> | AB | | | EQ 6MG BASE | N022008 | 006 | Apr 10, 2009 | Mar | CAHN |
| >A> | AB | | | EQ 8MG BASE | N022008 | 004 | Jun 13, 2008 | Mar | CAHN |
| >A> | AB | | | EQ 12MG BASE | N022008 | 005 | Oct 31, 2008 | Mar | CAHN |
| >D> | AB | + | SMITHKLINE BEECHAM | EQ 2MG BASE | N022008 | 001 | Jun 13, 2008 | Mar | CAHN |

TABLET, EXTENDED RELEASE; ORAL
REQUIP XL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | @ SMITHKLINE BEECHAM | EQ 3MG BASE | N022008 | 002 | Jun 13, 2008 | Mar | CAHN |
| >D> | AB | | EQ 4MG BASE | N022008 | 003 | Jun 13, 2008 | Mar | CAHN |
| >D> | AB | | EQ 6MG BASE | N022008 | 006 | Apr 10, 2009 | Mar | CAHN |
| >D> | AB | | EQ 8MG BASE | N022008 | 004 | Jun 13, 2008 | Mar | CAHN |
| >D> | AB | | EQ 12MG BASE | N022008 | 005 | Oct 31, 2008 | Mar | CAHN |

ROSIGLITAZONE MALEATE

TABLET; ORAL
AVANDIA

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | SB PHARMCO | EQ 2MG BASE | N021071 | 002 | May 25, 1999 | Jan | CFTG |
| | AB | | EQ 4MG BASE | N021071 | 003 | May 25, 1999 | Jan | CFTG |
| | AB | + | EQ 8MG BASE | N021071 | 004 | May 25, 1999 | Jan | CFTG |

ROSIGLITAZONE MALEATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | TEVA | EQ 2MG BASE | A076747 | 001 | Jan 25, 2013 | Jan | NEWA |
| | AB | | EQ 4MG BASE | A076747 | 002 | Jan 25, 2013 | Jan | NEWA |
| | AB | | EQ 8MG BASE | A076747 | 003 | Jan 25, 2013 | Jan | NEWA |

SAQUINAVIR MESYLATE

TABLET; ORAL
INVIRASE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | + HOFFMAN LA ROCHE | EQ 500MG BASE | N021785 | 001 | Dec 17, 2004 | Feb | CAHN |

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
SELEGILINE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ DAVA PHARMS INC | 5MG | A074641 | 001 | Aug 02, 1996 | Jan | DISC |

SILDENAFIL CITRATE

TABLET; ORAL
SILDENAFIL CITRATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AB | ACTAVIS PHARMA | EQ 20MG BASE | A200149 | 001 | Feb 25, 2013 | Feb | NEWA |
| | AB | AMNEAL PHARMS | EQ 20MG BASE | A202025 | 001 | Feb 28, 2013 | Feb | NEWA |

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | | MEDEFIL INC | 18MG/2ML (9MG/ML) | N202832 | 002 | Jan 06, 2012 | Mar | NEWA |
| >A> | | | 22.5MG/2.5ML (9MG/ML) | N202832 | 003 | Jan 06, 2012 | Mar | NEWA |
| >A> | | | 27MG/3ML (9MG/ML) | N202832 | 004 | Jan 06, 2012 | Mar | NEWA |
| >A> | | | 45MG/5ML (9MG/ML) | N202832 | 005 | Jan 06, 2012 | Mar | NEWA |
| >A> | | | 90MG/10ML (9MG/ML) | N202832 | 006 | Jan 06, 2012 | Mar | NEWA |

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | MEDEFIL | 9MG/ML | N202832 | 001 | Jan 06, 2012 | Mar | CPOT |
| >A> | | MEDEFIL INC | 9MG/ML (9MG/ML) | N202832 | 001 | Jan 06, 2012 | Mar | CPOT |

SOLUTION; IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | @ BAXTER HLTHCARE | 450MG/100ML | N017864 | 001 | | Jan | DISC |

SODIUM PHENYLBUTYRATE

POWDER; ORAL
BUPHENYL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | | + MEDICIS | 3GM/TEASPOONFUL | N020573 | 001 | Apr 30, 1996 | Mar | CFTG |
| >A> | AB | + | 3GM/TEASPOONFUL | N020573 | 001 | Apr 30, 1996 | Mar | CFTG |

POWDER; ORAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | SODIUM PHENYLBUTYRATE | | | | | | | |
| >A> | AB | SIGMAPHARM LABS LLC | 3GM/TEASPOONFUL | A202819 | 001 | Mar 22, 2013 | Mar | NEWA | |

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | SODIUM POLYSTYRENE SULFONATE | | | | | | | |
| >D> | AA | ROXANE | 15GM/60ML | A089049 | 001 | Nov 17, 1986 | Mar | DISC | |
| >A> | | @ | 15GM/60ML | A089049 | 001 | Nov 17, 1986 | Mar | DISC | |

SULFACETAMIDE SODIUM

LOTION; TOPICAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | KLARON | | | | | | | |
| | AB | + VALEANT BERMUDA | 10% | N019931 | 001 | Dec 23, 1996 | Feb | CAHN | |

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | SULFAMETHOXAZOLE AND TRIMETHOPRIM | | | | | | | |
| >D> | | + TEVA PARENTERAL | 80MG/ML;16MG/ML | A073303 | 001 | Oct 31, 1991 | Mar | CAHN | |
| >A> | | + TEVA PHARMS USA | 80MG/ML;16MG/ML | A073303 | 001 | Oct 31, 1991 | Mar | CAHN | |

TABLET; ORAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | SULFAMETHOPRIM | | | | | | | |
| >D> | AB | NOVEL LABS INC | 400MG;80MG | A070022 | 001 | Feb 15, 1985 | Mar | DISC | |
| >A> | | @ | 400MG;80MG | A070022 | 001 | Feb 15, 1985 | Mar | DISC | |
| >D> | | SULFAMETHOPRIM-DS | | | | | | | |
| >D> | AB | NOVEL LABS INC | 800MG;160MG | A070032 | 001 | Feb 15, 1985 | Mar | DISC | |
| >A> | | @ | 800MG;160MG | A070032 | 001 | Feb 15, 1985 | Mar | DISC | |

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | SUMATRIPTAN SUCCINATE | | | | | | | |
| | AP | SAGENT AGILA | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A090641 | 001 | Jul 28, 2010 | Feb | CAHN | |
| >D> | AP | TEVA PARENTERAL | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A077907 | 001 | Feb 06, 2009 | Mar | CAHN | |
| >A> | AP | TEVA PHARMS USA | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A077907 | 001 | Feb 06, 2009 | Mar | CAHN | |

SYSTEM; IONTOPHORESIS

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | ZECUITY | | | | | | | |
| | | + NUPATHE | EQ 6.5MG BASE/4HR | N202278 | 001 | Jan 17, 2013 | Jan | NEWA | |

>A> TECHNETIUM TC-99M TILMANOCEPT

>A> INJECTABLE; INJECTION

>A> LYMPHOSEEK KIT

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | + NAVIDEA BIOPHARMS | N/A | N202207 | 001 | Mar 13, 2013 | Mar | NEWA | |

TERBUTALINE SULFATE

INJECTABLE; INJECTION

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | TERBUTALINE SULFATE | | | | | | | |
| >D> | | @ TEVA PARENTERAL | 1MG/ML | A076853 | 001 | Jul 20, 2004 | Mar | CAHN | |
| >A> | | @ TEVA PHARMS USA | 1MG/ML | A076853 | 001 | Jul 20, 2004 | Mar | CAHN | |

TESTOSTERONE

GEL; TRANSDERMAL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | TESTOSTERONE | | | | | | | |
| | | PERRIGO ISRAEL | 25MG/2.5GM PACKET | N203098 | 002 | Jan 31, 2013 | Jan | NEWA | |
| | | | 50MG/5GM PACKET | N203098 | 003 | Jan 31, 2013 | Jan | NEWA | |

GEL, METERED; TRANSDERMAL
TESTOSTERONE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | PERRIGO ISRAEL | 12.5MG/1.25GM ACTUATION | N203098 | 001 | Jan 31, 2013 | Jan | NEWA |

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELATESTRYL

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AO | + | ENDO PHARMS | 200MG/ML | N009165 | 003 | | Jan | CAHN |
| | | @ | | 200MG/ML | N009165 | 001 | | Jan | CAHN |

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
THEOPHYLLINE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | + | PLIVA | 450MG | A081236 | 001 | Nov 09, 1992 | Mar | CAHN |
| >A> | AB | + | TEVA PHARMS | 450MG | A081236 | 001 | Nov 09, 1992 | Mar | CAHN |

THIOGUANINE

TABLET; ORAL
THIOGUANINE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | + | ASPEN GLOBAL INC | 40MG | N012429 | 001 | | Mar | CAHN |
| >D> | | + | GLAXOSMITHKLINE | 40MG | N012429 | 001 | | Mar | CAHN |

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC
TIMOPTIC-XE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | + | VALEANT PHARMS LLC | EQ 0.25% BASE | N020330 | 001 | Nov 04, 1993 | Jan | CAHN |
| | AB | + | | EQ 0.5% BASE | N020330 | 002 | Nov 04, 1993 | Jan | CAHN |

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL
TIZANIDINE HYDROCHLORIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | MYLAN PHARMS INC | EQ 2MG BASE | A076282 | 001 | Dec 16, 2003 | Feb | DISC |
| | | @ | | EQ 4MG BASE | A076282 | 002 | Dec 16, 2003 | Feb | DISC |

TOBRAMYCIN

>A> POWDER; INHALATION
>A> TOBI PODHALER

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | | + | NOVARTIS | 28MG | N201688 | 001 | Mar 22, 2013 | Mar | NEWA |

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | AB | | MYLAN | 250MG | A070259 | 001 | Jan 02, 1986 | Mar | CTEC |
| >D> | AB | + | | 500MG | A070259 | 003 | Mar 17, 1986 | Mar | CTEC |
| >A> | | | MYLAN PHARMS INC | 250MG | A070259 | 001 | Jan 02, 1986 | Mar | CTEC |
| >A> | | + | | 500MG | A070259 | 003 | Mar 17, 1986 | Mar | CTEC |
| >D> | AB | | WATSON LABS | 250MG | A070514 | 001 | Jan 09, 1986 | Mar | DISC |
| >A> | | @ | | 250MG | A070514 | 001 | Jan 09, 1986 | Mar | DISC |
| >D> | AB | | | 500MG | A070515 | 001 | Jan 09, 1986 | Mar | DISC |
| >A> | | @ | | 500MG | A070515 | 001 | Jan 09, 1986 | Mar | DISC |

TOPIRAMATE

TABLET; ORAL
TOPIRAMATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | ACTIVIS TOTOWA LLC | 25MG | A078637 | 001 | Feb 27, 2013 | Feb | NEWA |
| | AB | | | 50MG | A078637 | 002 | Feb 27, 2013 | Feb | NEWA |

TABLET; ORAL
TOPIRAMATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | ACTIVIS TOTOWA LLC | 100MG | A078637 | 003 | Feb 27, 2013 | Feb | NEWA |
| AB | | | 200MG | A078637 | 004 | Feb 27, 2013 | Feb | NEWA |
| AB | | UNICHEM LABS LTD | 200MG | A090162 | 004 | Feb 19, 2013 | Feb | NEWA |

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
TRAMADOL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> AB | | CSPC OUYI PHARM CO | 50MG | A091498 | 001 | Mar 29, 2013 | Mar | NEWA |

TABLET, EXTENDED RELEASE; ORAL
RYZOLT

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | @ | PURDUE PHARMA | 100MG | N021745 | 001 | Dec 30, 2008 | Jan | DISC |
| | @ | | 200MG | N021745 | 002 | Dec 30, 2008 | Jan | DISC |
| | @ | | 300MG | N021745 | 003 | Dec 30, 2008 | Jan | DISC |

TRAMADOL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB1 | | PAR PHARM INC | 100MG | A078783 | 001 | Nov 13, 2009 | Feb | CRLD |
| AB2 | + | SUN PHARMA GLOBAL | 100MG | A091607 | 001 | Dec 30, 2011 | Feb | CRLD |

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC
TRAVOPROST

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | PAR PHARM | 0.004% | A091340 | 001 | Mar 01, 2013 | Feb | NEWA |

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AB | | PLIVA | 50MG | A071523 | 001 | Dec 11, 1987 | Mar | CAHN |
| >D> AB | | | 100MG | A071524 | 001 | Dec 11, 1987 | Mar | CAHN |
| >A> AB | | TEVA PHARMS USA | 50MG | A071523 | 001 | Dec 11, 1987 | Mar | CAHN |
| >A> AB | | | 100MG | A071524 | 001 | Dec 11, 1987 | Mar | CAHN |

URSODIOL

TABLET; ORAL
URSODIOL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | PAR PHARM | 250MG | A202540 | 001 | Feb 14, 2013 | Feb | NEWA |
| AB | | | 500MG | A202540 | 002 | Feb 14, 2013 | Feb | NEWA |

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALACYCLOVIR HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> AB | | ACTAVIS GRP PTC | EQ 500MG BASE | A090370 | 001 | Mar 16, 2011 | Mar | CAHN |
| >A> AB | | | EQ 1GM BASE | A090370 | 002 | Mar 16, 2011 | Mar | CAHN |
| >D> AB | | ACTAVIS PHARMA | EQ 500MG BASE | A090370 | 001 | Mar 16, 2011 | Mar | CAHN |
| >D> AB | | | EQ 1GM BASE | A090370 | 002 | Mar 16, 2011 | Mar | CAHN |

VALPROIC ACID

CAPSULE; ORAL
VALPROIC ACID

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AB | | SUN PHARM INDS LTD | 250MG | A091037 | 001 | Feb 22, 2013 | Feb | NEWA |

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
VERAPAMIL HYDROCHLORIDE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> AP | | INTL MEDICATION | 2.5MG/ML | A070451 | 001 | Dec 16, 1985 | Mar | DISC |
| >A> | @ | | 2.5MG/ML | A070451 | 001 | Dec 16, 1985 | Mar | DISC |

VERTEPORFIN

INJECTABLE; INJECTION

VISUDYNE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | + | | VALEANT PHARMS INC | 15MG/VIAL | N021119 | 001 | Apr 12, 2000 | Jan | CAHN |

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | AMNEAL PHARMS | 1MG | A202202 | 001 | Mar 04, 2013 | Feb | NEWA |
| | AB | | | 2MG | A202202 | 002 | Mar 04, 2013 | Feb | NEWA |
| | AB | | | 2.5MG | A202202 | 003 | Mar 04, 2013 | Feb | NEWA |
| | AB | | | 3MG | A202202 | 004 | Mar 04, 2013 | Feb | NEWA |
| | AB | | | 4MG | A202202 | 005 | Mar 04, 2013 | Feb | NEWA |
| | AB | | | 5MG | A202202 | 006 | Mar 04, 2013 | Feb | NEWA |
| | AB | | | 6MG | A202202 | 007 | Mar 04, 2013 | Feb | NEWA |
| | AB | | | 7.5MG | A202202 | 008 | Mar 04, 2013 | Feb | NEWA |
| | AB | | | 10MG | A202202 | 009 | Mar 04, 2013 | Feb | NEWA |

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AB | | HEC PHARM USA INC | 300MG | A202058 | 001 | Oct 07, 2011 | Feb | CMFD |
| | | @ | | 300MG | A202058 | 001 | Oct 07, 2011 | Jan | DISC |

ZOLEDRONIC ACID

INJECTABLE; INJECTION

ZOLEDRONIC ACID

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AP | | DR REDDYS LABS LTD | EQ 5MG BASE/100ML | A091363 | 001 | Mar 29, 2013 | Mar | NEWA |
| >A> | AP | | EMCURE PHARMS LTD | EQ 5MG BASE/100ML | A201801 | 001 | Mar 29, 2013 | Mar | NEWA |

INJECTABLE; IV (INFUSION)

RECLAST

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >D> | | + | NOVARTIS | EQ 5MG BASE/100ML | N021817 | 001 | Apr 16, 2007 | Mar | CTEC |
| >A> | AP | + | | EQ 5MG BASE/100ML | N021817 | 001 | Apr 16, 2007 | Mar | CTEC |

ZOLEDRONIC ACID

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AP | | ACTAVIS INC | EQ 4MG BASE/5ML | A202472 | 001 | Mar 04, 2013 | Feb | NEWA |
| | AP | | AGILA SPECLTS | EQ 4MG BASE/5ML | A202650 | 001 | Mar 04, 2013 | Feb | NEWA |
| | AP | | DR REDDYS LABS LTD | EQ 4MG BASE/5ML | A091186 | 001 | Mar 04, 2013 | Feb | NEWA |
| >A> | AP | | EMCURE PHARMS LTD | EQ 4MG BASE/5ML | A201783 | 001 | Mar 12, 2013 | Mar | NEWA |
| >A> | AP | | HOSPIRA INC | EQ 5MG BASE/100ML | A202837 | 001 | Apr 05, 2013 | Mar | NEWA |
| | AP | | PHARMACEUTICS | EQ 4MG BASE/5ML | A091170 | 001 | Mar 04, 2013 | Feb | NEWA |
| | | + | SUN PHARMA GLOBAL | EQ 4MG BASE/VIAL | A090018 | 001 | Mar 04, 2013 | Feb | NEWA |
| | AP | | | EQ 4MG BASE/5ML | A202746 | 001 | Mar 04, 2013 | Feb | NEWA |

ZOMETA

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | AP | + | NOVARTIS | EQ 4MG BASE/5ML | N021223 | 002 | Mar 07, 2003 | Feb | CFTG |

ZOLPIDEM TARTRATE

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| >A> | AB | | WATSON LABS INC FL | 6.25MG | A090153 | 001 | Mar 25, 2013 | Mar | NEWA |
| >A> | AB | | | 12.5MG | A090153 | 002 | Mar 25, 2013 | Mar | NEWA |

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | @ | COREPHARMA | 25MG | A077876 | 001 | Feb 21, 2007 | Feb | DISC |

CAPSULE; ORAL

ZONISAMIDE

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | @ | COREPHARMA | 50MG | A077876 | 002 | Feb | 21, 2007 | Feb | DISC |
| | | @ | | 100MG | A077876 | 003 | Feb | 21, 2007 | Feb | DISC |
| >D> | AB | | DR REDDYS LABS LTD | 25MG | A077645 | 002 | Sep | 29, 2006 | Mar | DISC |
| >A> | | @ | | 25MG | A077645 | 002 | Sep | 29, 2006 | Mar | DISC |
| >D> | AB | | | 50MG | A077645 | 003 | Sep | 29, 2006 | Mar | DISC |
| >A> | | @ | | 50MG | A077645 | 003 | Sep | 29, 2006 | Mar | DISC |
| >D> | AB | | | 100MG | A077645 | 001 | Dec | 22, 2005 | Mar | DISC |
| >A> | | @ | | 100MG | A077645 | 001 | Dec | 22, 2005 | Mar | DISC |

ASPIRIN

CAPSULE; ORAL

ASPIRIN

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| + | PLX PHARMA | 325MG | N203697 | 001 | Jan 14, 2013 | Jan | NEWA |

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL

CHILDREN'S ZYRTEC ALLERGY

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| + | MCNEIL CONS | 5MG | N021621 | 003 | Nov 16, 2007 | Feb | CRLD |
| @ | | 10MG | N021621 | 004 | Nov 16, 2007 | Feb | DISC |

CHILDREN'S ZYRTEC HIVES RELIEF

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| + | MCNEIL CONS | 5MG | N021621 | 005 | Nov 16, 2007 | Feb | CRLD |
| @ | | 10MG | N021621 | 006 | Nov 16, 2007 | Feb | DISC |

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORASCRUB MAXI SWABSTICK

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | + | PROF DSPLS | 3.15%;70% (5.1ML) | N021524 | 003 | Jun 03, 2005 | Mar | CTNA |

CHLORASCRUB SWAB

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | + | PROF DSPLS | 3.15%;70% (1ML) | N021524 | 001 | Jun 03, 2005 | Mar | CTNA |

CHLORASCRUB SWABSTICK

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >D> | + | PROF DSPLS | 3.15%;70% (1.6ML) | N021524 | 002 | Jun 03, 2005 | Mar | CTNA |

PREVANTICS MAXI SWABSTICK

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | + | PROF DSPLS | 3.15%;70% (5.1ML) | N021524 | 003 | Jun 03, 2005 | Mar | CTNA |

PREVANTICS SWAB

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | + | PROF DSPLS | 3.15%;70% (1ML) | N021524 | 001 | Jun 03, 2005 | Mar | CTNA |

PREVANTICS SWABSTICK

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| >A> | + | PROF DSPLS | 3.15%;70% (1.6ML) | N021524 | 002 | Jun 03, 2005 | Mar | CTNA |

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | AVANTHI INC | 6MG;120MG | A078648 | 001 | Feb 27, 2013 | Feb | NEWA |

FEXOFENADINE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | DR REDDYS LABS LTD | 30MG | A202978 | 001 | Jan 18, 2013 | Jan | NEWA |

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | DR REDDYS LABS LTD | 30MG | A202978 | 002 | Jan 18, 2013 | Jan | NEWA |

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | LUPIN LTD | 0.75MG | A091328 | 001 | Jan 23, 2013 | Jan | NEWA |
| AB | NOVEL LABS INC | 1.5MG | A202508 | 001 | Feb 22, 2013 | Feb | NEWA |

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| @ | WATSON LABS INC FL | 5MG;120MG | A076208 | 001 | Jan 28, 2004 | Feb | DISC |

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE NITRATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | APHENA PHARMA MD | 2% | A074366 | 001 | Feb 22, 1996 | Jan | CAHN |

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | AKORN INC | 0.025%;0.3% | A202795 | 001 | Jan 24, 2013 | Jan | NEWA |

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL
OXYTROL FOR WOMEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| + | MSD CONSUMER | 3.9MG/24HR | N202211 | 001 | Jan 25, 2013 | Jan | NEWA |

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL
POLYETHYLENE GLYCOL 3350

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | PAR PHARM | 17GM/SCOOPFUL | A079214 | 001 | Jan 31, 2013 | Jan | NEWA |

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| >D> | WATSON LABS | EQ 75MG BASE | A075212 | 001 | Jan 14, 2000 | Mar | DISC |
| >A> | @ | EQ 75MG BASE | A075212 | 001 | Jan 14, 2000 | Mar | DISC |

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2013**

NO MARCH 2013 APPROVALS

# ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2013 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ACETYLCYSTEINE - ACETADOTE | | | | | | |
| N021539 001 | >A> 8399445 | Aug 24, 2025 | U-1373 | | | |
| ADAPALENE; BENZOYL PEROXIDE - EPIDUO | | | | | | |
| N022320 001 | | | | | NPP | Feb 01, 2016 |
| ALOGLIPTIN BENZOATE - NESINA | | | | | | |
| N022271 001 | 6150383 | Jun 19, 2016 | U-1330 | | NCE | Jan 25, 2018 |
| | 6211205 | Jun 19, 2016 | U-1331 | | | |
| | 6303640 | Aug 09, 2016 | U-1332 | | | |
| | 6303661 | Apr 24, 2017 | U-1333 | | | |
| | 6329404 | Jun 19, 2016 | DP U-1334 | | | |
| | 6890898 | Feb 02, 2019 | U-1335 | | | |
| | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | 8288539 | Mar 15, 2025 | DS | | | |
| ALOGLIPTIN BENZOATE - NESINA | | | | | | |
| N022271 002 | 6150383 | Jun 19, 2016 | U-1330 | | NCE | Jan 25, 2018 |
| | 6211205 | Jun 19, 2016 | U-1331 | | | |
| | 6303640 | Aug 09, 2016 | U-1332 | | | |
| | 6303661 | Apr 24, 2017 | U-1333 | | | |
| | 6329404 | Jun 19, 2016 | DP U-1334 | | | |
| | 6890898 | Feb 02, 2019 | U-1335 | | | |
| | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | 8288539 | Mar 15, 2025 | DS | | | |
| ALOGLIPTIN BENZOATE - NESINA | | | | | | |
| N022271 003 | 6150383 | Jun 19, 2016 | U-1330 | | NCE | Jan 25, 2018 |
| | 6211205 | Jun 19, 2016 | U-1331 | | | |
| | 6303640 | Aug 09, 2016 | U-1332 | | | |
| | 6303661 | Apr 24, 2017 | U-1333 | | | |
| | 6329404 | Jun 19, 2016 | DP U-1334 | | | |
| | 6890898 | Feb 02, 2019 | U-1335 | | | |
| | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | 8288539 | Mar 15, 2025 | DS | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO | | | | | | |
| N203414 001 | 5965584 | Jun 19, 2016 | U-1339 | | NCE | Jan 25, 2018 |
| | 6150383 | Jun 19, 2016 | U-1330 | | NC | Jan 25, 2016 |
| | 6150384 | Jun 19, 2016 | U-1340 | | | |
| | 6166042 | Jun 19, 2016 | U-1341 | | | |
| | 6166043 | Jun 19, 2016 | U-1342 | | | |
| | 6172090 | Jun 19, 2016 | U-1343 | | | |
| | 6211205 | Jun 19, 2016 | U-1331 | | | |
| | 6303640 | Aug 09, 2016 | U-1332 | | | |
| | 6303661 | Apr 24, 2017 | U-1333 | | | |
| | 6329404 | Jun 19, 2016 | U-1334 | | | |
| | 6890898 | Feb 02, 2019 | U-1335 | | | |
| | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | 8288539 | Mar 15, 2025 | DS | | | |
| ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO | | | | | | |
| N203414 002 | 5965584 | Jun 19, 2016 | U-1339 | | NCE | Jan 25, 2018 |
| | 6150383 | Jun 19, 2016 | U-1330 | | NC | Jan 25, 2016 |
| | 6150384 | Jun 19, 2016 | U-1340 | | | |
| | 6166042 | Jun 19, 2016 | U-1341 | | | |
| | 6166043 | Jun 19, 2016 | U-1342 | | | |
| | 6172090 | Jun 19, 2016 | U-1343 | | | |
| | 6211205 | Jun 19, 2016 | U-1331 | | | |
| | 6303640 | Aug 09, 2016 | U-1332 | | | |
| | 6303661 | Apr 24, 2017 | U-1333 | | | |
| | 6329404 | Jun 19, 2016 | U-1334 | | | |
| | 6890898 | Feb 02, 2019 | U-1335 | | | |
| | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | 8288539 | Mar 15, 2025 | DS | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI | | | | | | |
| N022426 001 | 5965584 | Jun 19, 2016 | DP U-1339 | | NCE | Jan 25, 2018 |
| | 6150383 | Jun 19, 2016 | U-1330 | | NC | Jan 25, 2016 |
| | 6150384 | Jun 19, 2016 | U-1340 | | | |
| | 6166042 | Jun 19, 2016 | U-1341 | | | |
| | 6166043 | Jun 19, 2016 | U-1342 | | | |
| | 6172090 | Jun 19, 2016 | U-1343 | | | |
| | 6211205 | Jun 19, 2016 | U-1331 | | | |
| | 6271243 | Jun 19, 2016 | U-1344 | | | |
| | 6303640 | Aug 09, 2016 | U-1332 | | | |
| | 6303661 | Apr 24, 2017 | U-1333 | | | |
| | 6329404 | Jun 19, 2016 | DP U-1334 | | | |
| | 6890898 | Feb 02, 2019 | U-1335 | | | |
| | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | 8288539 | Mar 15, 2025 | DS | | | |
| ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI | | | | | | |
| N022426 002 | 5965584 | Jun 19, 2016 | DP U-1339 | | NCE | Jan 25, 2018 |
| | 6150383 | Jun 19, 2016 | U-1330 | | NC | Jan 25, 2016 |
| | 6150384 | Jun 19, 2016 | U-1340 | | | |
| | 6166042 | Jun 19, 2016 | U-1341 | | | |
| | 6166043 | Jun 19, 2016 | U-1342 | | | |
| | 6172090 | Jun 19, 2016 | U-1343 | | | |
| | 6211205 | Jun 19, 2016 | U-1331 | | | |
| | 6271243 | Jun 19, 2016 | U-1344 | | | |
| | 6303640 | Aug 09, 2016 | U-1332 | | | |
| | 6303661 | Apr 24, 2017 | U-1333 | | | |
| | 6329404 | Jun 19, 2016 | DP U-1334 | | | |
| | 6890898 | Feb 02, 2019 | U-1335 | | | |
| | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | 8288539 | Mar 15, 2025 | DS | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI | | | | | | |
| N022426 003 | 5965584 | Jun 19, 2016 | DP U-1339 | | NCE | Jan 25, 2018 |
| | 6150383 | Jun 19, 2016 | U-1330 | | NC | Jan 25, 2016 |
| | 6150384 | Jun 19, 2016 | U-1340 | | | |
| | 6166042 | Jun 19, 2016 | U-1341 | | | |
| | 6166043 | Jun 19, 2016 | U-1342 | | | |
| | 6172090 | Jun 19, 2016 | U-1343 | | | |
| | 6211205 | Jun 19, 2016 | U-1331 | | | |
| | 6271243 | Jun 19, 2016 | U-1344 | | | |
| | 6303640 | Aug 09, 2016 | U-1332 | | | |
| | 6303661 | Apr 24, 2017 | U-1333 | | | |
| | 6329404 | Jun 19, 2016 | DP U-1334 | | | |
| | 6890898 | Feb 02, 2019 | U-1335 | | | |
| | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | 8288539 | Mar 15, 2025 | DS | | | |
| ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI | | | | | | |
| N022426 004 | 5965584 | Jun 19, 2016 | DP U-1339 | | NCE | Jan 25, 2018 |
| | 6150383 | Jun 19, 2016 | U-1330 | | NC | Jan 25, 2016 |
| | 6150384 | Jun 19, 2016 | U-1340 | | | |
| | 6166042 | Jun 19, 2016 | U-1341 | | | |
| | 6166043 | Jun 19, 2016 | U-1342 | | | |
| | 6172090 | Jun 19, 2016 | U-1343 | | | |
| | 6211205 | Jun 19, 2016 | U-1331 | | | |
| | 6271243 | Jun 19, 2016 | U-1344 | | | |
| | 6303640 | Aug 09, 2016 | U-1332 | | | |
| | 6303661 | Apr 24, 2017 | U-1333 | | | |
| | 6329404 | Jun 19, 2016 | DP U-1334 | | | |
| | 6890898 | Feb 02, 2019 | U-1335 | | | |
| | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | 8288539 | Mar 15, 2025 | DS | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI | | | | | | |
| N022426 005 | 5965584 | Jun 19, 2016 | DP U-1339 | | NCE | Jan 25, 2018 |
| | 6150383 | Jun 19, 2016 | U-1330 | | NC | Jan 25, 2016 |
| | 6150384 | Jun 19, 2016 | U-1340 | | | |
| | 6166042 | Jun 19, 2016 | U-1341 | | | |
| | 6166043 | Jun 19, 2016 | U-1342 | | | |
| | 6172090 | Jun 19, 2016 | U-1343 | | | |
| | 6211205 | Jun 19, 2016 | U-1331 | | | |
| | 6271243 | Jun 19, 2016 | U-1344 | | | |
| | 6303640 | Aug 09, 2016 | U-1332 | | | |
| | 6303661 | Apr 24, 2017 | U-1333 | | | |
| | 6329404 | Jun 19, 2016 | DP U-1334 | | | |
| | 6890898 | Feb 02, 2019 | U-1335 | | | |
| | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | 8288539 | Mar 15, 2025 | DS | | | |
| ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI | | | | | | |
| N022426 006 | 5965584 | Jun 19, 2016 | DP U-1339 | | NCE | Jan 25, 2018 |
| | 6150383 | Jun 19, 2016 | U-1330 | | NC | Jan 25, 2016 |
| | 6150384 | Jun 19, 2016 | U-1340 | | | |
| | 6166042 | Jun 19, 2016 | U-1341 | | | |
| | 6166043 | Jun 19, 2016 | U-1342 | | | |
| | 6172090 | Jun 19, 2016 | U-1343 | | | |
| | 6211205 | Jun 19, 2016 | U-1331 | | | |
| | 6271243 | Jun 19, 2016 | U-1344 | | | |
| | 6303640 | Aug 09, 2016 | U-1332 | | | |
| | 6303661 | Apr 24, 2017 | U-1333 | | | |
| | 6329404 | Jun 19, 2016 | DP U-1334 | | | |
| | 6890898 | Feb 02, 2019 | U-1335 | | | |
| | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | 8288539 | Mar 15, 2025 | DS | | | |
| AMOXICILLIN - MOXATAG | | | | | | |
| N050813 001 | 8357394 | Dec 08, 2026 | DP | | | |
| APIXABAN - ELIQUIS | | | | | | |
| N202155 001 | 6413980 | Dec 22, 2019 | DS DP U-1200 | | | |
| | 6967208 | Feb 03, 2023 | DS DP U-1323 | | | |
| | 6967208 | Feb 03, 2023 | DS DP U-1200 | | | |
| APIXABAN - ELIQUIS | | | | | | |
| N202155 002 | 6413980 | Dec 22, 2019 | DS DP U-1200 | | | |
| | 6967208 | Feb 03, 2023 | DS DP U-1323 | | | |
| | 6967208 | Feb 03, 2023 | DS DP U-1200 | | | |
| ARIPIPRAZOLE - ABILIFY MAINTENA KIT | | | | | | |
| N202971 001 | | | | | NDF | Feb 28, 2016 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ARIPIPRAZOLE - ABILIFY MAINTENA KIT | | | | | | | |
| N202971 | 002 | | | | | NDF | Feb 28, 2016 |
| BEDAQUILINE FUMARATE - SIRTURO | | | | | | | |
| N204384 | 001 | 7498343 | Oct 02, 2024 | DS DP U-1321 | | ODE | Dec 28, 2019 |
| BOCEPREVIR - VICTRELIS | | | | | | | |
| N202258 | 001 | | | | | M-126 | Feb 27, 2016 |
| | | | | | | NPP | Feb 13, 2016 |
| BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN | | | | | | | |
| N021398 | 001 | **>A>** 8354409 | Apr 19, 2022 | DP U-1371 | | | |
| BUDESONIDE - UCERIS | | | | | | | |
| N203634 | 001 | 7410651 | Jun 09, 2020 | DP U-1325 | | NDF | Jan 14, 2016 |
| | | 7431943 | Jun 09, 2020 | DP | | | |
| | | 8293273 | Jun 09, 2020 | DP | | | |
| | | RE43799 | Jun 09, 2020 | DP U-1325 | | | |
| BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT | | | | | | | |
| N021929 | 001 | **>A>** 8387615 | Nov 10, 2024 | DP | | | |
| BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT | | | | | | | |
| N021929 | 002 | **>A>** 8387615 | Nov 10, 2024 | DP | | | |
| CABOZANTINIB S-MALATE - COMETRIQ | | | | | | | |
| N203756 | 001 | | | | | ODE | Nov 29, 2019 |
| CABOZANTINIB S-MALATE - COMETRIQ | | | | | | | |
| N203756 | 002 | | | | | ODE | Nov 29, 2019 |
| CANAGLIFLOZIN - INVOKANA | | | | | | | |
| N204042 | 001 | | | | | **>A>** NCE | Mar 29, 2018 |
| CANAGLIFLOZIN - INVOKANA | | | | | | | |
| N204042 | 002 | | | | | **>A>** NCE | Mar 29, 2018 |
| CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE | | | | | | | |
| A090704 | 003 | | | | | **>A>** PC | Jun 02, 2013 |
| CELECOXIB - CELEBREX | | | | | | | |
| N020998 | 001 | RE44048 | Jun 02, 2015 | U-247 | | | |
| | | RE44048 | Jun 02, 2015 | U-1352 | | | |
| | | RE44048 | Jun 02, 2015 | U-1351 | | | |
| | | RE44048 | Jun 02, 2015 | U-1350 | | | |
| | | RE44048 | Jun 02, 2015 | U-1349 | | | |
| | | RE44048 | Jun 02, 2015 | U-1348 | | | |
| | | RE44048*PED | Dec 02, 2015 | | | | |
| CELECOXIB - CELEBREX | | | | | | | |
| N020998 | 002 | RE44048 | Jun 02, 2015 | U-247 | | | |
| | | RE44048 | Jun 02, 2015 | U-1352 | | | |
| | | RE44048 | Jun 02, 2015 | U-1351 | | | |
| | | RE44048 | Jun 02, 2015 | U-1350 | | | |
| | | RE44048 | Jun 02, 2015 | U-1349 | | | |
| | | RE44048 | Jun 02, 2015 | U-1348 | | | |
| | | RE44048*PED | Dec 02, 2015 | | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| CELECOXIB - CELEBREX | | | | | | |
| N020998 003 | RE44048 | Jun 02, 2015 | U-247 | | | |
| | RE44048 | Jun 02, 2015 | U-1352 | | | |
| | RE44048 | Jun 02, 2015 | U-1351 | | | |
| | RE44048 | Jun 02, 2015 | U-1350 | | | |
| | RE44048 | Jun 02, 2015 | U-1349 | | | |
| | RE44048 | Jun 02, 2015 | U-1348 | | | |
| | RE44048*PED | Dec 02, 2015 | | | | |
| CELECOXIB - CELEBREX | | | | | | |
| N020998 004 | RE44048 | Jun 02, 2015 | U-247 | | | |
| | RE44048 | Jun 02, 2015 | U-1352 | | | |
| | RE44048 | Jun 02, 2015 | U-1351 | | | |
| | RE44048 | Jun 02, 2015 | U-1350 | | | |
| | RE44048 | Jun 02, 2015 | U-1349 | | | |
| | RE44048 | Jun 02, 2015 | U-1348 | | | |
| | RE44048*PED | Dec 02, 2015 | | | | |
| CICLESONIDE - ALVESCO | | | | | | |
| N021658 002 | 8371292 | Aug 25, 2027 | U-1355 | | M-125 | Dec 17, 2015 |
| CICLESONIDE - ALVESCO | | | | | | |
| N021658 003 | 8371292 | Aug 25, 2027 | U-1355 | | M-125 | Dec 17, 2015 |
| CICLESONIDE - OMNARIS | | | | | | |
| N022004 001 | 8371292 | Aug 25, 2027 | U-1356 | | | |
| | **>A>** 8383611 | Oct 20, 2020 | DP | | | |
| CICLESONIDE - ZETONNA | | | | | | |
| N202129 001 | 8371292 | Aug 25, 2027 | U-1357 | | | |
| CLOBAZAM - ONFI | | | | | | |
| N203993 001 | | | | | ODE | Oct 21, 2018 |
| CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE | | | | | | |
| A201402 001 | | | | | PC | Jul 31, 2013 |
| COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD | | | | | | |
| N203100 001 | **>A>** 7635704 | Oct 26, 2026 | DS DP U-257 | | | |
| DARUNAVIR ETHANOLATE - PREZISTA | | | | | | |
| N021976 001 | | | | | D-135 | Feb 01, 2016 |
| | | | | | PED | Aug 01, 2016 |
| DARUNAVIR ETHANOLATE - PREZISTA | | | | | | |
| N021976 002 | | | | | D-135 | Feb 01, 2016 |
| | | | | | PED | Aug 01, 2016 |
| DARUNAVIR ETHANOLATE - PREZISTA | | | | | | |
| N021976 003 | | | | | D-135 | Feb 01, 2016 |
| | | | | | PED | Aug 01, 2016 |
| DARUNAVIR ETHANOLATE - PREZISTA | | | | | | |
| N021976 004 | | | | | D-135 | Feb 01, 2016 |
| | | | | | PED | Aug 01, 2016 |
| DARUNAVIR ETHANOLATE - PREZISTA | | | | | | |
| N021976 005 | | | | | D-135 | Feb 01, 2016 |
| | | | | | PED | Aug 01, 2016 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| DARUNAVIR ETHANOLATE - PREZISTA | | | | | | |
| N021976 006 | | | | | D-135 | Feb 01, 2016 |
| | | | | | PED | Aug 01, 2016 |
| DARUNAVIR ETHANOLATE - PREZISTA | | | | | | |
| N202895 001 | | | | | D-135 | Feb 01, 2016 |
| | | | | | PED | Aug 01, 2016 |
| DEFERASIROX - EXJADE | | | | | | |
| N021882 001 | | | | | I-665 | Jan 23, 2016 |
| DEFERASIROX - EXJADE | | | | | | |
| N021882 002 | | | | | I-665 | Jan 23, 2016 |
| DEFERASIROX - EXJADE | | | | | | |
| N021882 003 | | | | | I-665 | Jan 23, 2016 |
| DESVENLAFAXINE SUCCINATE - PRISTIQ | | | | | | |
| N021992 001 | **>A>** 6673838 | Feb 11, 2022 | DS DP U-860 | | | |
| | **>A>** 6673838 | Feb 11, 2022 | DS DP U-1364 | | | |
| DESVENLAFAXINE SUCCINATE - PRISTIQ | | | | | | |
| N021992 002 | **>A>** 6673838 | Feb 11, 2022 | DS DP U-860 | | | |
| | **>A>** 6673838 | Feb 11, 2022 | DS DP U-1364 | | | |
| DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX | | | | | | |
| N021038 001 | **>A>** 4910214 | Jul 15, 2013 | DS DP U-421 | | | |
| | **>A>** 4910214*PED | Jan 15, 2014 | | | | |
| | **>A>** 6716867 | Mar 31, 2019 | U-572 | | | |
| | **>A>** 6716867*PED | Oct 01, 2019 | | | | |
| DIFLUPREDNATE - DUREZOL | | | | | | |
| N022212 001 | **>A>** 6114319 | May 18, 2019 | DP | | **>A>** I-653 | Jun 13, 2015 |
| | **>A>** 6114319*PED | Nov 18, 2019 | | | **>A>** M-127 | Mar 22, 2016 |
| | | | | | **>A>** ODE | Jun 13, 2019 |
| | | | | | **>A>** PED | Dec 13, 2019 |
| | | | | | **>A>** PED | Sep 22, 2016 |
| | | | | | **>A>** PED | Dec 13, 2015 |
| DIMETHYL FUMARATE - TECFIDERA | | | | | | |
| N204063 001 | | | | | **>A>** NCE | Mar 27, 2018 |
| DIMETHYL FUMARATE - TECFIDERA | | | | | | |
| N204063 002 | | | | | **>A>** NCE | Mar 27, 2018 |
| DOXYCYCLINE - ORACEA | | | | | | |
| N050805 001 | **>A>** 8394406 | Dec 24, 2025 | DP U-925 | | | |
| DROSPIRENONE; ETHINYL ESTRADIOL - YAZ | | | | | | |
| N021676 001 | RE43916 | Jun 30, 2014 | U-1326 | | | |
| DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ | | | | | | |
| N022532 001 | RE43916 | Jun 30, 2014 | U-1326 | | | |
| DULOXETINE HYDROCHLORIDE - CYMBALTA | | | | | | |
| N021427 001 | | | | | M-61 | Oct 18, 2015 |
| | | | | | PED | Apr 18, 2016 |
| DULOXETINE HYDROCHLORIDE - CYMBALTA | | | | | | |
| N021427 002 | | | | | M-61 | Oct 18, 2015 |
| | | | | | PED | Apr 18, 2016 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| DULOXETINE HYDROCHLORIDE - CYMBALTA | | | | | | |
| N021427 004 | | | | | M-61 | Oct 18, 2015 |
| | | | | | PED | Apr 18, 2016 |
| EFAVIRENZ - SUSTIVA | | | | | | |
| N020972 001 | 5519021 | May 21, 2013 | DS DP | | | |
| | 5519021*PED | Nov 21, 2013 | | | | |
| | 5663169 | Sep 02, 2014 | U-257 | | | |
| | 5663169*PED | Mar 02, 2015 | | | | |
| | 6238695 | Apr 06, 2019 | DP | | | |
| | 6238695*PED | Oct 06, 2019 | | | | |
| | 6555133 | Apr 06, 2019 | U-248 | | | |
| | 6555133*PED | Oct 06, 2019 | | | | |
| | 6639071 | Feb 14, 2018 | DS | | | |
| | 6639071*PED | Aug 14, 2018 | | | | |
| | 6939964 | Jan 20, 2018 | DS | | | |
| | 6939964*PED | Jul 20, 2018 | | | | |
| EFAVIRENZ - SUSTIVA | | | | | | |
| N020972 002 | 5519021 | May 21, 2013 | DS DP | | | |
| | 5519021*PED | Nov 21, 2013 | | | | |
| | 5663169 | Sep 02, 2014 | U-257 | | | |
| | 5663169*PED | Mar 02, 2015 | | | | |
| | 6238695 | Apr 06, 2019 | DP | | | |
| | 6238695*PED | Oct 06, 2019 | | | | |
| | 6555133 | Apr 06, 2019 | U-248 | | | |
| | 6555133*PED | Oct 06, 2019 | | | | |
| | 6639071 | Feb 14, 2018 | DS | | | |
| | 6639071*PED | Aug 14, 2018 | | | | |
| | 6939964 | Jan 20, 2018 | DS | | | |
| | 6939964*PED | Jul 20, 2018 | | | | |
| EFAVIRENZ - SUSTIVA | | | | | | |
| N020972 003 | 5519021 | May 21, 2013 | DS DP | | | |
| | 5519021*PED | Nov 21, 2013 | | | | |
| | 5663169 | Sep 02, 2014 | U-257 | | | |
| | 5663169*PED | Mar 02, 2015 | | | | |
| | 6238695 | Apr 06, 2019 | DP | | | |
| | 6238695*PED | Oct 06, 2019 | | | | |
| | 6555133 | Apr 06, 2019 | U-248 | | | |
| | 6555133*PED | Oct 06, 2019 | | | | |
| | 6639071 | Feb 14, 2018 | DS | | | |
| | 6639071*PED | Aug 14, 2018 | | | | |
| | 6939964 | Jan 20, 2018 | DS | | | |
| | 6939964*PED | Jul 20, 2018 | | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| EFAVIRENZ - SUSTIVA | | | | | | |
| N021360 001 | 5519021 | May 21, 2013 | | | | |
| | 5519021*PED | Nov 21, 2013 | | | | |
| | 5663169 | Sep 02, 2014 | | | | |
| | 5663169*PED | Mar 02, 2015 | | | | |
| | 6639071 | Feb 14, 2018 | DS | | | |
| | 6639071*PED | Aug 14, 2018 | | | | |
| | 6939964 | Jan 20, 2018 | DS | | | |
| | 6939964*PED | Jul 20, 2018 | | | | |
| EFAVIRENZ - SUSTIVA | | | | | | |
| N021360 002 | 5519021 | May 21, 2013 | DS DP | | | |
| | 5519021*PED | Nov 21, 2013 | | | | |
| | 5663169 | Sep 02, 2014 | | | U-248 | |
| | 5663169*PED | Mar 02, 2015 | | | | |
| | 6639071 | Feb 14, 2018 | DS | | | |
| | 6639071*PED | Aug 14, 2018 | | | | |
| | 6939964 | Jan 20, 2018 | DS | | | |
| | 6939964*PED | Jul 20, 2018 | | | | |
| EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA | | | | | | |
| N021937 001 | 5519021 | May 21, 2013 | DS DP | | | |
| | 5519021*PED | Nov 21, 2013 | | | | |
| | 5663169 | Sep 02, 2014 | | | U-750 | |
| | 5663169 | Sep 02, 2014 | | | U-1170 | |
| | 5663169*PED | Mar 02, 2015 | | | | |
| | 6639071 | Feb 14, 2018 | DS | | | |
| | 6639071*PED | Aug 14, 2018 | | | | |
| | 6939964 | Jan 20, 2018 | DS | | | |
| | 6939964*PED | Jul 20, 2018 | | | | |
| EPINEPHRINE - AUVI-Q | | | | | | |
| N201739 001 | 7731686 | Jun 01, 2026 | DP | | | |
| | 7731690 | Jan 15, 2025 | DP | | | |
| | 7749194 | Oct 30, 2028 | DP | | | |
| | 7918823 | Nov 23, 2024 | DP | | | |
| | 7947017 | Mar 12, 2028 | DP | | | |
| | 8016788 | Mar 21, 2025 | DP | | | |
| | >A> 8206360 | Feb 27, 2027 | DP | | | |
| | 8361029 | Nov 23, 2024 | DP | | | |
| EPINEPHRINE - AUVI-Q | | | | | | |
| N201739 002 | 7731686 | Jun 01, 2026 | DP | | | |
| | 7731690 | Jan 15, 2025 | DP | | | |
| | 7749194 | Oct 30, 2028 | DP | | | |
| | 7918823 | Nov 23, 2024 | DP | | | |
| | 7947017 | Mar 12, 2028 | DP | | | |
| | 8016788 | Mar 21, 2025 | DP | | | |
| | >A> 8206360 | Feb 27, 2027 | DP | | | |
| | 8361029 | Nov 23, 2024 | DP | | | |
| EPOPROSTENOL SODIUM - VELETRI | | | | | | |
| N022260 001 | 8318802 | Mar 15, 2027 | DP | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| EPOPROSTENOL SODIUM - VELETRI | | | | | | |
| N022260 002 | 8318802 | Mar 15, 2027 | DP | | | |
| ESTRADIOL - MINIVELLE | | | | | | |
| N203752 001 | **>A>** 5646286 | Aug 12, 2014 | DS DP | | | |
| | **>A>** 6024976 | Jan 07, 2014 | DS DP | | | |
| | **>A>** 8231906 | May 24, 2030 | DS DP | | | |
| ESTRADIOL - MINIVELLE | | | | | | |
| N203752 002 | **>A>** 5646286 | Aug 12, 2014 | DS DP | | | |
| | **>A>** 6024976 | Jan 07, 2014 | DS DP | | | |
| | **>A>** 8231906 | May 24, 2030 | DS DP | | | |
| ESTRADIOL - MINIVELLE | | | | | | |
| N203752 003 | **>A>** 5646286 | Aug 12, 2014 | DS DP | | | |
| | **>A>** 6024976 | Jan 07, 2014 | DS DP | | | |
| | **>A>** 8231906 | May 24, 2030 | DS DP | | | |
| ESTRADIOL - MINIVELLE | | | | | | |
| N203752 004 | **>A>** 5646286 | Aug 12, 2014 | DS DP | | | |
| | **>A>** 6024976 | Jan 07, 2014 | DS DP | | | |
| | **>A>** 8231906 | May 24, 2030 | DS DP | | | |
| ESZOPICLONE - LUNESTA | | | | | | |
| N021476 001 | | | | | M-61 | Oct 10, 2015 |
| | | | | | PED | Apr 10, 2016 |
| ESZOPICLONE - LUNESTA | | | | | | |
| N021476 002 | | | | | M-61 | Oct 10, 2015 |
| | | | | | PED | Apr 10, 2016 |
| ESZOPICLONE - LUNESTA | | | | | | |
| N021476 003 | | | | | M-61 | Oct 10, 2015 |
| | | | | | PED | Apr 10, 2016 |
| ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE | | | | | | |
| N204061 001 | | | | | **>A>** NP | Mar 28, 2016 |
| EVEROLIMUS - AFINITOR | | | | | | |
| N022334 001 | **>A>** 8410131 | May 22, 2025 | DS DP U-1368 | | | |
| | **>A>** 8410131*PED | Nov 22, 2025 | | | | |
| EVEROLIMUS - AFINITOR | | | | | | |
| N022334 002 | **>A>** 8410131 | May 22, 2025 | DS DP U-1368 | | | |
| | **>A>** 8410131*PED | Nov 22, 2025 | | | | |
| EVEROLIMUS - AFINITOR | | | | | | |
| N022334 003 | **>A>** 8410131 | May 22, 2025 | DS DP U-1368 | | | |
| | **>A>** 8410131*PED | Nov 22, 2025 | | | | |
| EVEROLIMUS - AFINITOR | | | | | | |
| N022334 004 | **>A>** 8410131 | May 22, 2025 | DS DP U-1368 | | | |
| | **>A>** 8410131*PED | Nov 22, 2025 | | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| EVEROLIMUS - ZORTRESS | | | | | | |
| N021560 001 | **>A>** 5665772 | Sep 09, 2019 | DS DP U-1365 | | I-668 | Feb 15, 2016 |
| | **>A>** 5665772 | Sep 09, 2019 | DS DP U-1049 | | | |
| | **>A>** 5665772*PED | Mar 09, 2020 | | | | |
| | **>A>** 6004973 | Jul 12, 2016 | DP U-1365 | | | |
| | **>A>** 6004973 | Jul 12, 2016 | DP U-1049 | | | |
| | **>A>** 6004973*PED | Jan 12, 2017 | | | | |
| | **>A>** 6440990 | Sep 24, 2013 | DP U-1365 | | | |
| | **>A>** 6440990 | Sep 24, 2013 | DP U-1049 | | | |
| | **>A>** 6440990*PED | Mar 24, 2014 | | | | |
| | **>A>** 6455518 | Jul 29, 2017 | U-1365 | | | |
| | **>A>** 6455518 | Jul 29, 2017 | U-1049 | | | |
| | **>A>** 6455518*PED | Jan 29, 2018 | | | | |
| EVEROLIMUS - ZORTRESS | | | | | | |
| N021560 002 | **>A>** 5665772 | Sep 09, 2019 | DS DP U-1365 | | I-668 | Feb 15, 2016 |
| | **>A>** 5665772 | Sep 09, 2019 | DS DP U-1049 | | | |
| | **>A>** 5665772*PED | Mar 09, 2020 | | | | |
| | **>A>** 6004973 | Jul 12, 2016 | DP U-1365 | | | |
| | **>A>** 6004973 | Jul 12, 2016 | DP U-1049 | | | |
| | **>A>** 6004973*PED | Jan 12, 2017 | | | | |
| | **>A>** 6440990 | Sep 24, 2013 | DP U-1365 | | | |
| | **>A>** 6440990 | Sep 24, 2013 | DP U-1049 | | | |
| | **>A>** 6440990*PED | Mar 24, 2014 | | | | |
| | **>A>** 6455518 | Jul 29, 2017 | U-1365 | | | |
| | **>A>** 6455518 | Jul 29, 2017 | U-1049 | | | |
| | **>A>** 6455518*PED | Jan 29, 2018 | | | | |
| EVEROLIMUS - ZORTRESS | | | | | | |
| N021560 003 | **>A>** 5665772 | Sep 09, 2019 | DS DP U-1365 | | I-668 | Feb 15, 2016 |
| | **>A>** 5665772 | Sep 09, 2019 | DS DP U-1049 | | | |
| | **>A>** 5665772*PED | Mar 09, 2020 | | | | |
| | **>A>** 6004973 | Jul 12, 2016 | DP U-1365 | | | |
| | **>A>** 6004973 | Jul 12, 2016 | DP U-1049 | | | |
| | **>A>** 6004973*PED | Jan 12, 2017 | | | | |
| | **>A>** 6440990 | Sep 24, 2013 | DP U-1365 | | | |
| | **>A>** 6440990 | Sep 24, 2013 | DP U-1049 | | | |
| | **>A>** 6440990*PED | Mar 24, 2014 | | | | |
| | **>A>** 6455518 | Jul 29, 2017 | U-1365 | | | |
| | **>A>** 6455518 | Jul 29, 2017 | U-1049 | | | |
| | **>A>** 6455518*PED | Jan 29, 2018 | | | | |
| FEBUXOSTAT - ULORIC | | | | | | |
| N021856 001 | 8372872 | Sep 08, 2031 | U-1346 | | | |
| FEBUXOSTAT - ULORIC | | | | | | |
| N021856 002 | 8372872 | Sep 08, 2031 | U-1346 | | | |
| FESOTERODINE FUMARATE - TOVIAZ | | | | | | |
| N022030 001 | 8338478 | May 11, 2019 | DS DP U-913 | | | |
| FESOTERODINE FUMARATE - TOVIAZ | | | | | | |
| N022030 002 | 8338478 | May 11, 2019 | DS DP U-913 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| FLUTICASONE FUROATE - VERAMYST | | | | | | |
| N022051 001 | 8347879 | Apr 01, 2027 | DP | | | |
| FOLLITROPIN ALFA/BETA - FOLLISTIM AQ | | | | | | |
| N021211 001 | **>A>** 5929028 | Jan 14, 2018 | DP U-567 | | | |
| | **>A>** 5929028 | Jan 14, 2018 | DP U-1366 | | | |
| | **>A>** 7563763 | Aug 23, 2019 | U-993 | | | |
| | **>A>** 7563763 | Aug 23, 2019 | U-1367 | | | |
| | **>A>** 7563763 | Aug 23, 2019 | U-1183 | | | |
| FOLLITROPIN ALFA/BETA - FOLLISTIM AQ | | | | | | |
| N021211 002 | **>A>** 5929028 | Jan 14, 2018 | DP U-567 | | | |
| | **>A>** 5929028 | Jan 14, 2018 | DP U-1366 | | | |
| | **>A>** 7563763 | Aug 23, 2019 | U-993 | | | |
| | **>A>** 7563763 | Aug 23, 2019 | U-1367 | | | |
| | **>A>** 7563763 | Aug 23, 2019 | U-1183 | | | |
| FOLLITROPIN ALFA/BETA - FOLLISTIM AQ | | | | | | |
| N021211 003 | **>A>** 5929028 | Jan 14, 2018 | DP U-567 | | | |
| | **>A>** 5929028 | Jan 14, 2018 | DP U-1366 | | | |
| | **>A>** 7563763 | Aug 23, 2019 | U-993 | | | |
| | **>A>** 7563763 | Aug 23, 2019 | U-1367 | | | |
| | **>A>** 7563763 | Aug 23, 2019 | U-1183 | | | |
| FOLLITROPIN ALFA/BETA - FOLLISTIM AQ | | | | | | |
| N021211 004 | **>A>** 5929028 | Jan 14, 2018 | DP U-567 | | | |
| | **>A>** 5929028 | Jan 14, 2018 | DP U-1366 | | | |
| | **>A>** 7563763 | Aug 23, 2019 | U-993 | | | |
| | **>A>** 7563763 | Aug 23, 2019 | U-1367 | | | |
| | **>A>** 7563763 | Aug 23, 2019 | U-1183 | | | |
| FOLLITROPIN ALFA/BETA - FOLLISTIM AQ | | | | | | |
| N021273 001 | **>A>** 5767251 | Jun 16, 2015 | DS | | | |
| | **>A>** 5929028 | Jan 14, 2018 | DP U-1366 | | | |
| FOLLITROPIN ALFA/BETA - FOLLISTIM AQ | | | | | | |
| N021273 002 | **>A>** 5767251 | Jun 16, 2015 | DS | | | |
| | **>A>** 5929028 | Jan 14, 2018 | DP U-1366 | | | |
| GABAPENTIN - GRALISE | | | | | | |
| N022544 001 | 8333992 | Oct 25, 2022 | DP U-1114 | | | |
| GABAPENTIN - GRALISE | | | | | | |
| N022544 002 | 8333992 | Oct 25, 2022 | DP U-1114 | | | |
| GADOTERATE MEGLUMINE - DOTAREM | | | | | | |
| N204781 001 | | | | | **>A>** NCE | Mar 20, 2018 |
| GADOTERATE MEGLUMINE - DOTAREM | | | | | | |
| N204781 002 | | | | | **>A>** NCE | Mar 20, 2018 |
| GADOTERATE MEGLUMINE - DOTAREM | | | | | | |
| N204781 003 | | | | | **>A>** NCE | Mar 20, 2018 |
| GADOTERATE MEGLUMINE - DOTAREM | | | | | | |
| N204781 004 | | | | | **>A>** NCE | Mar 20, 2018 |
| GADOXETATE DISODIUM - EOVIST | | | | | | |
| N022090 002 | | | | | NCE | Jul 03, 2013 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| GANIRELIX ACETATE - GANIRELIX ACETATE INJECTION | | | | | | | |
| N021057 001 | | 6653286 | Jun 16, 2018 | U-1354 | | | |
| GLATIRAMER ACETATE - COPAXONE | | | | | | | |
| N020622 002 | >A> | 8367605 | May 24, 2014 | DS | | | |
| GLYCEROL PHENYLBUTYRATE - RAVICTI | | | | | | | |
| N203284 001 | | | | | | NE | Feb 01, 2016 |
| ICOSAPENT ETHYL - VASCEPA | | | | | | | |
| N202057 001 | | 8357677 | Feb 09, 2030 | U-1287 | | | |
| | | 8367652 | Feb 09, 2030 | U-1287 | | | |
| | | 8377920 | Feb 09, 2030 | U-1287 | | | |
| | >A> | 8399446 | Feb 09, 2030 | U-1287 | | | |
| | >A> | 8415335 | Feb 09, 2030 | U-1287 | | | |
| IMATINIB MESYLATE - GLEEVEC | | | | | | | |
| N021588 001 | | 7544799 | Jan 16, 2019 | DS DP | Y | I-666 | Jan 25, 2016 |
| | | RE43932 | Jan 16, 2019 | DS DP | | >A> ODE | Jan 25, 2020 |
| | | RE43932*PED | Jul 16, 2019 | | | | |
| IMATINIB MESYLATE - GLEEVEC | | | | | | | |
| N021588 002 | | 7544799 | Jan 16, 2019 | DS DP | Y | I-666 | Jan 25, 2016 |
| | | RE43932 | Jan 16, 2019 | DS DP | | >A> ODE | Jan 25, 2020 |
| | | RE43932*PED | Jul 16, 2019 | | | | |
| INGENOL MEBUTATE - PICATO | | | | | | | |
| N202833 001 | | 8372827 | Dec 18, 2026 | DS DP | | | |
| | | 8372828 | Dec 18, 2026 | DS DP | | | |
| | | 8377919 | Dec 18, 2026 | DS DP | | | |
| INGENOL MEBUTATE - PICATO | | | | | | | |
| N202833 002 | | 8372827 | Dec 18, 2026 | DS DP | | | |
| | | 8372828 | Dec 18, 2026 | DS DP | | | |
| | | 8377919 | Dec 18, 2026 | DS DP | | | |
| IOBENGUANE SULFATE I-123 - ADREVIEW | | | | | | | |
| N022290 001 | | | | | | >A> I-669 | Mar 20, 2016 |
| IRON SUCROSE - VENOFER | | | | | | | |
| N021135 005 | | | | | | >A> NPP | Sep 21, 2015 |
| ISOTRETINOIN - ABSORICA | | | | | | | |
| N021951 001 | | 8367102 | Sep 21, 2021 | U-1347 | | | |
| ISOTRETINOIN - ABSORICA | | | | | | | |
| N021951 002 | | 8367102 | Sep 21, 2021 | U-1347 | | | |
| ISOTRETINOIN - ABSORICA | | | | | | | |
| N021951 003 | | 8367102 | Sep 21, 2021 | U-1347 | | | |
| ISOTRETINOIN - ABSORICA | | | | | | | |
| N021951 004 | | 8367102 | Sep 21, 2021 | U-1347 | | | |
| KETOROLAC TROMETHAMINE - ACULAR LS | | | | | | | |
| N021528 001 | >A> | 8377982 | May 28, 2024 | U-1363 | | | |
| | >A> | 8377982*PED | Nov 28, 2024 | | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| LENALIDOMIDE - REVLIMID | | | | | | |
| N021880 001 | **>A>** 8404717 | Apr 11, 2023 | U-1215 | | | |
| LENALIDOMIDE - REVLIMID | | | | | | |
| N021880 002 | **>A>** 8404717 | Apr 11, 2023 | U-1215 | | | |
| LENALIDOMIDE - REVLIMID | | | | | | |
| N021880 003 | **>A>** 8404717 | Apr 11, 2023 | U-1215 | | | |
| LENALIDOMIDE - REVLIMID | | | | | | |
| N021880 004 | **>A>** 8404717 | Apr 11, 2023 | U-1215 | | | |
| LENALIDOMIDE - REVLIMID | | | | | | |
| N021880 005 | **>A>** 8404717 | Apr 11, 2023 | U-1215 | | | |
| LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE | | | | | | |
| A077756 001 | | | | | PC | Feb 16, 2013 |
| LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE | | | | | | |
| A077756 002 | | | | | PC | Feb 16, 2013 |
| LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE | | | | | | |
| A077756 003 | | | | | PC | Feb 16, 2013 |
| LEVOLEUCOVORIN CALCIUM - FUSILEV | | | | | | |
| N020140 001 | 6500829 | Mar 07, 2022 | DS DP | | | |
| LEVOLEUCOVORIN CALCIUM - FUSILEV | | | | | | |
| N020140 002 | 6500829 | Mar 07, 2022 | DS DP | | | |
| LEVOLEUCOVORIN CALCIUM - FUSILEV | | | | | | |
| N020140 003 | 6500829 | Mar 07, 2022 | DS DP | | | |
| LEVONORGESTREL - SKYLA | | | | | | |
| N203159 001 | 5785053 | Dec 05, 2015 | DP | | NP | Jan 09, 2016 |
| | 7252839 | Nov 13, 2023 | DP | | | |
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | |
| N203858 001 | 5712279 | Feb 21, 2015 | DS U-1317 | | ODE | Dec 21, 2019 |
| | 7932268 | Aug 19, 2027 | U-1316 | | | |
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | |
| N203858 002 | 5712279 | Feb 21, 2015 | DS U-1317 | | ODE | Dec 21, 2019 |
| | 7932268 | Aug 19, 2027 | U-1316 | | | |
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | |
| N203858 003 | 5712279 | Feb 21, 2015 | DS U-1317 | | ODE | Dec 21, 2019 |
| | 7932268 | Aug 19, 2027 | U-1316 | | | |
| LOPINAVIR; RITONAVIR - KALETRA | | | | | | |
| N021906 001 | 8025899 | Dec 14, 2027 | DP | | | |
| | 8025899*PED | Jun 14, 2028 | | | | |
| | **>A>** 8377952 | Oct 22, 2027 | U-1372 | | | |
| | **>A>** 8377952*PED | Apr 22, 2028 | | | | |
| | **>A>** 8399015 | Aug 25, 2024 | DP | | | |
| | **>A>** 8399015*PED | Feb 25, 2025 | | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| LOPINAVIR; RITONAVIR - KALETRA | | | | | | | |
| N021906 002 | | 8025899 | Dec 14, 2027 | DP | | | |
| | | 8025899*PED | Jun 14, 2028 | | | | |
| | >A> | 8377952 | Oct 22, 2027 | U-1372 | | | |
| | >A> | 8377952*PED | Apr 22, 2028 | | | | |
| | >A> | 8399015 | Aug 25, 2024 | DP | | | |
| | >A> | 8399015*PED | Feb 25, 2025 | | | | |
| LOTEPREDNOL ETABONATE - LOTEMAX | | | | | | | |
| N202872 001 | | 5800807 | Jan 29, 2017 | DP | | | |
| LOXAPINE - ADASUVE | | | | | | | |
| N022549 001 | >A> | 6716416 | May 20, 2022 | DP | | | |
| | >A> | 7052679 | Mar 20, 2022 | DP | | | |
| | >A> | 7078020 | Oct 26, 2021 | DP U-1375 | | | |
| | >A> | 7090830 | Oct 26, 2021 | DP | | | |
| | >A> | 7458374 | Aug 18, 2024 | DP | | | |
| | >A> | 7537009 | Oct 26, 2021 | DP | | | |
| | >A> | 7585493 | Oct 26, 2021 | DP | | | |
| | >A> | 7601337 | Oct 26, 2021 | DP | | | |
| | >A> | 8074644 | Oct 26, 2021 | DP | | | |
| | >A> | 8173107 | Oct 26, 2021 | DP | | | |
| | >A> | 8235037 | Oct 26, 2021 | DP | | | |
| | >A> | 8387612 | Oct 23, 2026 | DP | | | |
| LUBIPROSTONE - AMITIZA | | | | | | | |
| N021908 001 | | 8389542 | Nov 14, 2022 | DP U-1345 | | | |
| MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE - SUCLEAR | | | | | | | |
| N203595 001 | | | | | | NC | Jan 18, 2016 |
| METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR | | | | | | | |
| N202100 001 | >A> | 8062667 | Mar 29, 2029 | DP | | | |
| | >A> | 8287903 | Feb 15, 2031 | DP | | | |
| MIPOMERSEN SODIUM - KYNAMRO | | | | | | | |
| N203568 001 | | 5914396 | Jun 22, 2016 | DS | | NCE | Jan 29, 2018 |
| | | 6166197 | Dec 26, 2017 | DS | | ODE | Jan 29, 2020 |
| | | 6222025 | Mar 06, 2015 | DS | | | |
| | | 6451991 | Feb 11, 2017 | DS | | | |
| | | 7015315 | Mar 21, 2023 | DS | | | |
| | | 7101993 | Sep 05, 2023 | DS | | | |
| | | 7407943 | Aug 01, 2021 | U-1353 | | | |
| | | 7511131 | Dec 13, 2025 | DS | | | |
| MUPIROCIN CALCIUM - BACTROBAN | | | | | | | |
| N050703 001 | | 5569672 | Oct 29, 2013 | U-1358 | | | |
| MUPIROCIN CALCIUM - BACTROBAN | | | | | | | |
| N050746 001 | | 5569672 | Oct 29, 2013 | U-1358 | | | |
| NEPAFENAC - NEPAFENAC | | | | | | | |
| N203491 001 | | 5475034 | Jun 06, 2014 | U-100 | | | |
| | | 6403609 | Jul 17, 2018 | DP | | | |
| | | 7947295 | Jun 08, 2024 | DP | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA | | | | | | |
| N022068 001 | **>A>** 8389537 | Jul 18, 2026 | DS DP U-1374 | | | |
| NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA | | | | | | |
| N022068 002 | **>A>** 8389537 | Jul 18, 2026 | DS DP U-1374 | | | |
| OLOPATADINE HYDROCHLORIDE - PATANASE | | | | | | |
| N021861 001 | **>A>** 8399508 | Sep 17, 2022 | U-726 | | | |
| | **>A>** 8399508*PED | Mar 17, 2023 | | | | |
| OSELTAMIVIR PHOSPHATE - TAMIFLU | | | | | | |
| N021087 001 | | | | | NPP | Dec 21, 2015 |
| OSELTAMIVIR PHOSPHATE - TAMIFLU | | | | | | |
| N021087 002 | | | | | NPP | Dec 21, 2015 |
| OSELTAMIVIR PHOSPHATE - TAMIFLU | | | | | | |
| N021087 003 | | | | | NPP | Dec 21, 2015 |
| OSELTAMIVIR PHOSPHATE - TAMIFLU | | | | | | |
| N021246 001 | | | | | NPP | Dec 21, 2015 |
| OSELTAMIVIR PHOSPHATE - TAMIFLU | | | | | | |
| N021246 002 | | | | | NPP | Dec 21, 2015 |
| OSPEMIFENE - OSPHENA | | | | | | |
| N203505 001 | **>A>** 6245819 | Jul 21, 2020 | U-1369 | | NCE | Feb 26, 2018 |
| | **>A>** 8236861 | Feb 13, 2024 | U-1370 | | | |
| OXYBUTYNIN - OXYTROL FOR WOMEN | | | | | | |
| N202211 001 | 5601839 | Apr 26, 2015 | DP U-1329 | | NP | Jan 25, 2016 |
| | 5834010 | Apr 26, 2015 | DP U-1329 | | | |
| | 6743441 | Apr 26, 2020 | DP U-1329 | | | |
| | 7081249 | Apr 26, 2020 | DP U-1329 | | | |
| | 7081250 | Apr 26, 2020 | DP U-1329 | | | |
| | 7081251 | Apr 26, 2020 | DP U-1329 | | | |
| | 7081252 | Apr 26, 2020 | DP U-1329 | | | |
| | 7179483 | Apr 26, 2020 | U-1329 | | | |
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON | | | | | | |
| N020725 005 | | | | | **>A>** M-93 | Jul 29, 2019 |
| | | | | | **>A>** NCE | Apr 30, 2014 |
| PLERIXAFOR - MOZOBIL | | | | | | |
| N022311 001 | RE42152 | Dec 10, 2018 | DP | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| POMALIDOMIDE - POMALYST | | | | | | |
| N204026 001 | **>A>** 5635517 | Jul 24, 2016 | U-1359 | | NCE | Feb 08, 2018 |
| | **>A>** 6045501 | Aug 28, 2018 | U-1361 | | ODE | Feb 08, 2020 |
| | **>A>** 6315720 | Oct 23, 2020 | U-1361 | | | |
| | **>A>** 6316471 | Aug 10, 2016 | DP U-1360 | | | |
| | **>A>** 6476052 | Jul 24, 2016 | DP U-1360 | | | |
| | **>A>** 6561976 | Aug 28, 2018 | U-1361 | | | |
| | **>A>** 6561977 | Oct 23, 2020 | U-1361 | | | |
| | **>A>** 6755784 | Oct 23, 2020 | U-1361 | | | |
| | **>A>** 6908432 | Aug 28, 2018 | U-1361 | | | |
| | **>A>** 8158653 | Aug 10, 2016 | DP | | | |
| | **>A>** 8198262 | Oct 19, 2024 | U-1360 | | | |
| | **>A>** 8204763 | Aug 28, 2018 | U-1361 | | | |
| | **>A>** 8315886 | Oct 23, 2020 | U-1361 | | | |
| POMALIDOMIDE - POMALYST | | | | | | |
| N204026 002 | **>A>** 5635517 | Jul 24, 2016 | U-1359 | | NCE | Feb 08, 2018 |
| | **>A>** 6045501 | Aug 28, 2018 | U-1361 | | ODE | Feb 08, 2020 |
| | **>A>** 6315720 | Oct 23, 2020 | U-1361 | | | |
| | **>A>** 6316471 | Aug 10, 2016 | DP U-1360 | | | |
| | **>A>** 6476052 | Jul 24, 2016 | DP U-1360 | | | |
| | **>A>** 6561976 | Aug 28, 2018 | U-1361 | | | |
| | **>A>** 6561977 | Oct 23, 2020 | U-1361 | | | |
| | **>A>** 6755784 | Oct 23, 2020 | U-1361 | | | |
| | **>A>** 6908432 | Aug 28, 2018 | U-1361 | | | |
| | **>A>** 8158653 | Aug 10, 2016 | DP | | | |
| | **>A>** 8198262 | Oct 19, 2024 | U-1360 | | | |
| | **>A>** 8204763 | Aug 28, 2018 | U-1361 | | | |
| | **>A>** 8315886 | Oct 23, 2020 | U-1361 | | | |
| POMALIDOMIDE - POMALYST | | | | | | |
| N204026 003 | **>A>** 5635517 | Jul 24, 2016 | U-1359 | | NCE | Feb 08, 2018 |
| | **>A>** 6045501 | Aug 28, 2018 | U-1361 | | ODE | Feb 08, 2020 |
| | **>A>** 6315720 | Oct 23, 2020 | U-1361 | | | |
| | **>A>** 6316471 | Aug 10, 2016 | DP U-1360 | | | |
| | **>A>** 6476052 | Jul 24, 2016 | DP U-1360 | | | |
| | **>A>** 6561976 | Aug 28, 2018 | U-1361 | | | |
| | **>A>** 6561977 | Oct 23, 2020 | U-1361 | | | |
| | **>A>** 6755784 | Oct 23, 2020 | U-1361 | | | |
| | **>A>** 6908432 | Aug 28, 2018 | U-1361 | | | |
| | **>A>** 8158653 | Aug 10, 2016 | DP | | | |
| | **>A>** 8198262 | Oct 19, 2024 | U-1360 | | | |
| | **>A>** 8204763 | Aug 28, 2018 | U-1361 | | | |
| | **>A>** 8315886 | Oct 23, 2020 | U-1361 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| POMALIDOMIDE - POMALYST | | | | | | |
| N204026 004 | **>A>** 5635517 | Jul 24, 2016 | U-1359 | | NCE | Feb 08, 2018 |
| | **>A>** 6045501 | Aug 28, 2018 | U-1361 | | ODE | Feb 08, 2020 |
| | **>A>** 6315720 | Oct 23, 2020 | U-1361 | | | |
| | **>A>** 6316471 | Aug 10, 2016 | DP U-1360 | | | |
| | **>A>** 6476052 | Jul 24, 2016 | DP U-1360 | | | |
| | **>A>** 6561976 | Aug 28, 2018 | U-1361 | | | |
| | **>A>** 6561977 | Oct 23, 2020 | U-1361 | | | |
| | **>A>** 6755784 | Oct 23, 2020 | U-1361 | | | |
| | **>A>** 6908432 | Aug 28, 2018 | U-1361 | | | |
| | **>A>** 8158653 | Aug 10, 2016 | DP | | | |
| | **>A>** 8198262 | Oct 19, 2024 | U-1360 | | | |
| | **>A>** 8204763 | Aug 28, 2018 | U-1361 | | | |
| | **>A>** 8315886 | Oct 23, 2020 | U-1361 | | | |
| PONATINIB HYDROCHLORIDE - ICLUSIG | | | | | | |
| N203469 001 | | | | | ODE | Dec 14, 2019 |
| PONATINIB HYDROCHLORIDE - ICLUSIG | | | | | | |
| N203469 002 | | | | | ODE | Dec 14, 2019 |
| PRALATREXATE - FOLOTYN | | | | | | |
| N022468 001 | 6028071 | Jul 16, 2022 | DS DP U-1004 | | | |
| PRALATREXATE - FOLOTYN | | | | | | |
| N022468 002 | 6028071 | Jul 16, 2022 | DS DP U-1004 | | | |
| PREDNISONE - RAYOS | | | | | | |
| N202020 001 | **>A>** 8394407 | Apr 23, 2024 | DP U-1362 | | | |
| PREDNISONE - RAYOS | | | | | | |
| N202020 002 | **>A>** 8394407 | Apr 23, 2024 | DP U-1362 | | | |
| PREDNISONE - RAYOS | | | | | | |
| N202020 003 | **>A>** 8394407 | Apr 23, 2024 | DP U-1362 | | | |
| PREGABALIN - LYRICA | | | | | | |
| N022488 001 | | | | | I-651 | Jun 20, 2015 |
| RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE | | | | | | |
| N204736 001 | | | | | **>A>** NDF | Mar 26, 2016 |
| | | | | | **>A>** PED | Sep 26, 2016 |
| RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE | | | | | | |
| N204736 002 | | | | | **>A>** NDF | Mar 26, 2016 |
| | | | | | **>A>** PED | Sep 26, 2016 |
| REGORAFENIB - STIVARGA | | | | | | |
| N203085 001 | | | | | I-667 | Feb 25, 2016 |
| | | | | | **>A>** ODE | Feb 25, 2020 |
| RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE | | | | | | |
| A078173 001 | | | | | **>A>** PC | Jun 29, 2013 |
| RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE | | | | | | |
| A078173 002 | | | | | **>A>** PC | Jun 29, 2013 |
| ROPIVACAINE HYDROCHLORIDE - NAROPIN | | | | | | |
| N020533 001 | **>A>** 5670524 | Sep 23, 2014 | DS DP U-833 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ROPIVACAINE HYDROCHLORIDE - NAROPIN | | | | | | |
| N020533 003 | **>A>** 5670524 | Sep 23, 2014 | DS DP U-833 | | | |
| ROPIVACAINE HYDROCHLORIDE - NAROPIN | | | | | | |
| N020533 004 | **>A>** 5670524 | Sep 23, 2014 | DS DP U-833 | | | |
| ROPIVACAINE HYDROCHLORIDE - NAROPIN | | | | | | |
| N020533 005 | **>A>** 5670524 | Sep 23, 2014 | DS DP U-833 | | | |
| SAPROPTERIN DIHYDROCHLORIDE - KUVAN | | | | | | |
| N022181 001 | 8318745 | Nov 17, 2024 | DP | | | |
| SAQUINAVIR MESYLATE - INVIRASE | | | | | | |
| N020628 001 | | | | | M-61 | Nov 30, 2015 |
| | | | | | PED | May 30, 2016 |
| SAQUINAVIR MESYLATE - INVIRASE | | | | | | |
| N021785 001 | | | | | M-61 | Nov 30, 2015 |
| | | | | | PED | May 30, 2016 |
| SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO | | | | | | |
| N022239 001 | 8343130 | Oct 18, 2022 | DP | | | |
| SUMATRIPTAN SUCCINATE - ZECUITY | | | | | | |
| N202278 001 | 6745071 | Feb 21, 2023 | DP | | NDF | Jan 17, 2016 |
| | 7973058 | Apr 12, 2027 | U-1328 | | | |
| | 8155737 | Apr 12, 2027 | U-1328 | | | |
| | 8366600 | Apr 21, 2029 | U-1327 | | | |
| TAPENTADOL HYDROCHLORIDE - NUCYNTA ER | | | | | | |
| N200533 001 | 8114383 | Oct 10, 2024 | DP | Y | | |
| TAPENTADOL HYDROCHLORIDE - NUCYNTA ER | | | | | | |
| N200533 002 | 8114383 | Oct 10, 2024 | DP | Y | | |
| TAPENTADOL HYDROCHLORIDE - NUCYNTA ER | | | | | | |
| N200533 003 | 8114383 | Oct 10, 2024 | DP | Y | | |
| TAPENTADOL HYDROCHLORIDE - NUCYNTA ER | | | | | | |
| N200533 004 | 8114383 | Oct 10, 2024 | DP | Y | | |
| TAPENTADOL HYDROCHLORIDE - NUCYNTA ER | | | | | | |
| N200533 005 | 8114383 | Oct 10, 2024 | DP | Y | | |
| TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT | | | | | | |
| N202207 001 | | | | | **>A>** NCE | Mar 13, 2018 |
| TEDUGLUTIDE - GATTEX KIT | | | | | | |
| N203441 001 | 5789379 | Apr 14, 2015 | DS DP U-1320 | | ODE | Dec 21, 2019 |
| | 7056886 | Sep 18, 2022 | DP U-1320 | | | |
| | 7847061 | Nov 01, 2025 | U-1320 | | | |
| TELBIVUDINE - TYZEKA | | | | | | |
| N022011 001 | | | | | M-124 | Jan 28, 2016 |
| TELBIVUDINE - TYZEKA | | | | | | |
| N022154 001 | | | | | M-124 | Jan 28, 2016 |
| TESTOSTERONE - TESTOSTERONE | | | | | | |
| N203098 001 | | | | | NP | Jan 31, 2016 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TESTOSTERONE - TESTOSTERONE | | | | | | | |
| N203098 | 002 | | | | | NP | Jan 31, 2016 |
| TESTOSTERONE - TESTOSTERONE | | | | | | | |
| N203098 | 003 | | | | | NP | Jan 31, 2016 |
| TIGECYCLINE - TYGACIL | | | | | | | |
| N021821 | 001 | 8372995 | Oct 08, 2030 | DP | | | |
| TOBRAMYCIN - BETHKIS | | | | | | | |
| N201820 | 001 | 6987094 | Sep 22, 2022 | DP | | | |
| | | 7696178 | Mar 17, 2023 | DP | | | |
| | | 7939502 | Jun 14, 2022 | U-1324 | | | |
| TOBRAMYCIN - TOBI PODHALER | | | | | | | |
| N201688 | 001 | | | | | >A> NP | Mar 22, 2016 |
| TRANEXAMIC ACID - TRANEXAMIC ACID | | | | | | | |
| A202093 | 001 | | | | | >A> PC | Jul 02, 2013 |
| TRAVOPROST - TRAVATAN Z | | | | | | | |
| N021994 | 001 | 8388941 | Sep 20, 2027 | DP | | | |
| TROSPIUM CHLORIDE - TROSPIUM CHLORIDE | | | | | | | |
| A091289 | 001 | | | | | PC | Apr 10, 2013 |
| UNOPROSTONE ISOPROPYL - RESCULA | | | | | | | |
| N021214 | 001 | 6770675 | Nov 24, 2018 | DP U-1322 | | | |
| ZOLEDRONIC ACID - RECLAST | | | | | | | |
| N021817 | 001 | >A> 8052987 | Oct 27, 2023 | U-1199 | | | |

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

# PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 33rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm